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Medicinal inorganic chemistry -a sub discipline of bioinorganic chemistry is one of the 
most rapidly developing areas of pharmaceutical research. This field gained momentum 
after the prototypical success story of platinum based anticancer drug cisplatin, cis 
diamminedichloro platinum(II), cis-[Pt(NH3)2Cl2)] for treating solid cancers in particular, 
testicular, ovarian, small cell lung, head and neck cancers. Despite its success, there were 
serious concerns of this drug regarding its toxicity, intrinsic resistance, narrow spectrum 
of activity for phenotypes of cancer and patieht compliance. Therefore, studies pertaining 
to essential metallo elements received much more attention in contrast to Pt, since the 
drugs designed and synthesized "^m- endogenous metal, ions may be less harmful and 
more prone to antiproliferative activity against tumors. Much of the attention has been 
laid towards the design of metal-based cancer chemother^)eutics, predominantly Cu(II), 
Co(II) and Zn(II) complexes (endogenously biocompatible metal ion which are present as 
integral part of the active site of metalloprotein and thus familiarize their coordination 
with human body's function) with active ligand pharmacophore. In particular, these metal 
complexes could efficiently bind and cleave DNA, thereby exert artificial nucletise 
activity. The development of artificial nucleases with improved efficiency and selectivity 
is in high demand and requires binuclear metal centers to achieve a synergistic effect in 
the process of substrate recognition and scission. 
Additionally, it has been demonstrated that free radicals can damage proteins, lipids and 
DNA of bio-tissues, leading to increased rate of cancer. Redox behaviour of metal ion 
plays an important role in enzymatic activity and scavenge toxic ROS species. The 
superoxide radical anion; OT^ (a by product of normal cellular respiration) and protects 
cells from damage induced by reactive oxygen species (ROS). SOD catalyzes 
disproportionates superoxide to dioxygen and hydrogen peroxide, which later on 
decomposes to water and dioxygen by catalase. Transition metal complexes have shown 
remarkable antioxidant and DNA-binding properties which have been proven effective in 
cancer chemotherapy. DNA-complex binding causes distortion of the helical structure 
and results in inhibition of DNA replication and transcription, thereby cell death. Ligand 
scaffolds are also considered important in muting the toxicity of the metallodrug as well 
tailored multifunctional ligands offer exciting possibilities by providing appropriate 
anchoring sites for the metal ions, matching the structural motif at the molecular target 
and restricting the geometry. 
The specific delivery of a drug to their target cells may be achieved by the use of 
targeting groups or by tuning the chemical and physical characteristics of the drug or 
drug carrier, such as hydrophobicity and molecular size. Different types of 
macromoiecules (liposomes, dendrimers, polyethylene glycol polymers, nanoparticles, 
and protein biomolecules) have been used as carrier molecules. In particular, HSA is the 
most multifunctional transport protein and plays an important role in the transport and 
deposition of a variety of endogenous and exogenous substances in blood. The interaction 
of metal ions with small peptides has been a subject of great interest for bioinorganic 
chemists. Copper is the center of the active site of various metalloproteins and plays vital 
role in biological processes like electron transfer, endogenous oxidative DNA damage 
associated with aging and cancer. 
The thesis embodies the synthesis and characterization of new metallated chemical 
entities for use as antitumor agents. DNA is the primary cellular target for most of the 
chemotherapeutic agents therefore, preliminary in-vitro DNA binding profile of these 
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metal-based chemical entities were carried out by employing various bio-^hysical 
techniques. These studies are of paramount importance as the mode of binding to DNA 
gives an insight for the rationale of robust drug design. Our studies reveal that these 
complexes are capable of binding non-covalently to DNA and thereby they can act as 
efficient chemotherapeutic agents; however for the effective delivery of the potential 
drugs to the desired target, a strategy employing a protein carrier molecule is necessary to 
improve the pharmacokinetic profile of the drug or to target the drug to the pathogenic 
site addressing diseases. We have carried out binding studies with HSA to demonstrate 
specific targeted binding to the molecular DNA at the same time using HSA as a carrier 
protein. 
The thesis is divided in six chapters which includes Chapter I "Introduction" giving a 
detail overview of literature relevant to this field and also helps to justify the objectives 
of the woric done. Chapter n is "Experimental" where all details of methods and 
physical measurements employed in this woric are given. Chapter III-VI embodies the 
molecular design, synthesis of novel metal-based potential chemotherapeutic agents and 
exploring their in-vitro binding propensity towards the specific target DNA and HSA at 
the molecular level. 
Chapter HI deals with the synthesis of the new dinuclear copper(II) complex as 
metallopeptide drug [Cu2(glygly)2(pp2XH20)4]-2H20 achieved by mixing stoichiometric 
amounts of Cu(II) nitrate trihydrate with glycyl glycine anion (glygly) followed by 
reaction with piperazine (pip) hexahydrate. Molecular structure of representative complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 was determined by single X ray crystallogrphically. The 
crystal obtamed was monoclinic with space group P21/c. The in vitro DNA binding 
IV 
studies of complex [Cu2(glygly)2(ppz)(H20)4]-2H20 with CT DNA were carried out by 
employing UV-vis, fluorescence and circular dichroism which reveal electrostatic 
interaction via groove binding mode. Complex [Cu2(glygly)2(ppz)(H20)4] 2H2O cleaves 
pBR322 DNA via an oxidative mechanism and strongly binds to the DNA minor groove. 
Furthermore, complex [Cu2(glygly)2(ppz)(H20)4] 2H2O exhibits significant inhibitory 
effect on the catalytic activity of topoisomerase I at a very low concentration, -12.5 ^M, 
additionally it behaves as an excellent SOD mimic (IC50 ~ 0.086 ^M). The molecular 
docking technique was also utilized to ascertain the mechanism and mode of action 
towards the molecular target DNA and enzymes. 
In the second part of chapter m, the interaction of new dinuclear copper(II) complex 
[Cu2(glygly)2(ppz)(H20)4] 2H2O with human serum albumin (HSA) was examined by 
means of fluorescence spectroscopy which revealed that complex 
[Cu2(glygly)2(ppz)(H20)4]-2H20 has a strong ability to quench the intrinsic fluorescence 
of HSA through static quenching pathway. The alterations of HSA secondary structure in 
presence of complex [Cu2(glygly)2(ppz)(H20)4] 2H2O were confirmed by UV-visible, 
FT-IR, CD and 3D fluorescence spectroscopy. The binding constants (K), and binding 
site number (n), corresponding thermodynamic parameters AG, AH and AS at different 
temperatures were also calculated. The molecular docking technique was utilized to 
ascertain the mechanism and mode of action towards the molecular target HSA, 
indicating that complex [Cu2(glygly)2(ppz)(H20)4].2H20 was located to the entrance of 
site I by electrostatic and hydrophobic forces. Complex [Cu2(glygly)2(ppzXH20)4] 2H2O 
showed eflficient photo-induced HSA cleavage activity, indicating the involvement of 
hydroxyl radicals as the reactive species. Furthermore, the cytotoxicity of 
[Cu2(glygly)2(ppz)(H20)4] 2H2O was examined on a panel of human cancer cell lines of 
different histological origins revealing moderate GI50 values specifically towards 
MIAPACA2, A498 and A549 cell lines. These results complement the previous 
biological studies for specific targeted metallopeptide, providing additional information 
about the possibility of transport and disposition in blood plasma. 
Chapter IV describes synthesis of new water soluble complex 
[Zn(glygly)(sszXH20)].6H20 derived fix>m dipeptide (glycyl glycine anion) and 
sulfasalazine (ssz) and its characterization by spectroscopic (IR, UV-vis, NMR, ESI-
MS) and analytical methods. The in vitro DNA binding studies of complex 
[Zn(glygly)(ssz)(H20)].6H20 with CT DNA were carried out by employing various 
biophysical methods (UV-vis, Fluorescence and circular dichroism) and molecular 
docking technique which reveals strong electrostatic mode of binding, in addition to 
selective recognition towards the minor groove of DNA in A/T rich sequences. To gain 
further insight into the molecular recognition at the target site, interaction studies of 
complex [Zn(glygly)(ssz)(H20)].6H20 with nucleotide viz., 5'-TMP and S'-GMP were 
carried out by UV-vis titration. This observation was validated by ' H and ^'P NMR with 
5'-TMP which implicate the preferential selectivity of [Zn(glygly)(ssz)(H20)].6H20 
towards N3 of thymine. Complex [Zn(glygly)(ssz)(H20)].6H20 was accessible to minor 
groove of DNA and cleaved pBR322 DNA via hydrolytic pathway, the hydrolytic 
cleavage mechanism of the complex [Zn(glyglyXssz)(H20)].6H20 was supported by 
evidence fiom DNA religation employing T4 DNA ligase assay. The significance of 
such studies provides the rationale for design of novel metal-based drugs with 
VI 
proven pharmacokinetic properties that could overcome the intrinsic or acquired 
resistance of several tumors to platinum drugs and role of metal ions in enzyme catalysis. 
In the second part of chapter IV, [Cu(glygly)(ssz)(H20)].6H20 complex derived fh)m 
dipeptide (glycyl glycine anion) and sulfasalazine (ssz) was syntiiesized and 
characterized by elemental analysis (CHN), molar conductance measurements and 
specfroscopic methods (IR, UV-vis, ESI-MS). The complex 
[Cu(glygly)(sszXH20)].6H20 is water soluble, covalent in nature and possess octahedral 
geometry around Cu(II) metal ion. The interaction of complex 
[Cu(glygly)(ssz)(H20)].6H20 with human serum albumin (HSA) was investigated under 
physiological condition in Tris-HCl buffer solution at pH 7.4 by employing fluorescence, 
CD and FTIR spectroscopic and molecular docking technique. The fluorescence titration 
results revealed that the complex [Cu(glygly)(sszXH20)].6H20 strongly quench the 
intrinsic fluorescence of HSA through a static quenching procedure. Binding constants 
(Kb) and the number of binding sites (n=l) were calculated using modified Stem-Volmer 
equations. The thermodynamic parameters AG at different temperatures were calculated 
subsequently the value of AH and AS was also calculated which revealed that the 
hydrophobic and hydrogen bonding interactions play a major role in HSA-complex 
[Cu(glygly)(ssz)(H20)].6H20 association. The distance r between donor (HSA) and 
acceptor (complex) was obtained according to fluorescence resonance energy transfer 
and the alterations of HSA secondary structure induced by complex 
[Cu(glygly)(ssz)(H20)].6H20 were confirmed by FT-IR and CD measurements. Our 
results provide valuable information to understand the mechanistic pathway of drug 
delivery and to pharmacological behavior of drug. 
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Chapter V deals with the synthesis of new series of transition metal complexes 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl derived from 2,2'-bipyridyl (bipy), imidazole (im) and 
piperazine (pip). The proposed structure of the complexes was formulated on the basis of 
elemental analysis and other spectroscopic data (IR, ' H and '^ C NMR, EPR, UV-vis, 
ESI-MS and TGA). The proposed geometry of Cu(II) complex was distorted square 
pyramidal while square planar geometry was observed for Ni(II) and Zn(II) metal ions . 
The X-^ay powder diffraction (XRPD) confirmed the crystalline nature for the 
complexes. The in vitro DNA binding studies of these complexes 
[Cu2(bipy)2(im)2(pipXN03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl were carried out by employing UV-vis, fluorescence and 
circular dichroism which revealed that the complexes bind to CT-DNA by electrostatic 
groove binding mechanism. The binding afBnity of these complexes, the intrinsic binding 
constant Kb were determined and followed the order [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
> [Zn2(bipy)2(im)2(pip)].4Cl > [Ni2(bipy)2(im)2(pip)].4Cl. Therefore, the interaction 
study of [Cu2(bipy)2(im)2(pip)(N03)2].2N03 complex was carried out with 5 - guanosine 
monophosphate nucleotide (5'-GMP) by absorption titration and further validated by 'H , 
C and P NMR spectroscopy. From gel electrophoretic mobility assay, the complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 displayed efficient cleavage activity of plasmid 
pBR322 DNA followed by conversion of Form I (supercoiled DNA) to Form II (nicked 
circular DNA) and ultimately leading to the formation of linearized Form III with 
increasing concentrations of the complex. The complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 exhibited remaricable ability to affect DNA double 
VIU 
strand scission in hydrolytic cleavage manner. SOD activity exhibited the high 
superoxide dismutase activity (IC5o~0.28 nM) of complex 
[Cu2(bipy)2(im)2(pip)(NC)3)2].2NC)3 due to cooperation of two Cu(II) centers in close 
proximity, acting in concord in free radical binding and electron transfer or due to a 
vacant coordination site that permits the bonding of superoxide anion and die influence of 
ligand on SOD activity. 
Chapter VI embodies synthesis of new series of bis-macrocyclic complexes derived 
from salicylaldehyde derivative ligand (0,0'-bis{5-{(lE)-(2hydroxyphenyl)methylene] 
amino}-2-^iydroxybenzoic acid) (L) and its characterization by spectroscopic, analytical 
and visualization techniques. The crystalline nature of the complexes were authenticated 
by X-ray powder diffraction (XRPD) measurements. The in vitro DNA binding studies 
of complexes [Cu2(L)2].2N03, [Ni2(L)2] and [Sn2(L)2.4Cl] were carried out by 
absorption titrations, fluorescence, NMR and circular dichroism, which revealed that the 
noncovalent mode of binding by electrostatic interaction via phosphate backbone of the 
DNA double helix. To quantify the extent of DNA binding, the intrmsic binding constant 
Kb were determined and follows the order [Cu2(L)2].2N03> [Ni2(L)2] > [Sn2(L)2.4Cl] > 
[L]. Interaction between complex [Cu2(L)2].2N03 and pBR322 DNA was investigated by 
agarose gel electrophoresis, noticeably, the Cu(II) complex [Cu2(L)2].2N03 exhibited an 
outstanding ability to aflect DNA double strand scission tilirough hydrolytic pathway. 
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Abstract 
Medicinal inorganic chemistry -a sub discipline of bioinorganic chemistry is one of the 
most rapidly developing areas of pharmaceutical research. This field gamed momentum 
after the prototypical success story of platinum based anticancer drug cisplatin, cis 
diamminedichloro platinum(II), cis-[Pt(NH3)2Cl2)] for treating solid cancers in particular, 
testicular, ovarian, small cell limg, head and neck cancers. Despite its success, there were 
serious concerns of this drag regarding its toxicity, intrinsic resistance, narrow spectrum 
of activity for phenotypes of cancer and patient compliance. Therefore, studies pertaining 
to essential metallo elements received much more attention in contrast to Pt, since the 
drugs designed and synthesized from endogenous metal ions may be less harmful and 
more prone to antiproliferative activity against tumors. Much of the attention has been 
laid towards the design of metal-based cancer chemotherapeutics, predommantly Cu(II), 
Co(II) and Zn(II) complexes (endogenously biocompatible metal ion which are present as 
integral part of the active site of metalloprotein and thus familiarize theu* coordination 
with human body's function) with active ligand pharmacophore. In particular, these metal 
complexes could efficiently bind and cleave DNA, thereby exert artificial nuclease 
activity. The development of artificial nucleases with improved efficiency and selectivity 
is in high demand and requires binuclear metal centers to achieve a synergistic effect in 
the process of substrate recognition and scission. 
Additionally, it has been demonstrated that fi«e radicals can damage proteins, lipids and 
DNA of bio-tissues, leading to increased rate of cancer. Redox behaviour of metal ion 
plays an important role in enzymatic activity and scavenge toxic ROS species. The 
superoxide radical anion; O2*" (a by product of normal cellular respiration) and protects 
cells from damage induced by reactive oxygen species (ROS). SOD catalyzes 
disproportionates superoxide to dioxygen and hydrogen peroxide, which later on 
decomposes to water and dioxygen by catalase. Transition metal complexes have shown 
remarkable antioxidant and DNA-binding properties which have been proven effective in 
cancer chemotherapy. DNA-complex binding causes distortion of the helical structure 
and results in mhibition of DNA replication and transcription, thereby cell death. Ligand 
scaffolds are also considered important in muting the toxicity of the metallodrug as well 
tailored multifunctional ligands offer exciting possibilities by providing appropriate 
anchoring sites for the metal ions, matching the structural motif at tiie molecular target 
and restricting the geometry. 
The specific delivery of a drug to tiieir target cells may be achieved by the use of 
targeting groups or by tuning the chemical and physical characteristics of the drug or 
drug carrier, such as hydrophobicity and molecular size. Different types of 
macromolecules (liposomes, dendrimers, polyethylene glycol polymers, nanoparticles, 
and protein biomolecules) have been used as carrier molecules. In particular, HSA is the 
most multifunctional transport protein and plays an important role in the transport and 
deposition of a variety of endogenous and exogenous substances in blood. The interaction 
of metal ions with small peptides has been a subject of great interest for bioinorganic 
chemists. Copper is the center of the active site of various metalloproteins and plays vital 
role in biological processes like electron transfer, endogenous oxidative DNA damage 
associated with aging and cancer. 
The thesis embodies the synthesis and characterization of new metallated chemical 
entities for use as antitumor agents. DNA is the primary cellular target for most of the 
chemotherapeutic agents therefore, preluninary in-vitro DNA binding profile of these 
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metal-based chemical entities were carried out by employing various bio-i)hysical 
techniques. These studies are of paramount importance as the mode of binding to DNA 
gives an insight for the rationale of robust drug design. Our studies reveal that these 
complexes are cqiable of binding non-covalently to DNA and thereby they can act as 
efficient chemodienq)eutic agents; however for the effective delivery of the potential 
drugs to the desired target, a strategy employing a protein carrier molecule is necessary to 
improve the pharmacokinetic profile of die drug or to target the drug to the pathogenic 
site addressing diseases. We have carried out binding studies with HSA to demonstrate 
specific targeted binding to the molecular DNA at the same time using HSA as a carrier 
protein. 
The thesis is divided in six chapters which includes Chapter I "Introduction" giving a 
detail overview of literature relevant to this field and also helps to justify the objectives 
of the wotk done. Chapter n is "Experimental" where all details of methods and 
physical measurements employed in this woric are given. Chapter m-VI embodies the 
molecular design, synthesis of novel metal-based potential chemotherapeutic agents and 
exploring their in-vitro binding propensity towards the sp^ific target DNA and HSA at 
the molecular level. 
Chapter HI deals with the synthesis of the new dinuclear copper(II) complex as 
metallopeptide drug [Cu2(glygly)2(ppz)(H20)4]-2H20 achieved by mixing stoichiometric 
amounts of Cu(II) nitrate trihydrate with glycyl glycine anion (glygly) followed by 
reaction with piperazine (pip) hexahydrate. Molecular structure of representative complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 was determmed by single X ray crystallogrphically. The 
crystal obtained was monoclinic with space group P21/c. The in vitro DNA binding 
IV 
studies of complex [Cu2(glygly)2(ppz)(H20)4] 2H2O with CT DNA were carried out by 
employing UV-vis, fluorescence and circular dichroism which reveal electrostatic 
interaction via groove binding mode. Complex [Cu2(glygly)2(ppz)(H20)4] 2H2O cleaves 
pBR322 DNA via an oxidative mechanism and strongly binds to the DNA minor groove. 
Furthermore, complex [Cu2(glygly)2(ppz)(H20)4] 2H2O exhibits significant inhibitory 
effect on the catalytic activity of topoisomerase I at a very low concentration, ~12.5 \iM, 
additionally it behaves as an excellent SOD mimic (IC50 ~ 0.086 ^M). The molecular 
docking technique was also utilized to ascertain the mechanism and mode of action 
towards the molecular target DNA and enzymes. 
In the second part of chapter m , the interaction of new dinuclear copper(II) complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 with human serum albimiin (HSA) was examined by 
means of fluorescence spectroscopy which revealed that complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 has a strong ability to quench the intrinsic fluorescence 
of HSA through static quenching pathway. The alterations of HSA secondary structure in 
presence of complex [Cu2(glygly)2(ppz)(H20)4] 2H2O were confumed by UV-visible, 
FT-IR, CD and 3D fluorescence spectroscopy. The binding constants (K), and binding 
site number (n), corresponding thermodynamic parameters AG, AH and AS at different 
temperatures were also calculated. The molecular docking technique was utilized to 
ascertain the mechanism and mode of action towards the molecular target HSA, 
indicating that complex [Cu2(glygly)2(ppz)(H20)4] 2H2O was located to the entrance of 
site I by electrostatic and hydrophobic forces. Complex [Cu2(glygly)2(ppzXH20)4].2H20 
showed efficient photo-induced HSA cleavage activity, indicating the involvement of 
hydroxyl radicals as the reactive species. Furthermore, the cytotoxicity of 
[Cu2(glygly)2(ppz)(H20)4].2H20 was examined on a panel of human cancer cell lines of 
different histological origins revealing moderate GI50 values specifically towards 
MIAPACA2, A498 and A549 cell lines. These results complement the previous 
biological studies for specific targeted metallopeptide, providing additional information 
about the possibility of transport and disposition in blood plasma. 
Chapter IV describes synthesis of new water soluble complex 
[Zn(glygly)(ssz)(H20)].6H20 derived fix)m dipeptide (glycyl glycine anion) and 
sulfasalazine (ssz) and its characterization by spectroscopic (IR, UV-vis, NMR, ESI-
MS) and analytical methods. The in vitro DNA binding studies of complex 
[Zn(glygly)(sszXH20)].6H20 with CT DNA were carried out by employing various 
biophysical methods (UV-vis, Fluorescence and circular dichroism) and molecular 
docking technique which reveals strong electrostatic mode of binding, in addition to 
selective recognition towards the minor groove of DNA in A/T rich sequences. To gain 
further insight into the molecular recognition at the target site, interaction studies of 
complex [Zn(glygly)(sszXH20)].6H20 with nucleotide viz., 5'-TMP and 5'-GMP were 
carried out by UV-vis titration. This observation was validated by ' H and ^'P NMR with 
5'-TMP which implicate the preferential selectivity of [Zn(glygly)(sszXH20)].6H20 
towards N3 of thymine. Complex [Zn(glygly)(ssz)(H20)].6H20 was accessible to minor 
groove of DNA and cleaved pBR322 DNA via hydrolytic pathway, the hydrolytic 
cleavage mechanism of the complex [Zn(glygly)(sszXH20)].6H20 was supported by 
evidence fiom DNA religation employing T4 DNA ligase assay. The significance of 
such studies provides the rationale for design of novel metal-based drugs with 
VI 
proven phannacokinetic properties that could overcome the intrinsic or acquired 
resistance of several tumors to platinimi drugs and role of metal ions in enzyme catalysis. 
In the second part of chapter IV, [Cu(glygly)(ssz)(H20)].6H20 complex derived from 
dipeptide (glycyl glycine anion) and sulfasalazine (ssz) was synthesized and 
characterized by elemental analysis (CHN), molar conductance measurements and 
spectroscopic methods (IR, UV-vis, ESI-MS). The complex 
[Cu(glygly)(ssz)(H20)].6H20 is water soluble, covalent in nature and possess octahedral 
geometry around Cu(II) metal ion. The interaction of complex 
[Cu(glygly)(ssz)(H20)].6H20 with human serum albumin (HSA) was investigated under 
physiological condition in Tris-HCl buffer solution at pH 7.4 by employing fluorescence, 
CD and FTIR spectroscopic and molecular docking technique. The fluorescence titration 
results revealed that the complex [Cu(glygly)(sszXH20)].6H20 strongly quench the 
intrinsic fluorescence of HSA through a static quenching procedure. Binding constants 
(Kb) and the number of binding sites (n~l) were calculated using modified Stem-Volmer 
equations. The thermodynamic parameters AG at different temperatures were calculated 
subsequently the value of AH and AS was also calculated >\^ ich revealed that the 
hydrophobic and hydrogen bonding interactions play a major role in HSA-complex 
[Cu(glygly)(ssz)(H20)].6H20 association. The distance r between donor (HSA) and 
acceptor (complex) was obtained according to fluorescence resonance energy transfer 
and the alterations of HSA secondary structure induced by complex 
[Cu(glyglyXssz)(H20)].6H20 were confirmed by FT-IR and CD measurements. Our 
results provide valuable information to understand the mechanistic pathway of drug 
delivery and to pharmacological behavior of drug. 
vu 
Chapter V deals with the synthesis of new series of transition metal complexes 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl derived from 2,2'-bipyridyl (bipy), imidazole (im) and 
piperazine (pip). The proposed structure of the complexes was formulated on the basis of 
elemental analysis and other spectroscopic data (IR, *H and ''C NMR, EPR, UV-vis, 
ESI-MS and TGA). The proposed geometry of Cu(II) complex was distorted square 
pyramidal while square planar geometry was observed for Ni(II) and Zn(II) metal ions . 
The X-ray powder diffraction (XRPD) confirmed the crystalline nature for the 
complexes. The in vitro DNA binding studies of these complexes 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl were carried out by employing UV-vis, fluorescence and 
circular dichroism which revealed that the complexes bind to CT-DNA by electrostatic 
groove binding mechanism. The binding afiinity of these complexes, the intrinsic binding 
constant Kb were determined and followed the order [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
> [Zn2(bipy)2(im)2(pip)].4Cl > [Ni2(bipy)2(im)2(pip)].4Cl. Therefore, the interaction 
study of [Cu2(bipy)2(im)2(pipXN03)2].2N03 complex was carried out with 5 - guanosine 
monophosphate nucleotide (5'-GMP) by absorption titration and further validated by 'H, 
' C and ^'P NMR spectroscopy. From gel electrophoretic mobility assay, the complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 displayed efficient cleavage activity of plasmid 
pBR322 DNA followed by conversion of Form I (supercoiled DNA) to Form II (nicked 
circular DNA) and ultimately leading to the formation of linearized Form III with 
increasing concentrations of the complex. The complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 exhibited remarkable ability to affect DNA double 
VUl 
strand scission in hydrolytic cleavage manner. SOD activity exhibited the high 
superoxide dismutase activity (IC5o~0.28 nM) of complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 due to cooperation of two Cu(ir) centers in close 
proximity, acting in concord in fi-ee radical binding and electron transfer or due to a 
vacant coordination site that permits the bonding of superoxide anion and the influence of 
ligand on SOD activity. 
Chapter VI embodies synthesis of new series of bis-^nacrocyclic complexes derived 
from salicylaldehyde derivative ligand (0,0'-bis{5-{(lE)-(2hydroxyphenyl)methylene] 
amino}-2-hydroxybenzoic acid) (L) and its characterization by spectroscopic, analytical 
and visualization techniques. The crystalline nature of the complexes were authenticated 
by X-ray powder diffraction (XRPD) measurements. The in vitro DNA binding studies 
of complexes [Cu2(L)2].2N03, [Ni2(L)2] and [Sn2(L)2.4Cl] were carried out by 
absorption titrations, fluorescence, NMR and circular dichroism, which revealed that the 
noncovalent mode of binding by electrostatic mteraction via phosphate backbone of the 
DNA double helix. To quantify the extent of DNA binding, the intrinsic binding constant 
Kb were determined and follows the order [Cu2(L)2].2N03> [Ni2(L)2] > [Sn2(L)2.4Cl] > 
[L]. Interaction between complex [Cu2(L)2].2N03 and pBR322 DNA was investigated by 
agarose gel electrophoresis, noticeably, the Cu(II) complex [Cu2(L)2].2N03 exhibited an 
outstanding ability to affect DNA double strand scission through hydrolytic pathway. 
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Introduction 
Medicinal inorganic chemistry has emerged as a new discipline of inorganic chemistry 
after the serendipitous discovery of the antitumor activity of cisplatin cis-[Pt(NH3)2Cl2] 
for therapeutic use (Figure la) [1-6], Gd(ni) complexes as magnetic resonance imaging 
contrast agents (e.g. Dotaram) and ^Tc complexes in cardiovascular imaging (e.g. 
Cardiolyte) (Figure lb) [7-13]. Coordination complexes offer a diverse arena and their 
applications in medicine encompass cancer chemother^y [14,15], antimicrobial agents 
[16-18], anti HIV-AIDS drugs [19,21], anti-4iypertensive, etc [22]. 
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F^ure 1. Representative metallopharmaceuticals that are clinically used (a) as 
chemotherapeutic and (b) as MRI imaging agents. 
The use of metal-based therapeutic agents can be traced back to 3500 BC when copper 
was used to sterilize water by Egyptians and gold was used in the variety of medicines in 
Arabia and China. Gold-based drugs (sodium aurothiomalate and aurothioglucose) were 
employed for rheumatoid arthritis since twentieth century [23]. This implication was 
extended for modem medicine in 1985, when an orally bioavailable monomeric gold(I) 
phosphine drug (Auranofin) was mtroduced for rheumatoid arthritis. A curious 
connection between the discovery of a new precious element and its quick application 
into the medicinal armamentarium has been witnessed [24]. 
However, one of the major medical breakthrough for metal-based drugs was the 
discovery of potent antitumor activity of cisplatin. Cisplatin was approved for clinical use 
in 1978 and has become first line therapy for the treatment of testicular cancers. Platinum 
drugs are now widely used for the treatment the solid malignances, although they pose 
several serious limitations viz., systemic toxicity, drug resistance, non-selective reactions 
with a variety of biomolecules such as proteins and phospholipids [25-29]. 
Optimization of platinum drugs was carried out by designing targeted Pt drugs. The 
targeting strategy uses selective transport of functionalized drug molecules recognized by 
receptor highly or only expressed on the surface of cancers cells [30-31], leaving healthy 
or normal cells unaffected. It has been estimated that approximately half the patients 
being treated for cancers today by chemother^y receive a platinum compound. 
Nevertheless, these complexes do not serve the beneficial purpose or healing effect 
owing to their serious short comings and major drawbacks viz., systemic toxicity (such as 
nephrotoxicity, myelotoxicity, ototoxicity, hematological toxicity), an^hylactic 
reactions, gastrointestinal disorders, tumor cell resistance induced by chemotherapeutic 
agents [32]. Therefore considerable effort has been now focused on the development of 
new anticancer drugs based on non-platinum metal complexes [33]. 
Transition metals offer potential advantages over the common organic-based drugs, 
which include a wide range of coordination numbers and geometries, accessible redox 
states, electron shuttling thermodynamic and kinetic stability [34]. Metal complexes are 
more appealing for design of new lead ther^)eutic drugs as metals play an important role 
in the clu^eroning and delivery of drugs away fix)m the sides where they exert most 
toxicity and toward their sites of activity [35, 36] (Figure 2). Transition metal complexes 
can undergo ligand exchanges; thus they can serve as prodrug, where ligand substitution 
can activate the metal complexes toward binding to target molecules [37]. 
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Figure 2. Early-transition, late-transition and main-group metals and metalloids, which 
are known to form compounds that exhibit antitumor activity. 
The choice of metal ions and its oxidation state can be decisive in regulating the 
immediate in vivo response to metal-based chemotherapeutic agents. Most transition 
metal ions bind in site selective manner at physiological pH and generally bind to the 
most accessible N7 position of guanine or N3 of adenine in the DNA double helix [38]. 
Deoxyribonucleic acid (DNA), an inherently chiral molecule is a polymorphic structure 
with polyanionic nucleotide chains and sugar phosphate backbone [39]. The asymmetric 
D-ribose and D-2-deoxyribose units contain several stereogenic centers, whose 
configuration is important in overall DNA structure. It is well known that DNA does not 
exist in a three-dimensional structure, but can adopt different conformations which are 
defined both locally and macroscopically by different structural parameters (Figure 3). 
Double stranded DNA commonly adopts a right-handed helical conformation that of B-
and the A-form, however, they differ in the conformation of the sugar (C2'-endo for B-
DNA and C3'-endo for A-DNA, and in helical parameters). It was discovered that 
certain sequences of DNA have the propensity to undergo conformational transitions to 
left handed helical form termed as Z-DNA [40]. Z-DNA, first described in the late 
1970s, is a left handed helical form of DNA in which the double helbt wind to the left in 
a zig-zag pattern. DNA containing alternating purine and pyrimidine repeat tracts has the 
potential to adopt this non-B structure in vivo under physiological conditions. In a Z-
DNA structure, the purines are inverted and in the syn-conformation, while the 
pyrimidines remain in the anti-conformation; as a result, the pyrimidine nucleotide must 
rotate to maintain the Watson-crick base-pairmg. Such alternating syn-anticonformation 
drives the DNA backbone into a zig-zag shape. The major groove essentially disappears 
in a Z-DNA conformation, while the minor groove remains and maintains its narrow 
character, corresponding to the B-DNA stincture [41]. 
A large percentage of the chemotherapeutic anticancer drugs currently used fall into the 
category of DNA-binding drugs, which interact with DNA duplex by any of the three 
general binding modes which have been thoroughly characterized from a structural point 
of view. DNA intercalators [42], groove binders [43], and covalent binders [44-47] 
(Figure 4), with some peculiarities within each general category, may be cytotoxic and 
thus therapeutic either by direct interaction with DNA or by inhibition of topoisomerase 
enzymes (preventing DNA relaxation) [48]. 
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Figure 3. Different conformational variations of DNA structure. 
In eukaryotic cells, DNA is stored in its supercoiled duplex form and its arranged on 
supramolecular structures that are stabilized by ancillary proteins. However, during 
activation toward processes such as replication and transcription, this stable storage 
complex is rearranged and the DNA may form structures that differ from Watson-Crick-
induced B-DNA duplex [49]. Many classical DNA-intercalators have been tested as 
antitumor drugs [50], but their use is limited by the lack of specificity and frequent side 
effects. However, combinations of intercalators with groove binders, intercalators and 
molecules that form covalent adduct with DNA. Interestingly, few new classes of 
compounds in these categories have been identified and reported. The combination of 
binding modes has several potential advantages over molecules binding in a single mode. 
(a) Groove binder (b) Intercalation (c) Insertion 
Figure 4. The three binding modes of metal complexes with DNA: (a) groove binding, (b) 
intercalation and (c) insertion. 
Firstly, the stability of ligand-DNA complexes is expected to improve by the multiple 
interactions. In addition, the combination of covalent binding with non-covalent 
recognition represents an entropic advantage over molecules that do not localize 
covalently to the DNA. Furthermore, most molecules only have weak preference for a 
certain sequence, and binding to several alternative sites often occurs [51-57]. 
Cancer is defined as an abnormal cell behavior including irregular and rapid proliferation 
at the cellular level [58]. Cancer is caused by mutation of cellular genes that control cell 
growth and division [59]. The current treatment for cancer primarily includes surgery and 
chemotherapy, however, chemotherapy is used as mainstay due to its ability to cure 
widespread malignancies or metastatic cancers alone or in combination with radiotherapy 
[60]. The drugs used to treat cancer are often named as anticancer drugs. However, the 
drug is referred to as an antitumor agent if it is targeted against a malignant tumor. A 
malignant tumor is the result of the proliferation of the abnormal cancer cell, which 
generally spreads to distant parts of the body by the blood or lymph and consequently 
evolves into new cancer cells. This process is named metastasis [61]. 
All living cells (including cancer cells) contain genetic information necessary for 
replication and survival. When a cell is divided, its DNA is reproduced. Hence, one of the 
most approaches has been to inhibit the growth of cancer cells by disrupting the flow of 
their genetic information [62]. Ahnost all of the currently used agents exert their mode of 
action by the inhibition of DNA synthesis, direct chemical damage to the genomic DNA, 
or some alternative means of inhibiting the mechanics of cell division. DNA has been 
therefore, considered to be the major primary target for the action of a large number of 
currently used anticancer agents [63]. 
Metal-based pharmaceuticals can be arranged into seven categories depending on the 
function of the metal and ligand moieties accordmg to Hambley et al [64]: i) the metal 
complex is active m its inert form, ii) the metal complex is active in its reactive form, iii) 
the metal serves as a radiation enhancer, iv) the compound contains a radioactive metal, 
v) the metal or its biotransformation product is active, vi) ligand is biologically active, 
and vii) only a fragment of the complex is active. Transition metals have demonstrated 
remarkable cytotoxicity in cell culture or antitumor activity. Iron is biologically most 
significant metal ion and recently an orgwometallic compound (Ferrocifen), an analog of 
tamoxifen, an antagonist of the estrogen receptor (widely used in the clinic for the 
treatment of hormone dependent breast cancers) was discovered indicating a 
distinguished mode of antiproliferative action (Figure 5a) [65]. Because Ru derivative 
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does not show the same cytotoxicity profile, it was assumed that redox properties of 
ferrocene played an important role. 
A prodrug approach for the inhibition of enzymes by cobalt complexes has been explored 
by Hambley et al [66]. Their strategy involves the complexation of matrix 
metalloproteinase (MMP) inhibitor to a Co(ni) complex for selective delivery of MMP to 
tumor (Figure 5b). The prodrug is activated by a bio-reduction pathway producing a 
labile Co(II) complex, which results in the release of the MMP inhibitor [67]. 
(«) (b) 
Figure 5. (a) Ferrocifen, a ferrocene derivative of tamoxifen, shown in blue. The third 
phenyl ring in tamoxifen is replaced by ferrocene and (b) Co(III) complex with 
marimastat. 
The chemistry of copper is attractive for the development of hypoxia selective drugs, 
because Cu has two oxidation states and the reduction potential in accessible within the 
cellular potential range [68]. Recently, the 'Tirapazamine' ligand was employed as a 
hypoxic cytotoxin for use with radioactive Cu, combining the antitumor activity of the 
copper complex with its radioactivity, the "^ C^u or '^Cu isotopes with bis 
(thiosemicarbazone) and bis (salicylaldimine) ligands showed hypoxic selectivity against 
Chinese hamster ovary cancer cells [69]. Complexes with nitrogen mustard based as 
cyclen, cyclem and tacn are cytotoxic against leukemia cells. Cu(n) complex with 
1,4,7,10-tetraazacyclododecane, (Figure 6) exhibited good aqueous stability and, in vitro 
24-fold increased cytotoxicity under hypoxic conditions vs. oxic conditions [70]. 
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Figure 6. Cu(II) complex for releasing nitrogen mustards based on cyclen. 
In such complexes the tunable redox properties of the metal ion and ligand modifications 
can be exploited to control biological action. Ligand loss during reduction in hypoxic 
cancer tissue can activate metal complexes for binding to target molecules. Furthermore, 
as for Co and Cu, the loss of the ligand in a reductive environment can also trigger the 
release of an active species, a molecule that would have shown systemic toxicity if not 
bound to the deactivating metal center [64]. 
Zinc is the second most prominent trace metal in the human body and plays an important 
role in regulating the cellular response to DNA damage, including cell cycle arrest and 
the induction of apoptosis [71,72]. The deficiency of zinc may cause growth effects and 
disorders of the central nervous system [73-75]. In the literature, diverse zinc complexes 
with biological activity are reported [76], but drugs with zinc complexes are used for the 
treatment of Alzheimer diseases [77] and others showing antibacterial [78], anti-
convulsant [79], anti-diabetic [80] anti-inflammatory [81], anti-^nicrobial [82] and anti-
proliferative, anti-tumor [83] activity were structurally characterized. 
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A Tarushi et al [84] has described the synthesis and characterization of mononuclear zinc 
complex with first-generation quinoline antibacterial drug oxolinic acid in the absence or 
in presence of N-donor heterocyclic ligand bipyridyl. In the complex, oxolinic acid was 
found boimd to Zinc(II) via ketone oxygen and a carboxylate oxygen. The biological 
activity of the complexes was evaluated by their ability to bind to CT DNA by employing 
UV and fluorescence optical methods. Interaction of the complexes with DNA has shown 
that Zn(oxo)2(py)2 exhibits the highest Kb value, which was comparable to the Kb value 
with EB. EB (3, 8-Diamino-5-ethyl-6-phenyl-phenanthridinium bromide) is a 
phenanthridine fluorescence dye and is a typical indicator of intercalation [85]. It can 
form soluble complexes with nucleic acids emitting intense fluorescence in presence of 
CT DNA due to intercalation of the planar phenanthridinium ring between adjacent base 
pairs on the double helix [86]. The changes observed in the spectra of EB on its binding 
to CT DNA are used for the interaction study between DNA and metal complexes [87]. 
Recently, a novel organotin complex l-{(2-4iydroxyethyl)amino}-2-amino-l,2-
dideoxy-D-glucose triphenyltin(IV) (GATPT) (Figure 7), a sugar based apoptosis 
inducer was synthesized by our research group [88]. GATPT was tested for its cytotoxic 
properties against SY5Y, PC-12 and N2A neuronal tumor cell lines. GATPT induced 
significant apoptosis in the PC-12 cell line characterized by DNA fitigmentation and 
chromosome condensation. Treatment of PC-12 cells with GATPT resulted in a dramatic 
up-Hiegulation of Bax and Bak and down-regulation of the anti-apoptotic factor Bcl-2. 
Apoptotic induction by GATPT was shown to be mediated in a p53-dependent manner 
and loss of p53 impaired the release of cytochrome c from mitochondria to cytosol. 
Caspase-3 was found to be indispensable for the GATPT triggered apoptosis signaling 
pathway. Furthermore, in vivo studies using a nude mice model revealed that GATPT 
exhibits significant antiproliferative activity against tumor development with minimal 
cytotoxicity. 
HO" 
F^ure 7. Molecular structure of GATPT. 
Tailored multifunctional ligands for metal based medicinal drugs offer many exciting 
possibilities including targeting specific tissues, membrane receptors, or endogenous 
molecules and can play an integral role in modulating the potential toxicity of a 
metallodrugs [89]. Recent advances in ligand design have resulted in potent antitumor 
compounds that are active in cisplatin resistant cell lines, and also include additional 
features to allow for an increased understanding of the mechanism of action of drug. In 
addition, the carrier ligands may also affect bio-distribution and recognition of DNA 
adducts by repair enzymes, regulatory and DNA binding proteins. 
Recently, Dolenc et al [90] have designed and synthesized a series of novel 
desmuramyldipeptides for therapeutically useful muramyldipeptide (MDP) analogs. The 
MDP is an immune-amplifier and modulator of immune reaction, rather than an immune 
stimulant/7er se [91]. Some desmuramylpeptides were able to enhance the host defense 
against microbial infections as well as exhibit strong antiviral activity and remaricable 
antitumor potency [92-97]. LK-^09 (7-oxooctanoyl-L-Ala-D-isoglutamine) and LK-
12 
410 (N-(trans-2-(2-acetylaminocyclohexyloxy)acetyl)-L-alanyl-E)-glutaminic acid) 
(Figure 8) stimulated the macrophages in a dose-dependent manner to produce 
superoxide radicals and significantly accelerated the differentiation of mouse B 
lymphocytes in plaque ftmning cells [98]. 
Q> ^^ 
/ '^\ 
m 
MDP LK-123 LK^IO LK-»09 
Figure 8. Design of novel desmuramyldipeptide analogs. 
Furthermore, a phthalimido desmuramyldipeptide compound, LK-423 (N-[2-(2-
phthalimidoethoxy)acetyl]-L-alanyl-D-glutamic acid), proved to be the most promising 
analog and was selected for fiuther study to develop as an anti-inflammatory agent [99-
101]. 
Peptides play important roles as hormones, enzyme inhibitors, neurotransmitters, and 
immune modulators in living systems and therefore, are expected to play significant 
role in the treatment of many diseases viz., cancer, AIDS, Alzheimer's disease, 
malaria and as antimicrobials. Recently, it has been reported that some peptide 
derivatives show antitumor activity with little toxicity against non-malignant cells either 
by triggering apoptosis [102] or by forming ion channels/pores [103]. Furthermore, 
some peptides were found to be cytotoxic against MDR cancer cells [104,105]. 
Advantages of Peptides over other ligands are biocompatibility, non-toxicity, 
enantiomeric purity, and water solubility. An improved understanding of protein-DNA 
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interaction would find application in the design of repressors, transcription factors, and 
nucleases with altered sequence selectivity. 
Metals may be du^ctly bound into peptides and have been used for DNA selective 
recognition and/or cleavage [106-108]. It was reported that peptide functionalization of 
polypyridyl ruthenium(II) [109] or rhodium(III) [110,111] metallo-intercalators 
improved the selectivity of the parent intercalators, with similar effects observed by 
conjugating minor groove binders with short peptides that mimic natural protein motifs 
[112]. Thus, the metal complex serves to deliver tfie peptide to the DNA recognition site. 
This approach offers the opportunity to explore site-specific recognition of DNA by 
small peptides where residues may be varied in a systematic and well-defined fashion. 
Figure 9. (a) Metd-peptide conjugate [Rh(phi)2bpy'-Peptide] (b) Structures of the 
positional isomers of the ruthenium oligopyridine complexes with conjugated amino 
acids and (c) Structures of the positional isomers of the ruthenium oligopyridine 
complexes with conjugated amino acids. 
Cowan et al have studied the single- and double-strand DNA cleavage efficiency of 
Cu(II)- and Ni(II>-Lys-Gly-His-<lerived (ATCUN) metallopeptides binding motif of 
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proteins (Figure 10) and its impact of the positioning of charged Lys side chains and their 
stereochemistry on metal reduction potentials and DNA cleavage reactivity [113]. 
H 
Figure 10. Structure ofM(II),Gly-Gly-His. 
Since, ATCUN binding motifs of proteins occur naturally in the albumins and others 
native proteins, these metallotripeptide particularly Cu(II)»Gly-Gly-His was found active 
against Ehrlich ascites tumor cells [114]. It has been shown to induce DNA cleavage 
when activated with ascorbate [115], this system also effects DNA strand scission as a 
synthetic [116] or biosynthetic appendage to DNA binding proteins [117]. Enrique J. 
Baran and coworkers [118] have synthesized a new copper(II) complexes of 
stoichiometry [Cu(L-<iipeptide)].nH20, containing dipeptide ligands L-alanine- Lr-
isoleucine, L-alanine- L-threonine and L-alanine- L-tyrosine (Figure 11). 
(a) (b) (c) 
Figure 11. Structure of (a) Cu(ala-ile),(b) Cu(ala-thr) and (c) Cu(ala-tyr) complexes. 
The single crystal X-ray studies of the all complexes show the same elongated square 
pyramidal coordination, being equatorially cis coordinated by a N2O2 arrangement of 
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ligand atoms and axially by a carbonyl oxygen atom. Furthermore, comparative 
superoxide dismutases (SOD>-like activity were investigated for all complexes. These 
studies demonstrated that, only Cu(alar^he) complex (Table 1) revealed activity which 
was close to the ranges that were clinically interesting [119], due to the different dihedral 
angles subtended between the equatorial CUN2O2 planes, and it could be responsible for 
changes the overall environment around the active metal center due to differences in the 
stoichiometry of the dipeptides. 
Table 1. Cu(II) concentration required to yield 50% inhibition in SOD-assays 
Complex Concentration (M) [Cu] complex/ [CuJsOD 
Cu(ala-ile) 3.30x10"^ 32353 
Cu(ala-thr) 9.90x10"^ 9705 
Cu(ala-tyr) 2.52x10-^ 24706 
Cu(ala-val) 2.37x10"^ 23235 
Cu(ala-^he) 1.49x10"^ 1461 
Cu/SOD 1.02x10"* -
The results indicate that the chelated dipeptide ligand help to anchor copper metal ion and 
their spatial arrangement, often modulate very precisely and specifically the biological 
response of a metallic center [120,121]. 
Sulfa drugs have attracted special attention for their ther^jeutic importance as they were 
used against a wide spectrum of bacterial ailments [122-129]. Also, some sulfa drugs 
were used in the treatment of cancer, malaria, leprosy and tuberculosis [126]. Recently, 
Borr^ et al [130] have synthesized three dinuclear and one mononuclear copper(II)-
1,10-^henanthroline ternary complexes, [Cu(Ll)(phen)(OH)]2 (a), 
[Cu(L2)(phen)(OH)]2.3H20 (b), and [Cu(L4)2(phen)(H20)] (c), with thiadiazole 
sulfonamide derivative ligands: HLl (N-(5-ethyl-l,3,4-^iadiazol-2-yl) 
naphthalene-1-sulfonamide), HL2 (N-(5-ethylthio)-l,3,4-thiadiazol-2-ylH-
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methylbenzenesulfonamide), HL3 (N-(5-ethyl-l,3,4-thiadiazol-2-yl) 
benzenesulfonamide) and HL4 (N-(5-ethyl-l,3,4-thiadiazol-2-ylH-methyl-
benzcnesulfonamidc) and their pUC18 plasmid DNA cleavage activity were investigated 
in the presence of reactive oxygen intermediate (Figure 12). 
(a) (b) (c) 
F^ure 12. The ORTEP drawing of mononuclear unit of (a) [Co(HLl)(H20)2], (b) 
[Cu(HL2)(H20)zl and (c) [Cu(L4)2(phen)(H20)]. 
The condensation of primary amines with carbonyl compounds was first reported by 
Schiffand since then condensation products are referred to as Schiff bases [131]. Several 
Schiff base complexes were found to inhibit tumor growth [132]. A few structurally 
characterized amino acid derived SchifT bases and their metal complexes were reported 
[133-136]. SchifT base are considered as 'privileged ligands' as they bind with difTerent 
metal ion in various oxidation states [137]. 
Ghosh et al [138] has synthesized SchiflF-base ligand; [L' = N,N'-bis((pyridine-2-yl) 
phenylidene)-l,3-diaminopfopan-2-ol] and their Cu(lI)complex 
[CU(L')C1](C104).CH30H (Figure 13), and Aeir interaction studies with calf thymus 
DNA (CT DNA) were validated by using absorption and emission spectral studies. 
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Figure 13. Schematic diagrams ofligand{N,N'-bis((pyridine-2-yl)phenylidene)-l,3-
diaminopropan-2-ol) (left) and its copper(II) complex (right). 
DNA and enzymes involved in replication and transcription represent the most targeted 
bioreceptors for small molecules and a target for the control of gene expression. Most 
anticancer drug bind to DNA and proteins either in a reversible or irreversible manner 
suggesting a direct relationship between their interactions with macromolecules, hence, 
leading to their therapeutic effect. Numerous reports in literature are available for the 
binding studies using various biophysical techniques. 
H,-J. Yu et al [139] has carried out DNA binding studies of two ruthenium(II) complexes 
[Ru(bipy)2(mitatp)]+2 and [Ru(bipy)2(nitatp)]+2 where mitatp = 5-methoxy-isatino[l,2-
b]-l,4,8,9-tetraa2atriphenylene and nitatp = 5-nitro-isatino[l,2-b]-I,4,8,9-
tetraazatriphenylene) by employing absorption spectroscopy, fluorescence spectroscopy, 
DNA melting experiments and gel mobility shift assays. 
[Ru(bipy)2(mitatp)] +2 [Ru(bipy)2(nitatp)] +2 
Figure 14. Structure of the ruthenium(II) complexes. 
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For metallo-intercalators, DNA-binding is associated with hypochromism and a red shift 
in the MLCT and ligand bands [140]. The absorption spectra of [Ru(bipy)2(mitatp)]*^and 
[Ru(bipy)2(nitatp)]^ i^n the absence and presence of CT DNA (at a constant concentration 
of complexes, [Ru]= 20 |iM) has been depicted in figure 15 [139]. Upon increasing 
concentration of DNA, both complexes exhibited pronounced hyperchromism, along with 
a modest bathochromic shift. 
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Figure 15. Absorption spectra of (a) [Ru(bipy)2(nitatp)]^^ and (b) [Ru(bipy)2(mitatp)] 
in the presence of an increasing amount ofCT DNA. [Ru] = 20 fiM. Inset: (ea-e^/(eb-£^ 
vs. [DNA], and the non linear fit curve. 
Similar hypochromicity was reported for [Ru(phen)2(dppz)]+, implying binding to DNA 
through intercalation of the dppz ligand (dipyrido[3,2-a:2',3'-c]phenazine) [141]. 
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Figure 16. Emission spectra of (a) [Ru(bipy)2(nitatp)]*^ and (b) [Ru(bipy)2(mitatp)]*^ 
in Tris-HCl buffer in the absence and presence of CT DNA. Arrow shows the intensity 
change upon increasing DNA concentrations. [Ru] = 5 ^M. 
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The intrinsic binding constants "K" and binding site "n" derived for 
[Ru(bipy)2(mitatp)]"'^ and [Ru(bipy)2(nitatp)r^ complexes were (8.38 ± 0.3) x 10* M"' 
(n=1.06 ± 0.01 bp) and (1.07 ± 0.4) x 10^  M"'(n=0.73 ± 0.01 bp), respectively. The K 
values were C(»nparable to the known DNA intercalator (1.04 x lo ' M~') [142]. 
The luminescence titration experiments carried out in aqueous solution. As shown in 
figure 16, upon addition of CT DNA, revealed increase in emission intensity was 
observed for bodi complexes. This implies that both complexes exhibited strong 
interaction with DNA, since the hydrophobic environment inside the DNA helix reduces 
the accessibility of water molecules to the complex and the complex mobility is restricted 
at the binding site, leading to decrease of the vibrational modes of relaxation. 
Z.-W. Mao et al [143] has studied the CD ^jectral characteristics of CT DNA in the 
absence and presence of complexes [Cu(Ll)(ClO4)](ClO4).0.5H2O and 
[Cu(L2)(H20)](C104)2.H20 (Ll= 2-benzyl-l,3-bis(aminoethylthio) propane and L2= 2-
(4-butylben-zyl)-l,3bis(aminoetfiyltiiio)propane) (Figure 17). 
u-
•12. 
Figure 17. CD spectra ofCT-DNA (1.0 xKT* M) in the absence and the presence of 
[Cu(Ll)(ClO4)](ClO4).0.5H2O (a) and [Cu(L2)(H20)](Cl04)2.H20 (b) at ratio 
[complex]/[DNA] = 0.2, 0.4 in 5 mM Tris-50 mM NaCl aqueous buffer solution (pH 
7.5). 
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Upon addition of increasing concentrations of [Cu(LlXClO4)](ClO4).0.5H2O and 
[Cu(L2)(H20)](C104)2.H20, both positive and negative bands show slight change, which 
implies a non-intercalative mode between DNA and complexes. Since, the cationic core 
of [Cu(Ll)(ClO4)](ClO4).0.5H2O and [Cu(L2)(H20)](C104)2.H20 could exert a strong 
electrostatic attraction to ttie anionic phosphate backbone of DNA, consistent with the 
electrostatic bmding mode [144]. 
There has been considered interest in DNA endonucleolytic cleavage reactions that are 
activated by metal complexes [145,146] tfius, DNA mobility shift assay were carried out 
to investigate the ability of complexes to interact with plasmid DNA. Change in the 
electrophoretic mobility of plasmid DNA on agarose gel is commonly taken as evidence 
for direct DNA-nnetal interactions. Alteration of the DNA structure cause retardation in 
the migration of supercoiled, and slight increase in the mobility of c^ )en circular DNA to 
a point where both forms comigrate. Impairment of DNA function results in the 
inhibition of replicati(Hi and transcription processes and, eventually, if tiie DNA lesions 
are not rapidly and properly repaired, it results in cell death. Metal-DNA interaction 
cause alteration in the structure of DNA, where upon the mobility of supercoiled DNA 
decreases and the migration of open-circular DNA slightly increase at the comigration 
junction of both forms [147]. When a circular plasmid DNA is subjected to agarose gel 
electrophoresis, the festest migration will be observed for supercoiled form (Form I). If 
one strand is cleaved, the supercoils will be relax to produce a slower moving open 
circular form (Form II). If both strands cleaved, a linear form (Form III) will be generated 
that migrates in between [148]. One of the illustrative examples of concentration 
dependent pBR322 DNA cleavage of [Cu(Pyimpy)(C104XCl)] (Pyimpy = 1-phenyl-1-
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(pyridin-2- yl)-2-(pyridin-2-ylmethylene)hydr azine) was presented by Ghosh et al [149], 
enhancement of DNA cleavage activity was observed due to variation of incubation time 
(Figure 18, lane 10-14). Furthermore, nuclease activity of [Cu(Pyimpy)(C104KCl)] in 
presence of H2O2 or 2-mercaptoethanol increased the cleavage activity, followed by 
complete conversion of SC form to NC and LC form of DNA (Figure 19, lane 7, 8). 
1 2 3 4 5 6 7 8 9 1011 1213 14 
Figure 18. Gel electrophoresis showing the cleavage of supercoiled pBR322 DNA 
(lOOng) by complex [Cu(Pyimpy)(Cl04)(Cl)] . Incubated at 37 "Cfor 1.5 h. lane 1, DNA 
control; lane 2 DNA + 10% DMF; lanes 3- 9, DNA + [Cu(Pyimpy)(Cl04)(Cl)] = 10, 25 
40 50 60. 80, 100 fiM respectively; lanes 10 -14, DNA + [Cu(Pyimpy)(Cl04)(Cl)] (100 
fiM) + incubation time 5, 15, 30, 60 and 90 min respectively. 
8 9 10 
Figure 19. Gel electrophoresis showing the cleavage of supercoiled pBR322 DNA (100 
ng) by complex [Cu(Pyimpy)(Cl04)(Cl)] (50 nM) in presence of radical scavenger s (20 
mM). lane 1,DNA; lane 2, DNA + Cu(Cl04)r6H 20 (100 nM); lane 3, DNA + 
[Cu(Pyimpy)(Cl04)(Cl)] (50 fiM); lane 4-10 DNA + [Cu(Pyimpy)(Cl04)(Cl)] (50 ftM) 
+ DMSO, ethanol, urea, catalase (lU), D2O, L-histidine, NaNj, respectively. 
1 2 3 4 5 6 7 8 
Figure 20. Gel electrophore sis separations showing the cleavage of supercoiled pBR322 
DNA (100 ng) by complex [Cu(Pyimpy)(Cl04)(Cl)J in presence of H2O2 and BME. 
Incubated at 37 °Cfor 1.5 h.(a) lane 1, DNA control; lane 2, DNA + H2O2 (400 /iM); 
lane 3, DNA + BME (400 ft M); lanes 4- 6, DNA + [Cu(Pyimpy)(Cl04)(Cl)]= 25, 50 
100 fiM; respectively lane 7, DNA + [Cu(Pyimpy)(Cl04)(Cl)] (50 nM) + H2O2 (200 
HM); lane 8, DNA + [Cu(Pyimpy)(Cl04)(Cl)J (50 fiM) + BME (200 nM). 
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Involvement of reactive oxygen species (hydroxyl radical, superoxide ion, singlet oxygen 
and hydrogen peroxide) in nuclease activity could be diagnosed by monitoring the 
quenching of DNA cleavage in the presence of radical scavengers in solution [150]. The 
hydroxyl radical scavengers like DMSO, ethanol and urea showed the complete 
inhibition of nuclease activity (Figure 20, lane 4-6). These results suggested that 
hydroxyl radicals may be involved in the cleavage process. Addition of singlet oxygen 
scavengers like L-histidine and NaNs (Figure 20, lane 9,10) showed complete inhibition 
of nuclease. So these resuhs suggested that 'O2 or any other singlet oxygen-like entity 
may participate in the DNA strand scission. However, nuclease activity was not enhanced 
in presence of D2O (Figure 20, lane 8). Probable participation of hydrogen peroxide was 
excluded due to enhancement of nuclease activity upon addition of catalase (Figure 20, 
lane 7). On the basis of these observations, it was concluded that complex 
[Cu(Pyimpy)(C104XCl)] generated reactive oxygen species (ROS) which were 
responsible for nuclease activity. 
The SOD activity of [Cu(PhimpXH20)]2(C104) and [Cu(Phimp)(A0c)]2 were determined 
by using the xanthine/xanthine oxidase by monitoring the reduction of nitro blue 
tetrazolium (NBT) with Oj" generated xanthine/xanthine oxidase system [151]. The rate 
of absorption change was determined and the concentration required to produce 50% 
inhibition (IC50) was calculated by graphing the rate of NBT reduction (along Y-axis) 
versus the concentration of the test solution (along Y-axis) (Figure 21). The complexes 
[Cu(PhimpXH20)]2(C104) and [Cu(PhimpXA0c)]2 showed IC50 values 11.20 and 8.31, 
respectively. 
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Figure 21. Effect of complexes [Cu(Phimp)(H20)]2(ClOi^ (A) and[Cu(Phimp)(AOc)]2 
(m) on the inhibition of the reduction. Incubation time was 5 min. 
Most of the drugs exert their cytotoxic effect and thereby therapeutic effect by direct 
interaction with DNA or by inhibition of topoisomerases (preventing DNA relaxation) 
Thus, new light has been shed on the discovery of metal-based drugs that inhibit 
enzymatic activities or even target protein directly. There are many reviews which 
highlight some exciting results published recently on the development of metal as 
enzyme inhibitors for potential therapeutic applications [152]. Topoisomerase-I (Topo I) 
is one of the nuclear enzymes that control ihe topology of DNA by triggering single-
stranded breaks, passing the other strand through the cutting site and religating the cut 
strand [153]. These topoisomerases are important in DNA replication and transcription. 
Topo I inhibitors have been reported to be among the most widely used clinical drugs for 
treatment of cancer [154]. To determine catalysis or by altering the apparent topological 
state of DNA, the DNA strand passage assay was performed [155]. Chao et al [156] have 
investigated the Topo I inhibitory activity of [Ru(bpy)2(bfipH)](C104)2 and 
[Ru(phen)2(bfipH)](C104) (bfipH = 2-(benzofuran-2yl)imidazo[4,5-f|, phen = 1,10 
phenanthrolme) by gel electrophoresis. Both complexes inhibited the ability of Topo I to 
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relax negatively supercoiled plasmid DNA (IC50 is -17 pM for complex 
[Ru(bpy)2(bfipH)](C104)2 and ~8 i^M for complex [Ru(phen)2(bfipH)](CI04)2). These 
findings imply that these complexes block the DNA strand passage event of the enzyme, 
and can serve as catalytic inhibitors of Topo I. 
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Figure 22. Effects of different concentrations of complexes [Ru(bpy)2(bfipH)J(C 104)2 and 
[Ru(phen)2(bfipH)](Cl0^2 on the activity of DNA topoisomerase-I (Topo I) activity. 
As shown in Figure 23, the rate of Topo I-catalyzed DNA supercoiling in the presence of 
the Ru(II) complexes was lower than the rate of EB, which was identical to the rate of 
Topo I-catalyzed DNA relaxation in the absence of drug. These findings suggest that 
complexes Ru(bpy)2(bfipH)](C104)2 and [Ru(phen)2(bfipH)KC104)2 were catalytic 
iithibitors of topoisomerase-I. 
l(mio) < ^ EB(niin) 
0 ^ 2 5 10 15 20 2 5 10 15 20 2 5 10 15 20 
2 (mm) 
Form II 
Form I 
F^ure 23. The time dependence of Topo I DNA strand passage assays in the presence of 
ethidium bromide (EB) and complexes [Ru(bpy)2(bfipH)](ClOi)2 and 
[Ru(phen)2(bfipH)](Cl04)2. 
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Griffith et al [157] have analysed the docking poses of the two most active compounds, 
NSC0674004 (4-Chloro-2-mercapto-5-methyl-N-[5-amino-l-(quinoxalin-2-yl))-
l,2,4-triazol-3-yl}benzenesulphonamide) and NSC0039875 (sodium 3-amino-4-
chloro-9,10-dioxoanthracene-2-sulfonic acid), and compared to the docking pose of 
Scutellaprostin G (Figure 24, views down the DNA axis in A to C, and from the major 
groove in D). 
Figure 24. Interactions between protein side chains and docked ligand: (A) 
Scutellaprostin G (B) NSC 0674004 (C) NSC 0039875 and (D) Overlay of docking poses 
of Scutellaprostin G (gray carbons), NSC 0674004 (pink carbons) and NSC 0039875 
(green carbons) within the DNA cleavage site. 
Analysis and superimposition of the docking poses revealed that the three compounds 
intercalate between the DNA base pairs at the cleavage site, each providing three 
aromatic rings for extensive base pair stacking, and form hydrogen bonds to the side 
chains of the Topol residues Arg364 and Lys532. 
The X-ray structure shows that active-site cavity of bovine CuZnSOD is -15 A deep and 
12 A wide near the protein surface and narrows to ~3 A at the catalytic copper [158], 
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which has a solvent-exposed surface area of ~5A^ (Figure 25a). English et al has 
performed the docking studies of well-known chelator EDTA into the active-site channel 
of bovine CuZnSOD (Figure 25b). This implies that EDTA's carboxylate groups can 
coordinate to the active-site copper without reorganization of groups in the active-site 
cavity. Furthermore, the concentration of positive electrostatic potential (blue) around the 
cavity should promote binding of anionic ligands in the cavity [159,160]. 
Figure 25. Docking of EDTA into the active-site channel of bovine CuZnSOD. (a) 
Molecular surface and electrostatic potential map (blue, positive; red, negative) of the 
active-site channel of CuZnSOD and (b) Docking of the EDTA molecule into the active-
site channel demonstrates that a carboxylic group of EDTA can access the active-site 
copper. 
Human serum albumin (HSA) is emerging as a versatile protein carrier for drug targeting 
and for improving the pharmacokinetic profile of peptide or protein based drugs [161]. It 
is a transport protein per se trafficking fatty acids, metal ions (Ca^^ Zn^^ Cu^ )^ bilirubin, 
high binding drugs such as benzodiazepines, antibiotics, anti-inflamatory drugs, 
antianesthetic or platinum and gold complexes (cisplatin and omophin) within the body. 
The main role of HSA is to maintain the osmotic blood pressure and to scavenge free 
radicals as an antioxidant. It is an attractive macromolecular carrier, due to its lack of 
toxicity and immunogenicity make it an ideal candidate for drug delivery. 
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X-ray structure analysis of HSA (which appeared in Brookhaven data banic) depicted in 
Figure 26 showed an ellipsoid shape consisting three domains, I, II and III. The binding 
sites for metabolic substrate and diagnostic as well as therapeutic drugs have been 
extensively studies and reviewed [162]. 
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Figure 26. Modeling of X-ray crystallographic structure of HSA (PDB ID: lh9z). The 
domains and subdomains were displayed with different color, the every subdomain and 
classical binding site were marked in the corresponding location. 
The specific delivery of a drug to cancer cells may be achieved by the use of targeting 
groups or by tuning the chemical and physical characteristics of the drug or drug carrier, 
such as hydrophobicity and molecular size [163]. In particular, human serum albumin 
(HSA) is known to accumulate in tumors, being taken up by tumor cells at increased 
levels compared to normal cells because of enhanced tumor vascular permeability and 
prolonged retention time in the tumor interstitium due to the obstruction of lymphatic 
drainage, and has been exploited as the carrier conjugate of various anticancer drugs such 
as chlorambucil, doxorubicin, and paclitaxel [164,165]. Different types of 
macromolecules (liposomes, dendrimers, poly(ethylene glycol) polymers, nanoparticles, 
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and protein biomolecules) have been used as carrier molecules [166]. There are number 
of peer-reviewed articles on albumin and drug carriers and number of citation has 
essentially doubled from -250 to -500 citations between 2002 and 2010 (Figure 27) 
[167]. 
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Figure 27. Literature survey — impact of albumin on drug delivery: number of citations 
in PubMed combining the key word "albumin " with " drug carrier" from 1970 to 2010 
dis-playedas 2-year intervals. 
The interactions of drugs with protein results in the formation of a stable drug-protein 
complex, which can exert important effect on the distribution, free concentration and 
metabolism of the drug in the blood stream [168]. Therefore, drug binding to proteins 
such as HSA has become an important determinant of pharmacokinetics, restricting the 
unbound concentration and affecting distribution and elimination [169]. Although the 
unbound drug is regarded as the therapeutically active fraction that exerts its effect on 
the molecular target within cells and tissues-are three fold: (i) The half-life, clearance 
and tissue distribution of the vast majority of low-molecular weight drugs are so fast (in 
the order of minutes or at the most a few hours) that the fraction of the drug that is 
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actually protein-bound in the plasma is very small or sometimes negligible; (ii) The 
binding constants of the drug for albumin are generally low (Kd<10*M) so the drug 
displays a very rapid phannacokinetio-ijharmacodynamic equilibration time; (iii) As a 
consequence, protein-binding of a drug measured in an isolated non-dynamic system 
outside of the body can but often does not correlate with other pharmacokinetic 
parameters such as plasma half-life, clearance, area under the curve (AUC), or volume of 
distribution [170]. 
Due to the susceptibility of then^utic peptides to degradation by peptidases, lack of 
bioavailability and distribution to the target site, recent efforts have concentrated on 
improving their pharmacokinetic profile making use of albumin binding strategies. HSA 
has proved as an attractive molecular carrier due to its non-4oxic, non-immunogenicity 
and availability in pure form. Chlorambucil, Paclitaxel conjugated to HSA exhibited 
cytotoxicity comparable to that of parent drugs in vitro but are less toxic in vivo [171]. 
Similarly conjugate RAPTA ([Ru°(Ti6-areneXpta)Cl2]) moieties were developed with 
carrier protein molecules such as rHSA for passive drug targeting [172]. 
Many drugs and other small bioactive molecules bind reversibly to albumin and other 
serum components that then function as carriers. Serum albumin often increases the 
apparent solubility of hydrophobic drug in plasma and modulate their delivery to cells in 
vitro and in vivo. The subsequent increase of the concentration of released drug may lead 
to serious drug-drug interaction. Therefore, a very high affinity to HSA is undesirable in 
potential drugs. Thus studying the binding phenomena will be important in providing 
basic information on the pharmacological actions, bio-transformation, and bio-
distribution, etc. The interactions between plasma proteins and drug molecules such as 
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daunorubicin [173], 5-fluorouracil [174] have been explored by means of fluorescence 
spectra, UV spectra and CD spectra [175]. 
In recent years, novel methods such as fluorescence spectroscopy, UV-vis 
spectrophotometry, circular dichroism (CD) spectroscopy, Raman spectroscopy, nuclear 
magnetic resonance (NMR), electrochemistry, equilibrium dialysis, attenuated total 
reflectance-J'ourier transform infrared (ATR-FT-IR), resonance light scattering (RLS), 
capillary electrophoresis, high-performance liquid chromatography and 
chemiluminescence [176-180] have been developed m tiie study of interactions between 
small molecules and HSA. Measurement of quenching of albumin's natural fluorescence 
is an unportant method to study its interaction witii substances because of its high 
sensitivity, rapidity and ease of implementation. 
Chen et al has explored the binding of antineoplastic drug oxaliplatin (Figure 28A) with 
HSA by the fluorescence quenching method [181]. 
(A) (B) 
Figure 28. (A) Molecular structure of oxaliplatin and (B) Fluorescence spectra of HSA 
with various concentrations of oxaliplatin at 298 K (pH 7.40). (a) 3.0 piM HSA and 
(b)-(i) 3.0 nM HSA in the presence of 3.33, 6.67, 10.0, 13.33, 16.67, 20.0, 23.33, and 
26.67X 10~' Moxaliplatin: (j) 3.32 fiMoxaliplatin. 
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Fluorescence spectroscopy is a powerful method to study molecular interactions 
involving proteins. By measuring the intrinsic fluorescence quenching of HSA, the 
accessibility of quenchers to the fluorophore groups of HSA can be estimated. As shown 
in Figure 28B, there was no fluorescence emission for oxaliplatin at the range measured 
and the fluorescence intensity of HSA decreased gradually with the increase of 
oxaliplatin concentration without changing the emission maximum and shape of the 
peaks. These results indicated that there were interactions between oxaliplatin and HSA 
[182]. The fluorescence quenching effect was due to the formation of non-fluorescent 
complexes [183]. 
The circular dichroism spectroscopy is an important tool to understand the binding of 
drug to HSA. The CD spectra of HSA exhibit two negative bands at 208 and 222 nm, 
which are characteristic features of a-helical structure of proteins [184]. As evident from 
Figure 29, the band intensities of HSA at 208 and 222 nm decreased with negative cotton 
effect by the binding of oxaliplatin without causing any significant shift of the peaks, 
which indicated the considerable changes in the protem secondary structure. The a-
helical content of HSA decreased while the increase of the disorder structure content in 
the HSA [185]. The a-helical content of HSA was calculated and the results exhibited a 
reduction of a-helical structures from 57.53 to 52.76 at a molar ratio of HSA to 
oxaliplatin 1:2. 
32 
Wavalength (nm) 
F^ure 29. CD spectra of the HSA-oxaliplatin system, (a) 3.0 /iM HSA in Tris-HCl 
buffer and (b) 3.0 fiMHSA in the presence of 6.0 fiMoxdiplatin. 
The FT-IR specfra of free HSA and oxaliplatin-bound form of HSA with its difference 
absorption spectrum (Figure 30). The spectrum in Figure 30a was obtained by subtracting 
the absorption of the Tris-HCl from the spectrum of the protein solution. The spectrum in 
Figure 30a was obtained by subtracting the absorption of the oxaliplatin-free form from 
that of tfie oxaliplatin-bound form. Infitired spectra of proteins exhibited a number of the 
amide bands, which represent different vibrations of the peptide moiety. Among these 
amide bands of the protein, the protein amide I in the region 1600-1700 cm'' (mainly 
C=0 stretch) and amide II band in the region 1500-1600 cm"' (C-N stretch couple with 
N-H bendmg mode) both have a relationship with the secondary structure of protein, and 
the amide II band absorbance intoisity has been reported to be proportional to the amount 
of protein absorbed, and is believed not to be very sensitive to the conformation of the 
protein [186]. 
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Figure 30. FT-IR spectra and different spectra o/HSA: (a) FT-IR spectrum ofHSA in 
Tris-HCl buffer (pH 7.40) and (b) FT-IR difference spectrum of HSA obtained by 
subtracting the spectrum of the oxaliplatin-firee form from that of the oxaliplatin-bound 
form in the region of 1800-130 0 cm~\ [HSA] = 3.0 ^ 10~^ M, [oxdiplatin] = 6.0 ^ 
10~'M,pH 7.40, T =298 K. 
As shown in Figure 30, tlie peak position of amide I a band has changed from 1650.79 to 
1652.72 cm~\ which indicated that the secondary structure of the protein has been 
changed after oxaliplatin was added. These results also indicated that oxaliplatin 
interacted with the C=0 and C-N groups in the protein polypeptides. The HSA-
oxaliplatin complexes caused the rearrangement of the polypeptide carbonyl hydrogen 
bonding netwoik and finally the reduction of the protein a-4ielical structure. 
Fluorescence resonance energy transfer (FRET) is useful for measuring the distance 
between the donor fluorophore and acceptor in vitro and in vivo [187]. Seetharamappa et 
al monitored the distance r between donor (Trp-214) and acceptor carbamazepine (Figure 
31A) according to (FRET) [188]. 
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Figure 31. (A) Structure of carhamazepine (CBZ) and (B) The overlap of fluorescence 
emission spectrum ofHSA (a) with the UV absorption spectrum of CBZ and (b) [CBZ] = 
[HSAJ = 5ftM. 
It is a non-destructive spectroscopic method that can be employed to monitor the 
proximity and relative angular orientation of the donor and acceptor. Transfer of energy 
may take place through a direct electrodynamic interaction between the primarily excited 
molecule and its neighbors [189]. As shown in Figure 3IB, the overlap of the 
fluorescence spectrum of HSA with the absorption spectrum of carhamazepine (CBZ). 
Electronic absorption spectroscopy is a reliable tool to understand the morphological 
changes in secondary structure of HSA via complex formation between drug and HSA. 
The UV absorption spectra of CBZ, HSA and CBZ-HSA are shown in Figure 32. The 
absorbance of HSA increased regularly with increase in the concentration of CBZ. 
Moreover, the maximum peak position of CBZ-HSA was observed to be shifted slightly 
towards higher wavelength region. 
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F^ure 32. UV-vis absorption spectra of 5 fiM HSA (1) in presence of increasing 
concentration ofCBZ (1) 0, (2) 5, (3) 10, (4) 15 and (5) 20fiM. (a) Indicates 5 /iM of 
CBZonly. 
This change in Xmtx indicated the change in polarity around the tryptophan residue and 
the change in peptide strand of HSA molecules and hence the change in hydrophobicity. 
This indicated that the binding between carbamazepine and HSA molecule has led to 
changes in protein conformation [190]. 
The 3D fluorescence spectroscopy is a newly emerged analytical technique that can 
provide more detailed information about the conformational changes of proteins. One of 
the example illustrating the interaction of PPB (l-Picolyl-lH-benzo[d]imidazole) with 
HSA was reported by Zhuo et al [191]. As shown in figure 33, the fluorescence intensity 
of peak a increased with the addition of PPB. This is due to the formation PPB-HSA 
when PPB was added. The fluorescence intensity of peak b decreased maikedly and the 
maximum emission wavelength of the peak was changed following the addition of PPB. 
Peak c was the second-ordered scattering peak (A«n=2X«x). Analyzing from the intensity 
changes of peak a and peak b revealed that the binding of PPB to HSA induced some 
conformational and micro-environmental changes in HSA [192,193]. 
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Figure 33. Three-dimensional fluorescence spectra of HSA (A) and HSA-PPB system 
(B).C(HSA): (A)3fiM, (B) 3 nM; C(PPB): (A) 0, (B) 6 nM. 
Table 2. 3D Fluorescence Spectral Parameters of HSA in the Absence and Presents of 
PPB 
Peak 
HSA HSA-PPB 
Peak position 
X^IXaa (nm/nm) AX.(nm) Intensity 
Peak position 
X /^XOT (nm/nm) AX(nm) Intensity 
Peah a 250/250-360/360 0 59.40-999.13 250/250-360/360 0 6852-999.78 
Peakb 280/334 58 628.232 280/338 54 600.174 
There is a considerable interest in the development of synthetic chemical proteases that 
are activated by radical—generating metal complex [194,195]. Such chemical proteases 
can be utilized for breaking large proteins into smaller fragments that are more amenable 
to sequencing. One of the examples illustrated by Ferreira et al [196], in which the 
copper(II) complexes (Figure 34) were incubated with HSA for 30 min at 37 °C, 
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exhibited ejrtensive carbonyl group formation, only in the case of complex 
[Cu(isaepy)2] +2 
, - 1 2 * 
|Cu(ISMpy)H201* 
- | 2 + 
[CuOM«py)2f* 
a 
[Cu(«nlm>H20p* 
3 
Cu 
d 
•-N?*? 
- J 2 * 
* - N H 
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4 5 
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F^ure 34. Structures of the studied copper(II) complexes with oxindoleSchiff base 
ligands. 
However, in the presence of hydrogen peroxicte all the c(Mnplexes exhibited an increased 
level of protein oxidation (Figure 35a), depending on the ligand, in the order: 
[Cu(isaepy)2]^* » [CuCisapn)]^ ^ > [Cu(isaepy)H20]* ~ [Cu(isaenim)]^^ > 
[Cu(enim)H20]^^> [Cu(H20)4f *. 
|H8A]-7S|iM 
| C I I L ] - 7 S M M (H OJ . 790 iiM CZI IOKH.O) / ' 
••[Cii(lM^>y)H.or 
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Figure 35. (a) Carbonyl group formation in HSA protein (75 fiM) after incubation with 
copper(II) complexes (75 fiM), in the absence and in the presence ofH^2 (750 fiM), for 
30 min, at 37 °C and (b) SDS-PAGE showing HSA fragmentation treated with H202,in 
phosphate buffer 50 mM, pH 7.4. Lane I: HSA; Lane 2: HSA + [Cu(H20)4f^; Lane 3: 
HSA+ [Cu(isapn)f^; Lane4: HSA + fCu(isaepy)H20j\- Lane 5: HSA+ fCu(isaepy)2] ^\-
Lane 6: HSA +[Cu(enim)H20f*; Lane 7: HSA + [Cu(isaenim)f\ 
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Present Work 
To explore the biological activities including antioxidant, DNA binding, topoisomerase-I 
inhibition and cytotoxicity, new metallopeptide based dinuclear copper(II) complex 
[Cu2(glygly)2(ppz)(H20)4]-2H20 derived fix)m glycyl glycme anion (glygly) and 
piperazine (ppz) was synthesized by employing de novo synthetic strategy which was 
thoroughly characterized by spectroscopic (IR, EPR, UV-vis, ESI-MS) and analytical 
methods. The structural elucidation of the complex was done by elemental analysis, 
spectroscopic methods and single crystal X-nay diffraction. The ligand scaffold was 
designed to modulate the toxicity, intrinsic resistance &ctors that exist in present cancer 
drugs. The single crystal X-ray analysis revealed the complex crystallizes as monoclinic 
crystal system with space group P21/c and contains two six coordinated Cu(II) centers 
bridged by piperazine ligand, which adopted a chair-sh^)e conformation at the equatorial 
site. The interaction with CT DNA in Tris -^HCl buffer was studied by various biophysical 
methods viz., electronic absorption titrations fluorescence and circular dichroism. DNA 
cleavage activity employing agarose gel electrophoresis was also carried out examine the 
scission activity of the complex. A plasmid DNA cleavage assay was used to investigate 
the effect of complex on the activity of human Topo I by agarose gel electrophoresis. 
Superoxide dismutase activity of the complex was assayed by using its ability to inhibit 
the reduction of nitroblue tetrazolium, NBT, at 560 ran by superoxide ions produced by 
the xanthine-xanthine oxidase system. In vitro antitumor activity of the complex was 
screened against 9 different human carcinoma cell of different histological origin. The 
molecular docking technique was also utilized to ascertain the mechanism and mode of 
action towards the molecular target DNA and enzymes. Understanding the Topo 1 
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inhibitory activity and DNA binding modes viz.; covalent or non-covalent plays a 
pronounced influence on the efficacy of a drug or chemical entity as a potential drug. 
However, the efficient pass^es of drugs into cells remain a major hurdle in anticancer 
drug delivery to the molecular target. In this regard, the interaction studies of complex 
with HSA were performed to elucidate tfie mechanism and mode of action at the 
molecular target. The mteraction between complex and HSA was investigated by 
employmg different spectroscopic techniques (UV-vis, fluorescence, CD, FTIR and 3I>-
fluorescence measurements) in accordance with molecular docking technique. Photo-
induced degradation of HSA was carried out by employing SDS-PAGE analysis with 
increasing concentrations of complex. This woric embodies tiie design of new specific 
target metallopeptide drug as potential chemotherapeutic agent via topoisomerase-I 
inhibition, also providing additional information about their possibilities of transport and 
disposition in blood plasma and contribute to the molecular design of novel synthetic 
protem photo-degradation agents. In an another attempt, complexes 
[Zn(glygly)(ssz)(H20)].6H20 and [Cu(glygly)(sszXH20)].6H20 were synthesized by 
reacting glycyl glycine anion (glygly) and sulfasalazine (ssz) followed drop wise addition 
of KOH. These complexes were thoroughly characterized by various spectroscopic 
techniques viz., IR, UV-vis, 'H , '^C, NMR, EPR and elemental analysis and XRPD 
measurement. The interaction of Zn(II) complex with CT DNA was carried out by 
employing various biophysical methods such as UV-vis absorption, fluorescence and CD 
spectroscopy and molecular docking technique. A concentration dependent cleavage 
activity with pBR322 DNA was carried out by using agarose gel electrophoresis 
experiments in order to determine the mechanistic pathway for DNA cleavage. On the 
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other hand, interaction of Cu(II) complex with HSA was carried out by employing 
fluorescence, CD and FTIR measurement in accord with molecular docking technique. 
A new series of transition metal complexes [Cu2(bipy)2(im)2(pip)(N03)2].2N03, 
[Zn2(bipy)2(im)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl were synthesized to modulate 
the therapeutic profile to overcome inherent resistance and exhibit fewer side effects. In 
vitro DNA binding studies of all complexes were carried out to evaluate binding 
propensity towards DNA which demonstrate that [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
binds more avidly and readily to DNA in comparison to [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl complexes. To gain further insight into the molecular 
recognition at the target site, UV-vis titrations of complex [Zn2(bipy)2(im)2(pip)].4Cl 
with 5'-TMP and5'-GMP was carried out and validated by ' H and ^'P NMR. The DNA 
cleavage and SOD activity was measured for complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03. 
New bis-^nacrocyclic complexes [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] derived from 
Schiff base (L) of salicylaldehyde and 5-aminosalicylic acid and further reacted with the 
linker-ligand 1,2-dibromo-ethane. The proposed structures of these dinuclear complexes 
were consistent with the data obtained from elemental analysis, molar conductance, IR, 
EPR, UV-vis, ESI-MS, 'H , '^C and '"Sn NMR spectroscopy and XRPD measurement 
confirm its crystalline nature. The interaction studies of the complexes with CT DNA 
were carried out by using UV-vis absorption, emission, CD and NMR ( 'H and ^'P) 
spectroscopy. DNA cleavage studies of complex [Cu2(L)2] was carried out in absence and 
presence of external agents (activators, radical scavengers and groove binders). 
CHAPTER II 
Experimental 
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1. Materials 
Zn(N03)2.6H20, CUCI2.2H2O and ZnCl2.(anhydrous) (Ranketn), NiCb.eHaCXBDH), 
SnCU.5H20 (Lancaster), Cu(N03)2.3H20 (Fisher Scientific), Glycylglycine (Loba 
chemie), Saiicylaldhyde (Alfa Aesar), 1,2 dibromoethane and 1,10-Phenanthroline 
(merck), 5-aminosalcylic acid (Fluka), Sulfasalazine, Piperazine hexahydrate, 2,2'-
Bipyridyl, imdazole and Human Serum Albumin (fatty acid free, 99%) were purchased 
ftom Sigma, Tris(hydroxymethyl)aminomethane or Tris Buffer, Calf thymus DNA (CT 
DNA), Guanosine 5'-monophosphate disodium salt (5'-GMP) and Thymidine 5 -
monophosphate (5-TMP) were purchased from Fluka and were stored at -20 °C. 6X 
loading dye (Fermental Life Science), Agarose, Ascorbic acid. Sodium azide (NaNs), 
DMSO, Superoxide dismutase (SOD), Methyl green, DAPI, Mercaptopropionic acid 
(MPA) (Sigma-Aldrich) and Super coiled plasmid DNA pBR322 (Genei) were utilized 
as received. SOD activity was determined by using superoxide dismutase activity kit 
II Cat.No.S74601 (Calbiochem) according to the manufacturer's protocol. All reagents 
and solvents were of the best commercial grade and were used without further 
purification. 
2. Characterization techniqaes 
2.1 Infrared spectroscopy 
Infi«-red spectra of the ligands and complexes were recorded as KBr pellets on Interspec 
2020 FTIR spectrometer. The formation of the ligands and complexes behavior has been 
ascertained by scanning their infixed spectra in 4000-400 cm"'. 
2.2 Ultraviolet and visible spectroscopy 
The electronic spectral studies of metal complexes provide useful information about the 
stereochemistry, oxidation state of the metal ion and in suitable circumstances, the nature 
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of metaMigand bond. Electronic spectra were recorded on UV-1700 PharmaSpec UV-
vis spectrophotometer (Shimadzu). Data were reported in Ainax/nm. 
23 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The 
NMR spectroscopy is concerned with nuclei having nuclear spin quantum number I = 
1/2, example of which include 'H, ^^C, ^'P and ''^Sn. 
For a nucleus with 1=1/2, there are two values for the nuclear spin angular momentum 
quantum number mi = ±1/2 which are degenerate in the absence of a magnetic field. 
However, in the presence of the magnetic field, this degeneracy is destroyed such that the 
positive value of mi corresponds to the lower energy state and negative value to higher 
energy state separated by AE. 
In an NMR experiment, one applies strong homogeneous magnetic field causing the 
nuclei to presses. Radiation of energy comparable to AE is then imposed with radio 
frequency transmitter equal to precision or Larmor frequency and the two are said to be 
in resonance. The energy can be transferred fix)m the source to the sample. The NMR 
signal is obtained when a nucleus is excited from low energy to high energy state. 
The 'H , '^C and "'Sn NMR spectra were obtained on a Bruker DRX-400 spectrometer at 
400 MHz, respectively operating at room temperature. Chemical shifts were reported on 
the 5 scale in parts per million (ppm). 
2.4 Electron paramagnetic resonance spectroscopy 
Electron paramagnetic resonance (EPR) spectra of the Cu(II) complexes were obtained 
on a Varian E 112 EPR spectrometer usmg tetracyanoethylene (TCNE) as field marker. 
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The spectra were recorded for solid and solutions of the complexes in appropriate 
solvents at room temperature (RT) as well as at liquid nitrogen temperature (LNT). 
2.5 Mass spectroscopy 
Mass spectrometry is one of the most accurate microanalytical technique which requires 
only a few nano moles of the sample to obtain characteristic information regarding the 
molecular mass and to detect within a molecule the places at which it prefers to fragment 
from which the presence of recognizable group within the molecule can be deduced. 
Mass spectrometry is complementary to FT IR, NMR, UV-vis and EPR spectral 
techniques for structural identification of compounds. 
ESI mass spectra is relatively routine technique for mass spectrometric analysis of 
inorganic and organometallic compounds whether charged or neutral but involves 
complication by redox, fragmentation and clustering processes in the study of metal 
complexes. ESI mass spectra were recorded on a Micromass Quattro II triple quadrupol 
mass spectrometer. 
2.6 C, H, N and S elemental Analyzer 
Carbon, hydrogen and nitrogen contents were determined using Carlo Erba Analyzer 
Model 1106. The visualization of spots on TLC plates was effected by exposure to iodine 
or spraying with 10% H2SO4 and charring and single spots of the products were observed 
which were different from those of the starting materials. 
2.7 X-ray powder diffraction analysis (XRPD) 
To obtain fiirther evidence about the structure of the metal complexes. X-ray diffraction 
studies were performed on Rigaku Mini Flex II Instrument. 
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2.8 Single crystal X-ray crystallography 
Single crystal X-ray structural studies of complex was performed on a Bruker SMART 
instrument equipped with CCD-based detector at 298 K using graphite monochromated 
Mo Ka radiation (X= 0.71073 A) [197]. Data collections and their refinement were 
evaluated by using the Bruker SMART software. The collected data were reduced by 
using the program SAINT, [198] and empirical absorption corrections were done usmg 
the SADABS [199]. The structure was solved by direct methods and refined with the 
fiill-<natrix least squads techniques using SHELX-97 [200]. The positions of all atoms 
were obtained by direct methods. Anisotropic thermal parameter were assigned to all 
non-hydrogen atoms and the remaining hydrogen atoms were placed in geometrically 
constrained position and refined as riding atoms witii a common fixed isotropic thermal 
parameter. 0RTEP3 [201] was used to produce gn^hicai representation. 
2.9. CoBdnctance measorements 
The conductivity measurement is one of the simplest and easily available techniques used 
to study the nature of the complexes. It gives direct information regarding whether a 
given compound is ionic or covalent. For this purpose, the measurement of molar 
conductance (Am), which is related to the conductance value in the following manner is 
made. 
cell constant x conductance 
A. = (1) 
concentration of solute expressed in mol cm~^ 
Conventionally, solutions of 1 x 10"^  M strength are used for the conductance 
measurements. Molar conductances were measured at room temperature on a Digsun 
Electronic conductivity Bridge. 
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2.10. Thermal gravimetric analysis (TGA) 
TGA was performed with a universal V3.8 B TA SDT Q600 Build 51 Thermal Analyzer 
under nitrogen atmosphere using alumina powder as reference material. The final 
thermolysis product of metal complex as metal oxides was studied. 
3. DNA and HSA binding studies 
All the experiments involving interaction of the complexes with CT DNA were 
conducted in buffer containing Tris(hydroxymethyl)aminomethane or Tris Buffer (0.01 
M) adjusted to pH 7.2 with 4M hydrochloric acid. The CT DNA was dissolved in Tris 
HCl buffer and was dialyzed against the same buffer overnight. Solutions of CT DNA 
gave ratios of UV absorbance at 260 and 280 nm above 1.9:1, indicating that the DNA 
was sufficiently free of protein [202]. DNA concentration per nucleotide was determined 
by absorption spectroscopy using the molar absorption coefficient 6600 dm^ moP' cm"' at 
260 nm [203]. The stock sohition was stored at 4 °C. 
Human serum albumin of 1x10"^ M was prepared by dissolving protein in Tris-HCI 
buffer solution at pH 7.4. The protein concentration was determined 
spectrophotometrically using an extinction coefficient of 35219 M"' cm"' at 280 nm 
[204]. Stock solution of complex (1x10"^ M) was prepared by dissolving complex in 
doubly distilled water. NaCl (analytical grade, IM) solution was used to maintain the 
ionic strength of buffer at O.IM, pH was adjusted to 7.4 by using HCl. Working st^idard 
solution was obtained by appropriate dilution of the stock solution. 
3.1 Absorption spectral studies 
3.1.1 Absorption spectral studies for DNA 
These absorption spectral studies were performed on Shimadzu UV-1700 PharmaSpec 
UV-vis spectrophotometers. The intrinsic binding constant Kb of the complex to CT 
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DNA was determined from equation (2), through a plot of PNA]/ ea-er vs [DNA], where 
[DNA] represents the concentration of DNA, and £», Sf and Eb the apparent extinction 
coefficient (Aobs/[M]), the extinction coefficient for free metal complex (M), and the 
extinction coefficient for the free metal complex (M) in the fully bound form, 
respectively. In plots of pNAJ/eg-Cf vs. [DNA], Kb is given by the ratio of slope to 
intercept [205]. 
[DNA] _ [DNA] ^ 1 ^2) 
Absorption spectral titration experiments were performed by maintaining a constant 
concentration of die complex and varying the nucleic acid/nucleotide concentration. This 
was achieved by diluting an appropriate amount of the metal complex solutions and CT 
DNA/5'-GMP, 5'-TMP stock solutions while maintaining the total volume constant. This 
results in a series of solutions with varying concentrations of CT DNA/S'-GMP/S'-TMP 
but at constant concenfration of the complex. The absorbance (A) was recorded after 
successive additions of CT DNA/5'-GMP/5-TMP. While measuring the absorption 
spectra an equal amount of CT DNA/5'-GMP/5-TMP was added to both the compound 
solution and the reference solution to eliminate the absorbance of the CT DNA/S'-
GMP/S'-TMP itself. 
3.1.2 Absorption spectral studies for HSA 
The intrinsic binding constant Kb of the complex to HSA was determined from equation 
(3), through a plot of 1/A-Ao vs. 1/ Ccompiex, where A© and A are the absorbance of HSA 
at 280 nm, in the absence and presence of complex, respectively, EHSA and SB are the 
molar extinction coefficient of HSA and the bound complex, respectively. 
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^o ^ ^HSA ^ ^HSA . ^ , - , 
^~-^o ^B ^B^b ^complex 
The double reciprocal plot of 1/A-Ao vs. 1/ Ccompiex is linear and binding constant can be 
estimated from the ratio of intercept to the slope [206]. 
3.2 Fluorescence spectral studies 
3.2.1 Fluorescence spectral studies for DNA 
Emission intensity measurements were carried out using Hitachi F-2500 
spectrofluorometer in a 1 cm path-length quartz cell. The emission spectrum is obtained 
by setting the excitation monochromator at the maxunum excitation wavelength and 
scanning with emission monochromator. Often an excitation spectrum is first made in 
order to confirm the identity of the substance and to select the optimum excitation 
wavelength. Further experiments were carried out to gain support for the mode of binding 
of complexes with CT DNA. 
Non-fluorescent or weakly fluorescent compounds can often be reacted with strong 
fluorophores enabling them to be determined quantitatively. On this basis molecular 
fluorophore EthBr was used whidi emits fluorescence in presence of CT DNA due to its 
strong intercalation. Quenching of the fluorescence of EthBr bound to DNA were 
measured with increasing amount of metal complexes as a second molecule and Stem-
Volmer quenching constant K was obtained from the following equation (4) [207]: 
Ic/I=l+Kr (4) 
where r is the ratio of total concentration of complex to that of DNA and lo and 1 are the 
fluorescence intensities of EthBr in the absence and presence of complex. 
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Binding constant K of the metal complexes was also determined from Scatchard 
equations (3) and (4) by employing emission titration [208,209]: 
CF = CT(I/IO-P)(1-P) (5) 
r/CF = K(n-r) (6) 
where Cp is the free probe concentration, CT is the total concentration of the probe added. 
I and loare fluorescence intensities in presence and absence of CT DNA, respectively and 
P is the ratio of the observed fluorescence quantum yield of the bound probe to that of the 
free probe. The value P was obtained as the intercept by extrapolating from a plot of I/lo 
vs 1/pNA], r denotes ratio of CB (=Cr-CF) to the DNA concentration i.e., the bound 
probe concentration to the DNA concentration, K is the binding constant and CF, is the 
free metal complex concentration and "n" is the binding site niimber. Emission intensity 
measurements were carried out using Hitachi F-2500 spectrofluorometer at room 
temperature. 
3.2.1 Fluorescence spectral studies for HSA 
Fluorescence measurements were carried out on Hitachi F-2500 fluorescence 
spectrophotometer in a 1 cm path-length quartz cell with the excitation and emission 
wavelength set at 280 and 300-400 nm, respectively. The intensity at 350 nm 
(Tryptophan) was used to calculate the binding constant (K). The fluorescence quenching 
of HSA at different temperatures (299, 308 and 318 K) were determined using the Stem-
Volmer equation (7) [210]: 
y = l + V<.[e] = l+^5K[e] (7) 
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where Fo and F are the fluorescence intensities in absence and presence of quencher, 
respectively, [Q] is the quencher concentration, and Kgv Stem-Volmer quenching 
constant, which can be written as 
^ = ^ ^ (8) 
where K<, is the biomolecular quenching rate constant and to is the average lifetime of the 
fluorophore (Trp-214) in absence of quencher and its value is around 10"* s for most 
biomolecules [211]. Therefore, Equation (7) was applied to determine Ksv by linear 
regression of a plot of FQ/F VS [Q]. 
CalculatioB of binding constant 
The binding constant was calculated from the modified Stem-Vohner equation (Equation 
(9)): 
' . = -L.JL±l (9) 
[F„-F] F^ K,F„Q 
where Kb is the binding constant of complex with biomolecule which was calculated 
from the intercept and slope of slopes of the Lineweaver-Buric (l/(Fo-F) versus 1/[Q]) 
(intercept = 1/Fo, slope = 1/KbFo, so Kb = intercept/slope). Furthermore, the binding 
constant (K) and number of bound complex to HSA (n) were determined by plotting the 
double log graph of the fluorescence data using (Equation (10)): 
F-F' 
log = logA' + nlog[e] (10) 
F 
Determination of tiiermodynamic parameters 
The thermodynamic parameters were calculated from the van't HofT equation (Equation 
(11)): 
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\nK = + — (11) 
RT R 
where K is the Lineweaver-Burit static quenching constant at corresponding temperature 
and R is the gas constant, in which AH and AS of reaction was determined fix)m the linear 
relationship between In K and the reciprocal absolute temperature. Furthermore, the free 
energy change (AG) was calculated by the equation (12): 
AG = AH-T/SS = -RTlnK (12) 
Calculations of energy transfer 
According to Foster resoiuince energy transfer (FRET), the efficiency of energy transfer 
(E) is given by [212]: 
E = l-—= f° ^ (13) 
where F and Fo are the fluorescence intensities of HSA in the presence and absence of 
quencher, r is the distance between acceptor and donor and Ro is the critical distance 
when the transfer efficiency is 50%. The value of Ro was calculated using the equation 
(14): 
i?/ = SJixlQ-" k^ir*^ (14) 
where k^  is spatial orientation factor between the emission dipole of the donor and the 
absorption dipole of acceptor, N is the refractive index of the medium, (J) is the 
fluorescence quantum yield of the donor and J is the overlap integral of the fluorescence 
emission spectrum of the donor and the absorption spectrum of the acceptor and 
calculated by equation (IS): 
r_I.FiJl)eiA)A*AJi 
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where ¥(X) is the corrected fluorescence intensity of the donor at wavelength X and E(X,) is 
the molar absorption coefficient of the acceptor at wavelength X. Under the experimental 
condition, the value of K^  =2/3, N =1.336, and (|) = 0.188 [213]. 
3 J Circular dichroism (CD) and Fonrier Transfomi Infrared (FUR) 
measurements. 
CD spectra were measured on Jasco J-815-CD spectropolarimeter (Jasco, Japan) at room 
temperature using a 1 cm quartz cuvette. Measurements were taken at wavelengths 
between 200 and 250 nm. All observed CD spectra were baseline subtracted for buffer 
and the CD results were expressed in terms of MRE (mean residue ellipsticity) in deg 
cm^ d mor' as Eq. (16): 
ObservedCDimdegj 
MRE = C^nlxlO 
(16) 
where Cp is the molar concentration of the protein, n the number of amino acid residues 
(585) and / the path length (0.1 cm). The a-4ielical contents of free and combined HSA 
were calculated from the N4RE value at 208 nm using the Eq. (17) as described by Basu 
etal[214]: 
a-Ae/cc(%) = -(AiR£)^o,-4000 
33000-4000 
xlOO (17) 
where MRE208 is the observed MRE value at 208 nm, 4000 is the MRE of the p-form and 
random coil conformation cross at 208 tmi, and 33000 is the MRE value of a pure a-4ieiix 
at 208 nm. 
Fourier Transform Infrared measurements carried out on an Interspec 2020 FTIR 
spectrometers were recorded in liquid phase in 400-4000 cm"' range. 
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3.4 Three-dimensional (3D) fluorescence spectral studies 
Three-dimensional fluorescence spectroscopy is a vigorous method for providing 
confonnati<»ial and structural information of proteins. The outstanding advantage of 
three-dimensional fluorescence spectra is that the information regarding the 
fluorescence characteristics can be entirely acquired by simultaneously changing the 
excitation and emission wavelengths. The maximum emission wavelength and the 
fluorescence intensity of the residues have a close relation to the polarity of their 
micro-environment [215]. 3D-Fluorescence measiirements were performed on an FL-
4500 spectrofluorophotometer (Jeqian) under the following conditions: the emission 
wavelength scan range was recorded between 240 nm and 600 nm, the excitation 
wavelength scan range was recorded from 240 to 360 nm at 10 nm increments and other 
scanning parameters were just the same as the fluorescence quenching spectra. 
4. Gel electrophoresis (Cleavage Studies DNA & HSA) 
Cleavage experiments were performed with the help of Axygen electrophoresis supported 
by Genei power supply with a potential range of 50-500 Volts, visualized and 
photographed by Vilber-E^IFINITY gel documentation system. 
4.1. Agarose-Gel Electrophoresis of DNA 
The cleavage experiments of supercoiled pBR322 DNA (300 ng) in (5mM Tris-HCl, 50 
mM NaCl), buffer at pH 7.4 was carried out using agarose gel electrophoresis. The 
samples were incubated for 1 hour at 37 °C. A loading buffer containing 25% 
bromophenol blue, 0.25% xylene cyanol, 30% glycerol was added and electrophoresis 
was carried out at 60 V for Ihour in Tris-HCl buffer using 1% agarose gel containing 1.0 
Hg/mL ethidium bromide. The DNA cleavage with added reductant was monitored as in 
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case of cleavage experiment without added reductant using agarose gel electrophoresis. 
The reaction were also monitored upon addition of various radical inhibitors such as 
sodium azide (NaNs), DMSO, superoxide dismutase (SOD), distamycin, methyl green 
and mercaptopropionic acid (MPA). The samples were incubated for 45 minutes at 37 "C. 
The gel was visualized by photogrq)hing the fluorescence of intercalated ethidium 
bromide under a UV illuminator. The cleavage efficiency was measured by determining 
the ability of the complex to convert the supercoiled DNA (SC) to nicked circular form 
(NC) and linear form (LC). 
4.2. SDS-PAGE (sodinm dodecyl sulfate potyacrylamide gel electrophoresis) of HSA 
Photo-induced protein cleavage experiments were performed following to the standard 
methods and practices previously adopted by Kumar and co-workers. [216]. The photo-
induced protein cleavage studies were carried out using freshly prepared solution of HSA 
in 50 mM Tris-HCl buffer (pH 7.4). The protein solutions (15 \iM) containing complex 
with increasing concentrations 100 to 250 nM were photo-irradiated at 365 nm for 20 
min after 45 min incubation at 37 °C followed by SDS-PAGE analysis. 
5. Topoisomerase I inhibition assay 
DNA topoisomerase I, Human (Topo I) was purchased from CALBIOCHEM and was 
used without further purification. One unit of the enzyme was defined as completely relax 
1 ng of negatively supercoiled pBR322 DNA in 30 min at 310 K under the standard assay 
conditions. The reaction mixture (30 nL) contained 35 mM Tris-HCl (pH 8.0), 72 mM 
KCl, 5 mM MgCb, 5 mM DTT, 2 mM spermidine, 0.1 mg/mL BSA, 0.25 ^g pBR322 
DNA, 2 Unit Topo I and complex sample. These reaction mixtures were incubated at 310 
K for 30 min, and the reaction was terminated by addition of 4 nL of 5X buffer solution 
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consisting of 0.25% bromophenol blue, 4.5 % SDS and 45% glycerol. The samples were 
electrophoresed through 1% agarose in TBE at 30 V for 8h. 
6. Religation experiment with T4 DNA ligase enzyme 
The DNA religation experiments were performed using T4 DNA ligase enzyme to 
support the hydrolytic mechanism of DNA cleavage by following the standard DNA 
religation protocol [217]. The complex treated with pBR322 plasmid DNA (2 mg), 
ligation buffer of 1.5 mL in lOX, T4 ligase 1 mL (2 units) and 2.5 mL of H2O were 
mixed and incubated at 4 °C for Ih. Subsequently, the samples were loaded on 1% 
agarose gel and visualized by staining with an ethidium bromide solution. 
7. In vitro antitumor studies 
The cell lines used for in vitro antitumor screening activity were, MIAPaCa-2 
(Pancreatic), MCF-7, ZR-75-1 (Breast), SiHa ( Uterine Cervix), Colo205, HCT15, 
SW620 (Colon), HOP-62, A549 (Lung), DWD (Oral), K562 (Leukemia), DU145, PC-3 
(Prostate), A498 (Renal Cell), A2780 (Ovary), T24 (Urinary Bladder), U373MG 
(Astrocytoma), HT29 (colon adenocarcinoma grade II cell line) and Hela (Epithlial 
Carcinoma). G-adriamycin, standard anticancer drug was taken as control. These human 
malignant cell lines were procured and grown in RPMI-1640 medium supplemented with 
10% Fetal Bovine Serum (FBS) and antibiotics to study growth pattern of these cells. The 
proliferation of the cells upon treatment with chemotherapy entities was determined using 
the Sulphorhodamine-B (SRB) semi-automated assay [218,219]. The dose response 
parameters such as growth inhibition 50% (GI50), total growth inhibition (TGI) and lethal 
concentration 50% (LC50) were calculated. GI50 is the concentration of drug required to 
decrease the cell growth to 50%, compared with that of the untreated cell number. TGI is 
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the concentration of drug required to decrease the cell growth to 100%, compared with 
that of the untreated cell number, during drug incubation. LC50 is the concentration of 
drug required to decrease the cell growth by 50% of the initial cell number prior to the 
drug incubation. Cells were seeded in 96 well plates at an appropriate cell density to give 
optical density in the linear range (from 0.5 to 1.8) and were incubated at 37 °C in CO2 
incubator for 24 hour. Stock solutions of the complexes were prepared as 100 mg/mL in 
DMSO and four dilutions i.e. 10 ]iL, 20 ^L, 40 ^L, 80 ^L, in triplicates were tested, each 
well receiving 90 jiL of cell suspension and 10 \iL of the drug solution. Appropriate 
positive control (adriamycin) and vehicle controls were also run. The plates with cells 
were incubated in CO2 incubator with 5% CO2 for 24 hours followed by drug addition. 
The plates were incubated further for 48 hours. Termination of experiment was done by 
gently layering the cells with 50 ^L of chilled 30% TCA (in case of adherent cells) and 
50% TCA (in case of suspension cell lines) for cell fixation and kept at 4 °C for 1 h. 
Plates were stained with 50 ]iL of 0.4% SRB for 20 minutes. The bound SRB was eluted 
by adding 100 jiL 10 mM Tris (pH 10.5) to each of the wells. The absorbance was read at 
540 nm with 690 nm as reference wavelength. All experiments were repeated 3 times. 
8. Measurement of SOD like activity 
Superoxide dismutase (SOD)-like activity was investigated using Beauchamp and 
Fridovich's method - as improved by Imanari et al [220]. This method is based on 
the inhibitory effect of SOD on the reduction of nitrobluetetrazolium (NBT) by the 
superoxide anion generated by the xanthine/xanthine oxidase system. The assay was 
carried out in the assay buffer containing 50mM Tris HCl, pH 8.0, O.lmM diethylene 
triamine penta acetic acid (DTPA) and O.lmM hypoxanthine. Radical detector consists 
of a tetrazolium salt and is diluted by assay buffer. Similarly, the solutions of SOD 
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standards and xanthine oxidase were prepared in sample buffer consisting of 50mM Tris-
HCi, pH 8.0. The complex was dissolved in its solvent and absorbance was reported for 
each set of concentrations after 15 minutes interval. Results were graphed as % inhibition 
of NBT reduction taken at various concentrations (0^M-20^M) for each complex on the 
study. ICso values are reported equivalent concentrations {]xM) to lU bovine erythrocyte 
superoxide dismutase (native SOD). 
9. Molecular docking studies 
The rigid molecular docking studies were performed by using HEX 6.1 software [221 ], 
is an interactive molecular graphics program for calculating and displaying feasible 
docking modes of a pairs of protein, enzymes and DNA molecule. Structure of the 
complexes were sketched by CHEMSKETCH (http:// www.acdlabs.com) and convert 
it into pdb format from mol. Formate by OPEN BABEL (http://  
www.vccclab.org/lab/babely). The coordinates of metal complex was taken from its 
crystal structure as a CIF file and was converted to the PDB format using Mercury 
software. The crystal structure of Uie B-DNA dodecamer d(CGCGAATTCGCG)2 
(PDB ID: IBNA), native SOD (PDB ID: ISXA), human-DNA-Topo I complex (PDB 
ID: 1SC7) and human serum albumin (PDB ID: lh9z) were downloaded from the 
protein data bank (http://www.rcsb.org./pdb). All calculations were carried out on an 
Intel Pentium 4, 2.4 GHz based machine running MS Windows XP SP2 as operating 
system. Visualization of the dodaed pose has been done by using CHIMERA 
(http://www.cgl.ucsfedu/chimera/) and PyMol (http://pymol.sourceforget.net/) 
molecular gr^hics program. 
CHAPTER III (a) 
Molecular drug design, synthesis and structure elucidation of 
new specific target peptide based metallo drug for cancer 
chemotherapy as topoisomerase I inhibitor 
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Synthesis 
Synthesis of [Cu2(slygly)2(ppz)(H20)4].2H20 
To a stirred methanolic solution (15 ml) of Cu(N03)2.3H20 (0.483g, 0.002mol) was 
added an aqueous solution of glycyl glycine (0.26g, 0.002mol) followed by drop wise 
addition of KOH (0.224g, 0.004mol) and pH of the resulting solution was adjusted 
between 8.0 - 12. This reaction mixture was stirred for ca 2 h at room temperature to 
obtain clear blue color solution. A methanolic solution (10 cm )^ of piperazine 
hexahydrate (0.194g, 0.00 Imol) was added to the above reaction mixture and stirred for 
3h. The light blue colored solid precipitate was obtained and filtered off under vacuum, 
washed thoroughly with ice cold methanol and dried in vacuo over anhydrous CaCb 
(Yield: 0.255g, 44%). Crystals suitable for X-H^ ay analysis were collected after 
recrystallization from a mixture of MeOH:H20 (95:5) after several days at room 
temperature, m.p. 205 ± 2 °C (dec.). Anal. Calc. for C12H34CU2N6O12 (%): C, 24.79; H, 
5.89; N, 14.45, Found: C, 24.64; H, 5.67; N, 14.85. Selected IR data on KBr/nujol, cm"': 
3398 v(NH2+H20); 1602 v(C=0); 1376 v(C-N); 537 (Cu-O); 415 (Cu-N). Molar 
Conductance, AM (110~^ M, H2O): 20 fi"'cm^ mol"' (Non-electrolyte). UV-vis 
absorption: (H2O, 10"* M), X^/nm (e/10^ M"' cm"'): 232 (1.50); 278 (4.70); 644 (2.50). 
Results and Discussion 
In order to enhance the specificity of the molecular recognition towards DNA helices and 
inhibition of the catalytic activity of many enzymes, new drug candidate, complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 was synthesized and characterized. The synthesis of 
new dinuclear copper(n) complex [Cu2(glygly)2(ppz)(H20)4].2H20 was achieved by 
mixing stoichiometric amounts of Cu(II) nitrate trihydrate with glycyl glycine followed 
by the reaction with piperazine hexahydrate (Scheme 1). 
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Scheme 1. Synthesis scheme of[Cu2(glygly)2(ppz)(H20)4].2H20 
The resulting complex [Cu2(glygly)2(ppz)(H20)4].2H20 is stable towards air and 
moisture and readily soluble in H2O. The complex was characterized by using elemental 
analysis, IR, UV-vis and EPR spectral studies. Molar conductance value of complex in 
H2O (1 X 10"^  M) at 25 °C suggest its non-electrolyte nature (20 fi"'cm^ mol"'). The 
formulation of the complex [Cu2(glygly)2(ppz)(H20)4].2H20 was further confirmed by 
determination of the X-ray crystal structure. 
X-ray structure of [Cu2(glygly)2(ppz)(H20)4].2H20 
The single crystal X-ray analysis reveals the complex [Cu2(glygly)2(ppz)(H20)4].2H20 
crystallizes as monoclinic crystal system with space group P2\lc. An ORTEP view of the 
complex is illustrated m Figure 36, while selected bond lengths and bond angles are listed 
in Table 4. The packing diagram in the unit cell is shown in Figure 37. The 
[Cu2(glygly)2(ppz)(H20)4].2H20 contams two six coordinated Cu(II) centers bridged by 
piperazine ligand, which adopted a chair-shi4)e conformation at the equatorial site. Both 
Cu(II) centers are in a N3O3 coordmation environment arranged in distorted octahedral 
geometries, as evidenced by all of the angles around them, which deviate from 180° and 
90** (Table 4). The coordination sites around each Cu(II) centers is achieved by the 
terminal amino nitrogen (Cu(l>-N(2), 2.063 A), the deprotonated peptide nitrogen 
(Cu(l)-N(2), 1.897 A) and one of the carboxylate oxygen (Cu(l)-0(1), 2.017 A) of the 
dipeptide and the fourth is ligated by the piperazine nitrogen (Cu(l)-N(3), 1.993 A). 
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Figure 36. ORTEP view of the [Cu2(glygly)2(ppz)(H20)4].2H20 with atom numbering 
scheme, thermal ellipsoids are drawn at 50% probability level and solvent molecules 
were omitted for clarity. 
Besides these coordinations, the axial position is occupied by two oxygen atoms, 04 and 
05 (Cu(l)-0(4), 2.381 A, Cu(l)-0(5), 2.381 A) provided by an aqua ligands. The Cu-
Nimine distances (involving sp^ N) are slightly shorter than the Cu-Namine distances 
(involving sp^ N) indicating that deprotonated nitrogen is more strongly coordinated to 
metal center than terminal amino group [222, 223]. On the other hand, the Cu-Ocaitioxyiate 
bond lengths exhibit smaller values than the Cu-0,vater- The intramolecular Cu...Cu 
distance is near 6.803 A, which is short as compared to 6.908 and 6.881 A in previously 
reported chair-piperazine-bridged Cu: complexes [224]. As a consequence of small bite 
angles of N(l)-Cu(l)-N(2) and N(l)-Cu(l)-0(1) are 82.44° and 82.38°, respectively, is 
primarily responsible for distortion from the regular octahedral geometry. Whereas, the 
angle between N(l)-Cu(l)-N(3), N(3)-Cu(lH)(l), N(3)-Cu(l)-N(2), 0(1)-Cu(l)-N(2) 
andN(l)-Cu(l)-0(4) are 173.20°, 98.77°, 95.56°, 163.48° and 92.83°, respectively. The 
stability of the complex is reinforced by the intra-molecular interligand interaction (ppz) 
N3-H3-02 (glygly) (2.079 A; Figure 37). Thus, the molecular recognition pattern 
between the Cu(ppz) chelate and the glygly ligand was featured by the cooperative effect 
of the Cu(l)—N3(ppz) coordination bond and referred as interligand H-bond. Moreover, 
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it seems clear that such intra-molecular H-bond noticeably influences the molecular 
topology [225]. 
Table 3. Crystallographic data for the complex [Cu2(glygly)2(ppz)(H20)4]-21^20  
Parameter 
CCDC No 
formula 
Fw(gmor') 
cryst syst 
space group 
a (A) 
b(A) 
c(A) 
a(deg) 
|3(deg) 
Y(deg) 
V(A3) 
Z 
Dcaic (Mg m'^) 
|ji (mm"') 
F(OOO) 
crystal size (mm) 
temp (K) 
measured reflns 
unique reflns 
6 range (deg)/ completeness (%) 
no.of data/parameters/restraints 
GoF" 
/?^[I>2a(I)] 
w7?/(all data) 
largest difF. peak/hole (e.A~ )^ 
CCDC 794697 
C12H34CU2N6O12 
581.55 
Monoclinic 
FlMc 
8.704(4) 
10.611(5) 
12.345(5) 
90 
105.085 
90 
1100(9) 
2 
1.754 
2.003 
604.0 
0.15x0.14x0.12 
298(2) 
9480 
1943 
2.42 to 25.00 
1943/172/0 
0.981 
0.0418 
0.1006 
0.478/-0.405 
"GoF is defined as (^{yv{F^ - F/)] l{n - p)f^ where n is the number of data and p is the 
number of parameters. "^ = 0^O\-\KI^'ZH^^ = E ^ ^ o ' -f^f / S ^ ^ o ' ) ' ) " ' 
Furthermore, it is believed that mode of coordination has a major influence on the 
conformational changes of a peptide molecule that influences its reactivity towards the 
receptor sites. So, complex formation plays significant role on the biological activity of 
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peptides where metal ions can be regarded as catalysts for many reactions and have been 
used for DNA selective recognition and/or cleavage. 
Table 4. Selected bond lengths (A) and angles f) for [Cu2(glygly)2(ppz)(H20)4].2H20 
Bond lengths 
Cu(l)-N(l) 
Cu(l)-N(3) 
Cu(l)-0(1) 
Cu(l)-N(2) 
Cu(l)-0(4) 
Bond Angles 
N(l)-Cu(l)-N(3) 
N(l ) -Cu( l ) -0(1) 
N(3)-Cu(l)-0(1) 
N(3)-Cu(l)-N(2) 
N(3)-Cu(l)-N(2) 
0(1)-Cu(l)-N(2) 
N(l ) -Cu(l ) -0(4) 
N(3)-Cu(l)-0(4) 
0 ( l ) -Cu( l ) -0 (4 ) 
N(2)-Cu(l)-0(4) 
(A) 
1.897(3) 
1.993(3) 
2.017(3) 
2.063(3) 
2.381(4) 
(°) 
173.20(15) 
82.38(13) 
98.77(13) 
82.44(15) 
95.56(15) 
163.48(13) 
92.83(14) 
93.89(14) 
89.36(15) 
97.85(17) 
Figure 37. The Packing diagram of [Cu(glygly)2(ppz)(H20)4].2H20, showing 0-H 
interactions. 
63 
Spectroscopic studies 
Infrared spectra 
The assignment of the IR bands of complex [Cu2(glygly)2(ppzXH20)4].2H20 was carried 
out in comparison to the IR spectra of the free dipeptide. The formation of complex was 
evidenced by the q)pearance of characteristic absorption bands at 3100-2950 cm"', 
1625-1600 cm"\ 1585-1550 cm"^  and 1393-1348 cm"* which were attributed to 
VasCNHs"), 5(NH3^, Va,(C02) and Vs(C02), respectively. Disappearance of the Vas(NH3^ ), 
and 5(NH3^ bands (associated with the zwitterions structure) in complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 was coupled with the appearance of broad band in the 
range 3398-3267 cm"' assigned to the stretching vibrations of coordinated water 
molecules and terminal amino groups. The v(CO)peptide [amide I] band observed at -1665 
cm"' in the free dipeptide was shifted to lower frequency at -1602 cm"' in complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 after complexation confirming the coordination of metal 
ion through O atom of deprotonated carboxylate group [226,227]. The bands around 1575 
cm"' and 1254 cm"' observed in the free dipeptides attributed to amide II and III bands 
[due to 5(hfH)+v(C-N) in compound contaming neutral secondary peptide groups] were 
replaced by a new absorption band at 1376 cm"' in complex 
[Cu2(glygly)2(ppz)(H20)4].2H20. This is characteristic for deprotonated secondary 
peptide complex, since on removal of peptide proton the band becomes a pure C-N 
stretch [228]. The formation of complex [Cu2(glygly)2(ppz)(H20)4].2H20 was also 
revealed by the presence of intense bands around ~ 415, ~537 cm"' corresponding to Cu-
N and Cu-O, respectively. 
Electronic spectra 
The electronic absorption spectrum of complex [Cu2(glygly)2(ppz)(H20)4].2H20 in 
freshly prepared aqueous solutions was carried out in the region 200-1100 nm at room 
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temperature. TTie electronic spectra of free dipeptides displayed an intense absorption 
bands at 220 nm due to n-*n* transition which was shifted to 232 nm upon coordination 
with Cu(II) metal ion, and has been assigned to N"-»Cu(II) ligand-to-metal charge 
transfer (LMCT) transition. A band at 278 nm was tentatively assigned to a COO' 
-*Cu(II) charge-transfer transition [229]. The low energy d-d band at 644 nm was 
assigned to ^Big->^B2g transitions suggesting an octahedral geometry around Cu(II) metal 
ion [230], as deduced by EPR and validated by X-ray crystal structure. 
EPR studies 
The solid state X-band EPR spectra of the complex [Cu2(glygly)2(ppz)(H20)4].2H20 was 
acquired at a frequency of 9.1 GHz under the magnetic field strength 3000±1000 Gauss 
using tetracyanoediylene (TCNE) as field maricer at LNT (Figure 38). The complex 
exhibited an anisotropic spectrum with gy = 2.19 and gi = 2.06 and gav = 2.08 computed 
from the expression gav^  = (g|| ^  + 2giV3. These values are consistent with an octahedral 
geometry of copper with d (Cu ) configuration i.e. (eg) (alg) (b2g) (big), occupied 
by an unpaired electron. The trend g|| > gi > ge (2.0023) reveals that the unpaired electron 
is localized in the dx%^ orbital [231]. For a Cu(II) complex, gy is a parameter sensitive 
enough to indicate covalence. For a covalent complex, gy < 2.3 and for an ionic 
envirormient, gy = 2.3 or more. In the present complex gy < 2.3 indicates an appreciable 
metal-ligand covalent character [232]. The exchange interaction parameter G < 4 (1.89), 
indicated considerable exchange interaction between the Cu(II) centers in the solid phase 
[233]. 
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Figure 38. EPR spectra of complex [Cu(glygfy)2(ppz)(H20)4] .2H2O at variables 
temperature in solid state. 
DNA binding studies 
Electronic absorption titration 
Electronic absorption spectroscopy is an effective method to examine the binding modes 
of complexes with DNA followed by the changes in the absorbance and shift in the 
wavelength. The absorption spectra of complex [Cu2(glygly)2(ppz)(H20)4].2H20 in the 
absence and presence of CT DNA are shown in Figure 39. Binding of the complexes to 
DNA is expected to perturb the ligand centered transitions of complexes. Upon the 
addition of increasing amounts (0.067-0.33 x 10"^  M) of CT DNA to complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 of fixed concentration (0.067 x 10"* M), there was an 
increase in the absorption intensity of complex [Cu2(glygly)2(ppz)(H20)4].2H20 
indicative of hyperchromism with no band shift. Hyperchromism with no shift in 
absorbance is consistent with groove binding, therefore in this complex it can be 
attributed to external contact (surface binding) with the duplex through hydrogen-
66 
bonding interactions between coordinated -NH and -NH2 with functional groups 
positioned on the edge of DNA bases which are accessible both in the major and minor 
grooves or due to strong binding of complex to CT DNA possibly via electrostatic 
interaction indicating DNA stabilization [234,235]. These results suggest the possibility 
of groove binding for the complex [Cu2(glygly)2(ppz)(H20)4].2H20 to DNA and clearly 
rule out the intercalative binding of complex to DNA, as intercalation mode of binding 
leads to "hypochromism" in the spectral bands [236]. Since complex 
[Cu2(glygly)2(ppz)(H20)4],2H20 possesses coordinated -NH- piperazine and amino 
functionality of dipeptide (glygly) which is quite likely to be engaged in hydrogen 
bonding with H-bond acceptor groups (die purine N(3) and pyrimidme 0(2) at the floor 
of the groove walls). To assess the binding ability of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 with CT DNA, the intrinsic binding constant (Kb) value 
was calculated and found to be 2.14 x 10^  M~'. The Kb value suggest that complex 
[Cu2(glygly)2(ppz)(H'20)4].2H20 has a sb^ng binding affinity for CT DNA, which was 
further validated by molecular docking technique. 
mm 
wavdength (nm) 
F^ure 39. Absorption spectral traces of complex [Cu2(glygly)2(ppz)(H20)4].2H^ in 
5mM Tris HCl/ 50 mMNaCl buffer at pH 7.2 upon addition ofCTDNA. Inset: Plots of 
[DNA]/ Sa-Cf (hi cm) \s [DNA] for the titration of CT DNA with complexes m, 
experimental data points; full lines, linear fitting of the data. [Complex] 0.67 x ICT' M. 
[DNA] 0.067-O.33 x 10^ M. 
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Ethidiam bromide displacement assay 
No luminescence was observed for the complex [Cu2(glygly)2(ppz)(H20)4].2H20 at room 
temperature in aqueous solution, in any organic solvent, or in presence of CT DNA. So, 
the binding of complex [Cu2(glygly)2(ppz)(H20)4].2H20 with DNA can not be directly 
predicted dirougfa the emission spectra. Therefore, interaction of the complex 
[Cu2(glygly)2(ppzXH20)4].2H20 with DNA was carried out by the competitive binding 
experiment using ethidiimi bromide (EB) as a probe. EB does not show any qjpreciable 
emission in the buffer solution due to fluorescence quenching of the free EB by solvent 
molecules, while in presence of CT DNA, tiie fluorescence intensity of EB was highly 
enhanced due to its strong intercalation between the adjacoit DNA base pairs [237]. The 
addition of a second DNA-binding molecule can quench the emission intensity of DNA-
EB adduct by either replacing the EB and/or by accepting the excited-state electron of 
the EB through a photoelectron transfer mechanism [238] The addition of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 to DNA pretreated with EB (Figure 40) caused 
significant reduction in emission intensities, which indicated that the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 could bind to DNA through the groove binding mode 
releasing some EB molecules from the EB-DNA system [239]. The extent of reduction 
of the emission intensity gives a measure of the binding propensity of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 to CT DNA. According to the classical Stem-Volmer 
equation: 
M=l+Ksv.r 
where lo and I represent the fluorescence intensities in the absence and presence of the 
complex [Cu2(glygly)2(ppzXH20)4].2H20, respectively; r is the concentration ratio of the 
complex to DNA and Ksv used to evaluate the quenching efficiency is obtained as the 
slope of lo/I versus r. The Ksv value for the complex [Cu2(glygly)2(ppz)(H20)4].2H20 
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was found to be 2.15, indicating the strong affinity of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 to CT-DNA, consistent with the studies of absorption 
titrations. 
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Figure 40. Emission spectra ofEB bound to DNA in the absence and presence complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 in 5 mM Tris-HCl/50 mM NaCl buffer Arrows shows 
the intensity changes upon increasing concentration of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20. Inset: Plots of yi \s [complex]/[DNA]. (m) 
experimental data points; full lines, linear fitting of the data. 
Circular dichroism spectral stody 
CD spectroscopy is a useM technique in diagnosing changes in DNA morphology during 
drug-DNA interactions. The CD spectrum of CT DNA exhibits a positive band at 275 
nm (UV: kmax> 260 nm) due to base stacking and a negative band at 245 nm due to the 
right-handed helicity of B-DNA form which are quite sensitive to the mode of DNA 
interactions with small molecules. Simple groove binding and electrostatic interaction of 
the complexes with DNA shows less or no perturbation on the base stacking and helicity 
bands while intercalator enhances the intensities of both bands [240,241]. The interaction 
of the complex [Cu2(glygly)2(ppz)(H20)4].2H20 with DNA induces a change in the CD 
spectrum of B DNA (Figure 41). The intensities of both Ae negative and positive bands 
decrease significantly (shifting to zero levels). This suggests that the DNA binding of the 
complex induces certain conformational changes, such as the conversion fi-om a more B-
like to a more C-like structure within the DNA molecule [242]. From the results of UV 
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absorption, fluorescence and CD spectroscopic studies, we conclude that the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 binds avidly to CT DNA. 
Wavelength (nm) 
Figure 41. CD spectra of (A) CT DNA done and (B) CT DNA in presence of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 in 5 mM Tris-HCl/50 mM NaCl buffer at 25 °C. 
[Complex] 1.0 X10^ M, [DNA] 1.0 x KT* M. 
DNA Cleavage Stadies 
Concentration dependent cleavage activity 
In order to assess the chemical nuclease activity of [Cu2(glygly)2(ppzXH20)4].2H20 
complex for DNA strand scission, pBR322 DNA was incubated with 
[Cu2(glygly)2(ppz)(H20)4].2H20 complex under the reaction conditions. The cleavage 
reaction can be monitored by gel electrophoresis. When circular plasmid DNA is 
conducted by electrophoresis, the fiistest migration will be observed for the supercoiled 
form (Form I). If one strand is cleaved, the supercoils will relax to produce a slower-
moving nicked circular form (Form II). If both strands are cleaved, a linear form (Form 
III) that migrates between Form I and Form II will be generated. 
The nuclease activity of the complex has been studied by agarose gel 
electrophoresis using supercoiled pBR322 plasmid DNA m a medium of 5 mM Tris-
HCl/50 mM NaCl buffer solution (pH 7.2) in the absence of external agents. The 
cleavage reactions have been studied usmg different complex concentrations incubated at 
310 K for 45 min as depicted in Figure 42. With increasing concentration of the complex 
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[Cu2(glygly)2(ppz)(H20)4].2H20 (lanes 2-A), the amount of Form I of pBR322 DNA 
diminished gradually, whereas Form II increased. At the same time, when the 
concentration of complex [Cu2(glygly)2(ppz)(H20)4].2H20 reached 25 \M, the linear 
Form III was manifested in the gel (lane 5), and the percoitage of linear DNA increased 
with the increase of the concentration of complex [Cu2(glygly)2(ppz)(H20)4].2H20. So, it 
is clear that cleavage of pBR322 DNA is highly dependent on metal ions concentration. 
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Figure 42. Agarose Gel electrophoresis pattern for the cleavage ofpBR322 supercoiled 
DNA (300 ng) by complex [Cu2(glygly)2(ppz)(H20)4].2H20 at 310 K after 45 min of 
incubation; Lane 1, DNA control; Lane 2, 10 fiM of [Cu2(glygly)2(ppz)(H20)4j.2H20 + 
DNA; Lane 3: 15 fiM of [Cu2(glygly)2(ppz)(H20)4j.2H20 + DNA; Lane 4: 20 fiM of 
[Cu2(glygly)2(ppz)(H20)4].2H2O + DNA; Lane 5: 25 fiM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + DNA; Lane 6: 30fiMofl + DNA. 
DNA cleavage in presence of activators 
To ascertain whether any adventitious agents present in the reaction mixture could 
account for the increased DNA degradation by complex [Cu2(gIygly)2(ppz)(H20)4].2H20. 
The nuclease efficiency of the copper(II) complexes is known to depend on the activators 
used for initiating the DNA cleavage. Thus, further activity of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 was carried out with different activators viz; H2O2 as an 
oxidizing agent, ascorbate (Asc), 3^nercaptopropionic acid (MPA) and glutathione 
(GSH) as reducing agents. As shown in Figure 43 (Lane 2-5), the cleavage activity of 
complex [Cu2(glygly)2(ppzXH20)4].2H20 was significantly enhanced in presence of 
these activators and follows the order H202>MPA>ASC=<JSH. The complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 exhibited a significant DNA cleavage activity in the 
presence of H2O2. 
71 
The proposed mechanistic pathway proposed for the interaction of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 with DNA in the presence of H2O2 has been illustrated 
below: 
SCDNA 
[Cu(II) complex] •[CuGO complex] SC DNA 
H2O2 
NC DNA - — {OH'} -* [Cu(I) complex] SC DNA 
Reactive oxygen species responsible for DNA Cleavage 
Copper complexes can cleave DNA both by hydrolytic and/or oxidative mechanisms. For 
the oxidative process, the complexes have been shown to react with molecular oxygen or 
hydrogen peroxide to produce a variety of active oxidative intermediates (reactive 
oxygen species or non-diffusible copper-oxene species) [243]. In order to gain 
information about the reactive oxygen species (ROS) which was responsible for the DNA 
cleavage catalyzed by the complex [Cu2(glygly)2(ppz)(H20)4].2H20, reactions were 
carried out in the presence of typical scavengers such as hydroxyl radical scavengers 
(DMSO, EtOH), singlet oxygen quencher (NaNa) and superoxide scavenger (SOD) under 
our experimental conditions. As shown in Figure 43, the DNA breakdown mediated by 
complex [Cu2(glygIy)2(ppz)(H20)4].2H20 was diminished in presence of DMSO (lane 6) 
and EtOH (lane 7), which indicated that the participation of hydroxyl radical in the 
oxidative DNA cleavage. Since, sodium azide had no significant effect on the DNA 
cleavage (lane 8). The participation of 'O2 or singlet oxygen-like entities is ruled out 
[244]. On the other hand, DNA cleavage inhibited slightly in presence of SOD (lane 9), 
which demonstrate the involvement of superoxide radical anion (02'~) in DNA strand 
scission suggestive of oxidative cleavage mechanism [245]. From these results, we could 
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conclude that a Cu(I) species, superoxide O2 and hydroxyl radical OH' are the active 
species involved in the DNA strand scission. 
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Figure 43. Agarose Gel electrophoresis pattern for the cleavage ofpBR322 supercoiled 
DNA (300 ng) by complex [Cu2(glygly)2(ppz)(H20)^.2H20 in presence of different 
activating agents at 310 K cffier incubation for 45 min. Lane 1: DNA Control; Lane 2: 25 
fiM of [Cu2(glygly)2(ppz)(H20)4j.2H20 + H2O2 (0.4 M) + DNA; Lane 3: 25 nM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + MPA (0.4 M) + DNA; Lane 4: 25 fiM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + GSH (0.4 M) + DNA; Lane 5: 25 fiM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + ASc (0.4 M) + DNA; Lane 6: 25 fxM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + DMSO (0.4 M) + DNA; Lane 7: 25 nM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + Ethyl alcohol (0.4 M) + DNA; Lane 8 : 25 nM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + sodium azide (0.4 M) + DNA; Lane 9 : 25 fiM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + SOD (15 units) + DNA. 
DNA cleavage in presence of recognition elements (groove binding) 
To determine the groove binding preference of [Cu2(glygly)2(ppz)(H20)4l.2H20 with 
pBR322 DNA, the supercoiled pBR322 DNA was treated with DNA groove binders such 
as DAPI (minor groove binding agent) and methyl green (major groove binding agent) 
prior to the addition of complex [Cu2(glygly)2(ppz)(H20)4].2H20. As shown in Figure 44, 
DNA cleavage was uihibited in the presence of DAPI (lane 2). However, no apparent 
inhibition of DNA damage was observed in presence of methyl green (lane 3), suggesting 
that the complex has interaction with DNA through minor groove, which was further 
validated by molecular docking studies. 
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Figure 44. Agarose Gel electrophoresis pattern for the cleavage ofpBR322 supercoiled 
DNA (300 ng) by complex fCu2(glygly)2(ppz)(H20)4j.2H20 in presence of DNA minor 
binding agent DAPI and major binding agent methyl green at 310 K after incubation for 
45 min. Lane 1, DNA control; Lane 2, 25 fiMof [Cu2(glygly)2(ppz)(H20)4].2H20 + DNA 
+ DAPI (8 fxM); Lane 3, 25 nM of [Cu2(glygly)2(ppz)(H20)4].2H20 + DNA+ methyl 
green (2.5 nL of a O.Olmg/ml solution). 
Topoisomerase I Inhibition 
A plasmid DNA cleavage assay was used to investigate the effect of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 on the activity of human Topo-I by agarose gel 
electrophoresis. This assay provides direct means of determining whether the drug affects 
the unwinding of a supercoiled (SC) duplex DNA to nicked open circular (NOC) and 
relaxed (R) DNA. When catalytic activity of topoisomerase I was assayed, complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 inhibited this process in a concentration-dependent 
manner [246]. As shown in Figure 45, supercoiled DNA was fully relaxed by the enzyme 
in the absence of complex [Cu2(glygly)2(ppz)(H20)4].2H20 (Lane 2, Topo-I). However, 
upon increasing the concentration of complex [Cu2(glygly)2(ppz)(H20)4].2H20 (5-12.5 
HM), the levels of relaxed form were inhibited (Lane 3-6). At 12.5 MM the DNA 
relaxation effect caused by Topo-I was completely inhibited by complex 
[Cu2(gIygly)2(ppz)(H20)4].2H20. These observations suggest that complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 inhibits topoisomerase I catalytic activity due to the 
relatively sm)ng DNA binding affmity of complex ICu2(gIygly)2(ppz)(H20)4].2H20, 
which prevents the enzyme from efficiently binding to the DNA. Thus, the metal-based 
drug entity can exert its antitumor activity via topoisomerase I inhibition as it was found 
that most of the cancer cells (kidney, colon, prostate, ovary and esophagus) showed 
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significantly increased levels of topoisomerase, required for r^id and unchecked 
proliferation of cancer cells [247]. 
Figure 45. Agarose Gel electrophoresis pattern showing effect of different concentration 
of complex [Cu2(glygly)2(ppz){H^)4].2H20 on the activity of DNA topoisomerase I 
(Topo-I); Lane 1, DNA control; lane 2, Topo-I + DNA; Lane 3, 5 nM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + DNA^ Topo-I; Lane 4: 7.5 fiM of 
[Cu2(glygly)2(pp2)(H20)4].2H20 + DNA + Topo-I; Lane 5: 10 fdM of 
[Cu2(glygly)2(ppz)(H20)4].2H20 + DNA + Topo-I; Lane 6: 12.5 nM of 
fCu2(glygly)2(ppz)(H20)4j.2H20+ DNA + Topo-L 
Superoxide Dismatase Activity 
Superoxide dismutase (SOD) is one of the most crucial enzymes in the defense system of 
organisms for its ability to protect cells from the damage of the toxic superoxide by 
catalyzing the dismutation of superoxide radicals effectively [248]. Therefore, it was 
interesting to investigate the SOE>-like activity of this new dipeptide based binuclear 
Cu(II)-complex by using the xanthine-xanthine oxidascHiitroblue tetrazolium (NBT) 
assay. A plot (Figure 46) of NBT percent inhibition with an increase in concentration of 
complex [Cu2(glygly)2(ppz)(H20)4].2H20, necessary to produce 50% inhibition (ICso) of 
the reaction are presented in Table 5, together with the values found for the previously 
investigated dipeptide complexes and the one obtained with native SOD [249]. The IC50 
value of complex [Cu2(glygly)2(ppz)(H20)4].2H20 was found to be 0.086 jiM, which is 
considered to be an excellent SOD mimic among the most active dipeptide complexes 
although it is somewhat less active than the IC50 value obtained for native enzyme (IC50 = 
0.04 fiM). In the enzyme, the flexible dipeptides together with piperazine ligand can 
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accommodate and stabilize the space structure of the protein and provide needed protons 
to the peroxide anion during the catalytic cycle. Since, the proton exchange between 
substrates and buffer is a rapid process in the small model systems; the buffer can directly 
transfer protons to peroxide anion in the mechanism [250]. 
Cu(II) + 02'' =*-*- Cu(I) + O2 
Cu(I) + Oz'" + 2 i r - * - ^ Cu(II) + H2O2 
Furthermore, the high superoxide dismutase activity of complex 
[Cu2(glygly)2(ppzXH20)4].2H20 may be possibly due to cooperation of two Cu(II) 
centers in close proximity, acting in concord in free radical binding and electron transfer. 
ao4 aos 0.06 o.c7 aw ao9 0.10 
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Figure 46. A plot of percental of NET inhibition reduction with an increase in the 
concentration of complex [Cu2(glygly)2(ppz)(H^)4].2H20. 
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Tabie 5. IC50 (M¥) values of the complex [Cu2(glygly)2(PPz)(H20)^.2H20, some of the 
dipeptide-based SOD mimicking compounds and the native Cu,ZnSOD enzyme 
Complexes ICsoCuM) 
[Cu2(glygly)2(ppz)(H20)4]. 2H2O 0.086 (This work) 
[Cu(ala-ile)] 330 
[Cu(ala-thr)] 0.99 
[Cu(ala-tyr)] 252 
[Cu(ala-val)] 237 
[Cu(ala^Phen)] 0.149 
Native Cu,Zn-SOD 0.045 
Molecular Docking 
Molecular docking with DNA 
Molecular docking techniques is an attractive scaffold to understand the Drug-DNA 
interactions in raticmal drug design, as well as in the mechanistic study by placing a small 
molecule into the binding site of the target specific region of the DNA mainly in a non-
covalent fashion [251]. Targeting the minor groove of DNA through binding to a small 
molecule has long been considered as an important tool in molecular recognition of 
specific DNA-sequence [252]. 
In our experiment, rigid molecular docking (two interacting molecules were 
treated as rigid bodies) studies was performed to |M-edict the binding modes of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 with DNA duplex of sequence d(CGCGAATTCGCG)2 
dodecamer (PDB ID:1BNA) provide an energetically favorable docked pose tfiat is 
shown in Figure 47. The results show that complex [Cu2(glygly)2(ppz)(H20)4].2H20 
interacts with DNA via electrostatic mode involving outside edge stacking interactions 
with tfie oxygen atom of Ac phosphate backbone of DNA. In this model, it is clearly 
indicated tliat complex [Cu2(glygly)2(ppz)(H20)4].2H20 fits snugly into the curved 
contour of the targeted DNA in the minor groove and is situated within G-C rich region 
thus, leads to van der Waals interaction and hydrophobic contacts with DNA functional 
groups that define the groove [253]. Moreover, the piperazine ring of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 arranged in a parallel fashion with respect to the 
deoxyribose groove walls of the DNA and was stabilized by hydrogen bonding (2.8-3.0 
A) between NH of piperazine with N3 and anomeric oxygen of deoxyribose of G16B and 
02 of ClOA with amino functionality of dipeptide (glygly), while the remaining amino 
group point outside the minor groove. The resulting relative binding energy of docked 
[Cu2(glygly)2(ppz)(H20)4].2H2O-DNA was found to be -256 KJmol"'. This value was 
consistent with the high binding constant obtained fi"om spectroscopic titration and 
groove binding in presence of minor groove binder DAPI and major groove binder MG 
from DNA cleavage studies. 
Thus, we can conclude that there is a mutual complement between spectroscopic 
techniques and molecular modeling, which can provide valuable information about the 
mode of interaction of the complex with DNA and the conformation constraints for 
adduct formation. 
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Figure 47. Molecular docked model of complex [Cu2(glygly)2(pp2)(H20)4].2H20 
showing chemically significant hydrogen-bonding interactions into adjacent C:G base 
pairs fi-om minor side with DNA dodecamer duplex of sequence d(CGCGAATTCGCG)2 
(PDB ID: IBNA). 
Molecular docking with Topoisomerase I 
In order to further rationalize the observed Topo-I inhibitory assay with complex 
[Cu2(glygly)2(ppz)(H20)4].2H20, molecular docking studies were performed to 
understand the binding mode of complex [Cu2(glygly)2(ppz)(H20)4].2H20 with human-
DNA-Topo-I complex (PDB ID: 1SC7) as depicted in Figure 48. The X-ray 
crystallographic structure of the human-DNA-Topo I complex was retrieved from 
Protein Data Bank in which Topo I is bound to the oligonucleotide sequence 5 ' -
AAAAAGACTTsX-GAAAATTTTT-3', where's' is 5 ' - bridging phosphorothiolate of 
the cleaved strand and 'X' represents any of the four bases A, G, C or T. The 
phosphoester bond of 012 in 1SC7 was rebuilt and SH of Gil on the scissile strand was 
changed to OH [254]. The resuhing docked model with minimum relative binding energy 
-299 KJmoP' speculate that the complex [Cu2(glygly)2(ppz)(H20)4].2H20 intercalated 
between the purine ring of Gl 1 (+1) and pyrimidine ring of TIO (-1) in the minor groove 
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on the scissile strand and CI 12 and Al 13, on the non-scissile strand, parallel to the plane 
of base pairs without having hydrogen bonds with the enzyme (Figure 49), subsequently 
leading to inhibitory effect on topoisomerase I [255]. Furthermore, DNA intercalating 
force was much more important than hydrogen bonding of the ligand to the surrounding 
amino acids residues of the protein, or to the base pairs [256]. So, we can concluded that 
the complex occupies the topoisomerase binding site which may suppress the association 
of topoisomerase with DNA, thus influencing the topoisomerase inhibition activity or 
form stable complex with DNA and have a high potential to act as DNA-targeting 
anticancer drugs [257]. 
Figure 48. Molecular docked model of complex [Cu2(glygly)2(ppz)(H20)4].2H20 in the 
cleavage site of human DNA topoisomerase I (PDB ID: 1SC7). 
Figure 49. View is a cut-out of sequence 5'--AAAAAGACTTsX-GAAAATTTTT-3' 
showing complex [Cu2(glygly)2(ppz)(H20)4] .2H2O (spacefilling model) docked in DNA 
sequence between CI 12, All3 andTlO, TGPll. 
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Molecular docking with superoxide dismutase 
In order to further evaluate the SOD inhibitory assay obtained from experimental results, 
complex [Cu2(glygly)2(ppzXH20)4].2H20 was successively docked with an enzyme to 
search the tai^eted active-site (Ai^l41). The X-^ny structure of the enzyme shows that a 
positively charged ArgMl is located in the outer sphere of the active site and is ~S.9 A 
away from the copper ion which is coordinated by His44, His46, His61, Hisl 18, and a 
weakly bound water molecule which occupies the axial position of a distorted square 
pyramid and is directed toward die cavity caning. However, the zinc ion is completely 
buried in the protein, is bridged to the copper by the imidazolate side chain of His61 ion 
and plays a key structural role in maintaining active site structural integrity during the 
catalytic cycle [258,259]. Since the only access to the copper ion is from the active-site 
cavity, the chelators must enter the charmel. This interaction would be facilitated by the 
positive residues lining the channel such as Argl41, Lysl20, and Lysl34 as illustrated in 
Figure 50. The resulting docked model clearly indicated that dipeptide carbonyl group of 
complex [Cu2(glygly)2(ppzXH20)4].2H20 can coordinate to the active-site copper as well 
as guanidyl cation of Argl41 and positively charged ammonia ion of Lysl34 amino acid 
residues surrounding the active redox center of SOD (i.e., the Cu^*) (Figure 51). In 
addition, the concentration of positive electrostatic potential around the channel facilitate 
the binding of anionic ligands in the cavity. 
Hence, in design for SOD mimic using binuclear copper complexes with dipeptide 
ligands through the hydrogen bonding moiety near outer coordination sphere of the 
copper site may be essential for SOD activity. 
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Figure 50. Schematic representation of the key-lock interaction between the CuZnSOD 
enzyme (PDB ID: ISXA) and the complex [Cu2(glygly)2(ppz)(H20)4].2H20. 
Figure 51. Docking of complex [Cu2(glygly)2(ppz)(H20)4].2H20 into the active-site 
channel demonstrates that a carhonyl group of complex can access the active-site 
copper. An electrostatic loop consisting of the positively charged side chains ofArgNl, 
LysllO, and Lysl34 guides the anionic superoxide substrate to the copper center. Argl41 
and Thrl35 act as a "bottleneck" for the active site, limiting the access of bulky anions 
to the copper shown as a green sphere at the bottom of the active-site channel 
82 
In this work, we have designed and synthesized a new dinuclear coppeitll) complex 
derived firom the dipq>tkk (glygly) and piperazine as me^a&(^peptids drug to examiiw its 
effect on the binding {ntjpensity of DNA and to ehicidate tiie medianism of action at the 
molecuiiu' target The in vitro DNA binding ^udies of cixnplex 
[Cu2(glygly)2(ppz)(H20)4].2H20 revealed an elect-ostatic mode of binding as well as 
selective binding to minor groove of DNA. The complex 
[Cu2(glygly)2(ppzXH20)4].2H20 cleave supercoiled piasmid DNA through an oxidative 
(02-pathway) cleavage mechanism induced by reactive oxygen species (ROS). 
Furthermore, complex [Cu2(glygly)2(ppzXH20)43.2H20 exhibits significant inhibitory 
effects on Topo-I activity at a very low concentration -12.5 pM, including excellent 
SOD mimics with an ICso of 0.086 ^M. Additionally, molecular docking studies was 
performed with molecular target DNA and the active site of enzymes in order to validate 
the experimental results. TTierefore, it is concluded tiiat present chemical entity can acts 
as potent drug binding to DNA minor groove and inhibit DNA-processing enzymes; 
which can be exploited as an important class of anticancer drugs. 
CHAPTER III (b) 
Interaction and Photo-induced Cleavage Studies of Copper 
based Chemotherapeutic Drug with Human Serum Albumin: 
Spectroscopic and Molecular Docking Study 
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Synthesis 
The synthesis and single crystal X-rays crystallographic studies of a new metal lopeptide 
complex of the formulation [Cu2(glygly)2(ppzXH20)4].2H20 was described previously 
[260]. 
Results and discussion 
Electronic absorption studies 
Electronic absorption spectroscopy is a reliable tool to understand the morphological 
changes in secondary structure of HSA via complex formation between drug and HSA. 
On addition of complex [Cu2(glygly)2(ppz)(H20)4]. 2H2O with incremental increase of 
concentration (0.67-2.33 x lO' M) to HSA of constant concentration (1.80 x 10"^  M), 
there was a sharp increase in absorption intensity, "hyperchromism" (Figure 52) of the 
intraligand band at 278 nm was observed which implicates that complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 interacts with HSA by non-covalent interaction by 
electrostatic attraction and could be facilitated by hydrogen—bond formation due to the 
molecular topology of peptide ligand scaffold of complex 
[Cu2(glygly)2(ppzXH20)4].2H20. In order to evaluate the binding propensity 
quantitatively with HSA, the intrinsic binding constant (Kb) of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 with HSA was calculated using Equation (3) and Kt 
value was found to be 1.48 x 10* M"'. The Kb value of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 suggests moderate binding propensity to HSA followed 
by conformational transition. 
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Figure 52. UV absorption spectra of the HSA-complex [Cu2(glygly)2(ppz)(H20)4].2H20 
system obtained in 5 mM Tris-HCl/50 mMNaCl buffer, pH 7.4, at room temperature: (a) 
complex [Cu2(glygly)2(ppz)(H20)4].2H20, 0.60 x 10'^ M; (b) HSA, 1.80 x Iff^ M; (c-h) 
complex [Cu2(glygly)2(pp2)(H^)4].2H20-HSA, the complex concentrations were 0.67, 
1.0, 1.33, 1.67, 2.00, 2.33 x 10^^ M, respectively. Arrows show the intensity changes upon 
increasing concentration of the complex [Cu2(glygly)2(ppz)(H20)4]-21120. Inset: Plot of 
1/A-AoVS. 1/ [Complex]. 
Fluorescence quenching mechanism 
Fluorescent quenching techniques involves a variety of molecular interactions such as 
excited state reactions, molecular rearrangements, energy transfer, the formation of 
ground-state complex, collision, etc [261]. Therefore, fluorescence quenching 
experiments were undertaken to investigate the interaction between complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 and HSA. When HSA molecule is excited at 280 nm, 
both tryptophan and tyrosine amino acid residues give fluorescence emissions at an 
excitation wavelength of 295 nm in which tryptophan has strong fluorescence emissions 
while tyrosine does not absorb in this region [262]. The fluorescence spectra of HSA in 
the absence and presence of complex [Cu2(glygly)2(ppz)(H20)4].2H20 as a quencher in 
Tris-HCl buffer (pH 7.4) were monitored with an excitation wavelength of 295 nm 
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(Figure 53). HSA exhibits a strong fluorescence emission with a peak at 370 nm due to 
the emission fix>m the single tryptophan residue (Trp-214). However, intrinsic 
fluorescence intensity of HSA decreased regularly and no shift was observed in the 
emission wavelength with the increase in concentration of complex 
[Cu2(glygly)2(ppz)(H20)4].2H20. The strong quenching of the HSA fluorescence 
implicated the existence of interaction between [Cu2(glygly)2(ppz)(H20)4].2H20 and 
HSA which changes the local environment aroimd Trp-214 residues [263]. 
ht order to determine the fluorescence quenching mechanism, the fluorescence quenching 
data at different temperatures (299, 309 and 318 K) were analyzed using the classical 
Stem-Volmer equation (7). Figure 54 shows the Stem-Volmer plots of Fo/F versus [Q] 
at three different temperatures and the calculated Ksv and kq values are summarized in 
Table 6. 
>VavclcBgth (nm) 
Figure 53. The fluorescence quenching spectra of HSA by different concentrations of 
complex[Cu2(glygly)2(pp2)(H20)4].2H20 with the excitation wavelength at 295 nm in 5 
mM Tris-HCl/50 mMNaCl buffer, pH 7.4, at room temperature: [HSA], 1.0 xW^ M; (1-
5) the concentration of complex [Cu2(glygly)2(ppz)(H20)4].2H20 corresponding to 0, 
0.60, 1.00, 2.00, 3.33 x 10' M, respectively. Arrow shows the intensity changes upon 
increasing concentration of the quencher. 
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Figure 54. Stem-Volmer plots showing HSA tryptophan quenching caused by complex 
[Cu2(glygly)2(PP2)(H20)4].2H20 at three different temperatures (pH 7.40. A« = 295 nm, 
kern = 370nm). 
The results revealed that the Stem-Volmer quenching constant Ksv is inversely 
correlated with temperature and k<, is larger than the limiting difliision constant Kdif of the 
biomolecule (Kjif = 2.0 x 10'° M-1 s'^ ) [264], indicating that fluorescence quenching was 
caused by a specific interaction between HSA and complex 
[Cu2(glygly)2(ppz)(H20)4].2H20, consistent with the static quenching mechanism 
(Scheme 2) [265]. 
Table 6. Stem-Volmer quenching constant of the complex 
fCu2(glygly)2(ppz)(H20)4].2H20-HSA system at different temperatures 
pH T(K) Ksv ( loV) Kq (lO'^M-'s-') R 
299 2.13 2.13 0.998 
7.40 309 2.06 2.06 0.995 
318 1.94 1.94 0.981 
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Scheme 2. Mechanism of fluorescence quenching. 
For static quenching, the equation (10) was employed to calculate the binding constant 
and number of binding sites [266]. Thus, a plot of log[(Fo-F)/F] versus log[Q] was used 
to determine K as well as n. The binding data {K and n) at different temperatures were 
presented in Figure 55 and Table 7. It was found that the binding constant (K) decreased 
with the increase of temperature, resulting in a reduction of the stability between complex 
[Cu2(glygly)2(ppz)(H20)4].2H20-HSA binding reaction. Literature reveals that Cu(ir) 
metal ion most likely binds to the hydrophobic pocket located within subdomain IIA, 
Trp-214 which is near or within the binding site. These results were further validated by 
docking simulation studies. 
Table 7. Binding constant (K) and the number of binding sites (n) for the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20-HSA system at different temperatures 
pH T(K) K(IO^M') n R 
7.40 
299 6.48 1.68 0.998 
309 5.02 1.71 0.995 
318 3.62 2.10 0.981 
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Figure 55. Logarithmic plot of the fluorescence quenching of HSA at different 
temperatures. 
Energy transfer and Binding distance between [Cu2(glygly)2(ppz)(H20)4].2H20 and 
HSA 
Fluorescence energy transfer occurs via overlapping of a fluorophore (donor) with the 
absorption spectrum of molecule (acceptor). The overlap of the absorption spectrum of 
the complex [Cu2(glygly)2(ppz)(H20)4].2H20 with the fluorescence emission spectra of 
HSA is shown in Figure 56. According to fluorescence resonance energy transfer theory 
[267], the rate of energy transfer depends on the extent of overlapping between 
fluorescence emission spectrum of donor with the absorption spectrum of acceptor, the 
relative orientation of the donor and acceptor transition dipoles, and the distance between 
donor and acceptor [268]. 
A Foster resonance energy transfer (FRET) mechanism (Figure 57) is involved in the 
quenching of Trp fluorescence by complex [Cu2(glygly)2(ppz)(H20)4].2H20. 
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Figure 56. The overlap of UV absorption spectra of complex 1 with the fluorescence 
emission spectra ofHSA. (a) The fluorescence emission spectrum ofHSA (1.0 x 10~ M); 
(b) the UV absorption spectrum of complex [Cujigfygly) 2(ppz) (H2O) 4]-IHjO (0.60 x 10"^ 
M). 
Under the experimental condition, K^ =2/3, A^  =1.336, ^= 0.188, according to Eqs. (13) -
(15), the value ofE, Ro, r and J were calculated and found to be 0.99, 2.5 nm, 3.7 nm and 
1.6 X 10"''* M'' cm ,^ respectively. The donor to acceptor distance r <7 nm indicated that 
the energy transfer from tryptophan residue in HSA to complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 occur with high probability [269]. 
F R E T 
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Wavelength {>.) 
la J_=n 
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Figure 57. Fluorescence resonance energy transfer (FRET) mechanism. 
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Binding mode 
The acting forces between a small molecule and bio-macromolecule are mainly include 
weak interactions such as hydrogen bonds, van der Waals forces, electrostatic and 
hydrophobic interactions [270]. The thermodynamic parameters, enthalpy change (A//), 
entropy change (AS) and free energy change (AG) are the main evidence to determine the 
binding mode. From the thermodynamic standpoint, AH> 0 and AS> 0 implies a 
hydrophobic interaction; AH< 0 and AS< 0 reflects the van der Waals force or hydrogen 
bond formation; and A / ^ and AS> 0 suggests an electrostatic force. The thermodynamic 
temperatures chosen for measurements were 299, 309 and 318 K, so that HSA does not 
undergo any structural degradation. The thermodynamic parameters can be calculated 
from the Van't Hoff equation, in which A/f and AS of reaction could be determined from 
the linear relationship between In K and the reciprocal absolute temperature (Figure 58). 
The free energy change (AG) could be calculated by the Equation (12). As shown in 
Table 8, AG and AH were negative, and AS was positive. Therefore, the formation of 
complex [Cu2(glygly)2(ppz)(H20)4].2H20-HSA was spontaneous and exothermic 
process. From the point of water structure, a positive AS value is frequently taken as 
evidence for a hydrophobic interaction. Furthermore, the negative AH value (-6.02 kJ 
mol"') observed cannot be mainly attributed to electrostatic interactions since for 
electrostatic interactions AH is very small, abnost zero [271]. Therefore, the negative AH 
and positive AS values suggest that hydrophobic and hydrogen bond interactions play 
major roles in the complex [Cu2(glygly)2(ppz)(H20)4].2H2C>-HSA binding reaction and 
contributed to the stability of the complex. 
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F^ureSS. Van'tHoffplot for the interaction of [Cu2(glygly)2(ppz)(H20)4].2H2O and 
HSA. 
Table 8. Thermodynamic parameters of complex fCu2(glygly)2(PPz)(H20)4j-2H20 -
(HSA) interaction atpH 7 
Complex T(K) A(7(kJ/mole) Aff(kJ/mole) AS (J/mole K) 
Complex-HSA 
299 
309 
318 
-24.232 
-25.044 
-25.773 
-6.062 +81.03 
Ionic strength 
In order to exunine the electrostatic interaction between complex 
[Cu2(glygly)2(ppzXH20)4].2H20 and human serum albumin, fluorescence titrations were 
carried out under the conditions of increasing ionic strength through added amounts of 
NaCl at constant concentration of complex [Cu2(glygly)2(ppiz)(H20)4].2H20. The results 
were depicted in Table 9, which indicate that the binding constant decreases maricedly 
with the increase in ionic strength due to the change of ionic environment and 
competition between coexistent ions and Cu(II) ions, leads to shortening of the storage 
time of complex [Cu2(glygly)2(ppz)(H20)4].2H20 in blood plasma. Thus, we suggest that 
92 
the electrostatic and hydrophobic interactions exist between complex 
[Cu2(glygly)2(ppzXH20)4].2H20 and serum albumin, well corroborated by the 
thermodynamic data [272]. 
Table 9. The binding constant according to Stem-Volmer curves at different NaCl 
concentrations in Tris-HCl buffer (pH 7.4) 
NaCl(mM) T(K) ^ ^ 0 ^ ^ / ^ 
33 299 1.301 0.995 
83 309 0.958 0.997 
116 318 0.762 0.999 
Investigations on the circniar dichroism of HSA 
To ascertain the possible influence of complex [Cu2(glygly)2(ppz)(H20)4].2H20 binding 
on the secondary structure of HSA, CD measurement was also performed in the presence 
of complex [Cu2(glygly)2(ppzXH20)4]. 2H2O at different concentrations. As shown in 
Figure 59, CD spectra of free HSA (line a) exhibited two negative bands in the ultraviolet 
region at 208 and 222 nm attributed to n-»)i* transfer for the peptide bond of a-4\elix 
[273]. It was observed that with the increase in complex [Cu2(glygly)2(ppz)(H20)4].2H20 
concentration, the CD signal of HSA increased, suggestive of the binding of complex 
[Cu2(glygly)2(ppzXH20)4]. 2H2O to HSA induces a significant conformational change in 
HSA (line b and c). However, the CD spectra of HSA in the presence or absence of 
complex [Cu2(glygly)2(ppz)(H20)4].2H20 is similar in shape, indicating that the structure 
of HSA is also predominantly a-4ielical. 
93 
Wavelength (nm) 
Figure 59. CD Spectra of the HSA-complex[Cu2(glygly)2(ppz)(H20)4j.2H20 system, (a) 
1.5 X 10'^ M HSA; (b) 1.5 x 10'^ M HSA + 3.0 x 10~^ M complex 
[Cu2(glygly)2(ppz)(H20)4].2H20; (c) 4.5 x 10~^ M HSA + 3.0 x 10~^ M complex 
[Cu2(glygly)2(ppz)(H20)4].2H20. pH 7.40, at room temperature. 
From Equation (17), the quantitative analysis results of the a-helix in the secondary 
structure of HSA were obtained. They differed from that of 59.79% in free HSA to 
49.14% and 46.33% in the complex [Cu2(glygly)2(ppz)(H20)4].2H20-HSA system at pH 
7.4 and temperature 25 °C (curves a-c in Figure 59). The a-helix gradually decreases 
with the increase in concentration of complex [Cu2(glygly)2(ppz)(H20)4].2H20, which 
reveals that interaction between complex [Cu2(glygly)2(ppz)(H20)4].2H20 and HSA 
leads to a change in secondary structure of HSA [274]. 
Fourier transform infrared (FTIR) measorements 
To fiirther investigate the conformational change of HSA induced by complex 
[Cu2(glygly)2(ppz)(H20)4]. 2H2O, FT-IR experiment was performed. The spectrum in 
Figure 60a was obtained by subtracting the absorption of the Tris-HCl fix)m the spectrum 
of the HSA solution. The spectrum in Figure 60b was obtained by subtracting the 
absorption of the complex [Cu2(glygly)2(ppz)(H20)4].2H20-fi«e form from that of the 
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complex [Cu2(glygly)2(ppz)(H20)4].2H20-bound form. Infrared spectra of HSA exhibit a 
number of the amide bands, which represent different vibrations of the peptide moiety. 
The amide I peak observed in the range 1600-1700 cm'' (mainly C=0 stretch) and amide 
II band in the region 1500-1600 cm' (C-N stretch coupled with N-H bending mode). It 
is well known that the amide bands have a relationship with the secondary structure of 
HSA, and amide I is more sensitive than amide 11 for change of secondary structure of 
HSA. As shown in Figure 60, the peak position of amide I bands were shifted from 
1633.9 cm"' to 1641.4 cm"', indicating the secondary structure of the HSA was changed 
in presence of complex [Cu2(glygly)2(ppz)(H20)4].2H20 [275]. 
I 
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Figure 60. FT-IR spectra of (a) free HSA; (b) different spectra [(HSA solution + complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 solution)-complex [Cu2(glygly)2(ppz)(H20)4].2H20 
solution)] in 5 mM Tris-HCl/50 mM NaCl buffer, pH 7.4, at room temperature in the 
region ofl 750-1400 cm''. [HSA], 1.5 x 10'^ M; [complex], 3.0 x 10'^ M. 
3]>-Flaorescence studies 
3D fluorescence spectroscopy is a newly emerged analytical technique to investigate the 
conformational and structural changes of proteins by changing excitation and emission 
wavelength simultaneously [276]. By comparing the 3D fluorescence spectral changes of 
HSA in the absence and presence of complex [Cu2(glygly)2(ppz)(H20)4].2H20, the 
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conformational and micro-environmental changes of HSA can be obtained. The 3D 
fluorescence spectra and contour ones of HSA and complex 
[Cu2(glygly)2(ppz)(H20)4].2H20-HSA system are shown in Figure 61, respectively, and 
the corresponding characteristic parameters are shown in Table 10. Peak a was the 
Rayleigh scattering peak (X«x=X«n)- Peak b (280, 346 nm, X«x, X«„) mainly reflected the 
spectral behavior of Trp residue, and the maximum emission wavelength and the 
fluorescence intensity of the residue associated with its microenvironment's polarity. 
Peak c was the second-ordered scattering peak (Xan=2Xex) [277]. As shown in Figure 61 
[Cu2(glygly)2(ppz)(H20)4].2H20, it was observed that the fluorescence intensities of peak 
a and b both decreased significantly and the maximum emission wavelength of the peak 
was changed in the presence of complex [Cu2(glygly)2(ppz)(H20)4].2H20 indicated the 
quenching of fluwescence of HSA. We can conclude that the interaction of complex 
[Cu2(glygIy)2(ppz)(H20)4].2H20 with HSA induced some conformational and micro-
environmental changes in HSA, corroborated well with our spectroscopic results obtained 
from UV-vis, FT—IR and CD measurements. 
Table 10. 3D fluorescence spectral characteristic parameters of HSA and HSA-complex 
[Cu2(glygly)2(ppz)(H:P) 4].2H2O system 
HSA HSA-complex 1 
Peak position 
\JK^(rmltm) SiX Intensity 
Peak position AX Intensity 
Peak a 280/280-360/360 0 4.43-62.69 Peak a 280/280-360/360 0 5.25-62.69 
Peakb 280/344 64 48.23 Peakb 280/348 68 26.23 
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Figure 61. 3D fluorescence spectrum and con-esponding contour diagrams of (a) HSA, 
and (b) complex [Cu2(glygly)2(ppz)(H20)4].2H20-HSA conjugate system. The 
concentration of HSA is fixed at 2.5 fjM and that of complex 
[Cu2(glygly)2(ppz)(H20)4] .2H2O is fixed at 22.5 ^iM. pH = 7.4, at room temperature. 
HSA photocleavage studies 
There is a considerable interest in the development of synthetic chemical proteases that 
are activated by radical—generating metal complex. Such chemical proteases can be 
utilized for breaking large proteins into smaller fragments that are more amenable to 
sequencing. The ability of Cu(II) complexes to mediate protein cleavage is well 
established in literature [278,279] owing to the fact that these complexes show their own 
selectivity for a cleavage mechanism, it is therefore imperative to study the effect of 
97 
Cu(II) complex on HSA in presence of different concentration and reactive oxygen 
species. 
In order to ascertain the ability of the complex [Cu2(glygly)2(ppzXH20)4].2H20 to serve 
as a synthetic metalloproteases, the HSA photocleavage activity of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 was studied using 4 nM HSA in 50 mM Tris-HCl 
buffer on exposure to UV-Al light of 365 nm with different complex concentrations for 
20 min and the extent of cleavage was compared with tiie untreated HSA band. The 
photoinduced protease activity of complex [Cu2(glygly)2(ppz)(H20)4].2H20 was assayed 
by SDS-PAGE (12%3%) analysis. As shown in Figure 62a, it was observed that HSA 
alone (Lane 1) did not show any {^parent cleavage under these conditions. However, 
upon increasing the concentration of complex [Cu2(glygly)2(ppzXH20)4].2H20 (100-250 
jiM), HSA showed significant smearing or fading of the band (Lane 2-5), indicating 
photocleavage of HSA under physiological reaction conditions. At the same time, when 
the concentration of complex [Cu2(glygly)2(ppz)(H20)4].2H20 reached to 250 ^M, HSA 
cleaved into smaller fragment that could not be observable by SDS-PAGE. The smearing 
of the band results from non-specific cleavage of the HSA by the highly diffusible HO" 
radicals generated by the complex upon photoexcitation, leading to the cleavage of HSA 
into very small fragments. The complex [Cu2(glygly)2(ppz)(H20)4].2H20 did not show 
any cleavage activity in the dark, thus ruling out any hydrolytic cleavage of HSA (Lane 
6). To explore the mechanistic pathway of the cleavage activity, comparative HSA 
cleavage experiment of complex [Cu2(glygly)2(ppz)(H20)4].2H20 was carried out in 
presence of standard radical scavengers such as DMSO and KI as hydroxyl radical 
scavenger (HO') and sodium azide (NaNs) as singlet oxygen ('O2) quencher were used 
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prior to the exposure to UV-Al light. As shown in Figure 62b, the HSA cleavage 
mediated by complex [Cu2(glygly)2(ppz)(H20)4].2H20 in the presence of DMSO and KI 
(Lane 3 and 4, respectively) show significant reduction in the HSA cleavage activity, 
indicating the involvement of hydroxy 1 radicals as the reactive species. 
Figure 62. SDS-PAGE electrophoresis of complex [Cu2(glygly)2(ppz)(H20)4].2H20 in 
1.2% polyacrylamide gel showing photocleavage of human serum albumin (HSA, 15 nM) 
with 20 min photoexposure to UV-Al light at 365 nm Tris HCl buffer (pH 7.4), (a) at 
different concentration; lane-1, HSA control; lane-2, HSA + (100 fiM); lane-3, HSA + 
(150 nM); lane-4, HSA + (200 fxM); lane-5, HSA + (250 fxM); lane-6, HSA + (250 /JM, 
in dark) and (b) in presence of standard radical scavengers; lane-1, HSA + (250 fiM, in 
dark); lane-2, HSA + (250 fiM); lane-3, HSA + DMSO (20 nL) + (250 fiM); lane-4, 
HSA +KI(3 mM) + (250 fiM); lane-5, HSA + NaNs (3 mM) + (250 fiM); lane-6. HSA + 
TEMP (3 mM)+ (250 fiM). 
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On the other hand, addition of NaNsand TEMP (Lane 5 and 6, respectively) did not show 
any inhibition suggesting that the singlet oxygen quencher was not involved in the 
cleavage process. Since, the present complex [Cu2(glygly)2(ppz)(H20)4].2H2O contains 
Lewis acid Cu(II) metal ion and coordinated water molecule, which facilitates the 
nucleophilic attack on amide bond mediating internal attack by a coordinated Cu-OHj 
molecule. So, it is clear that the delivery of high concentrations of metal ion to the HSA, 
in locally generating oxygen or hydroxide radicals, yields an efficient HSA cleavage 
reaction. 
Antitumor activity assays 
The results obtained from the previous biological studies, namely, DNA binding and 
cleavage, Topo-I inhibition, and antioxidative studies for complex 
[Cu2(glygly)2(ppz)(H20)4]. 2H2O, encouraged us to evaluate their in vitro cytotoxic 
activity. The activity of complex [Cu2(glygly)2(ppz)(H20)4].2H20 was evaluated in terms 
of GIso, TGI and LCso values against human carcinoma cell lines of different histological 
origin: 786-0, A498 (kidney), Zi--75-l (Breast), SiHa (Cervix), A549, Hop-62 (Lung), 
SW620, HCT15 (Colon), ML\PACA2 (Pancreatic) by Sulforhodamine B test (SRB) 
assay [280]. The cytotoxic screening data (Table 11) shows that the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 act as a potential selective anticancer agent with a 
significant GI50 values specifically towards ML\PACA2, A498, and A549 tumor cell 
Imes. 
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Table 11. Summary of the screening data of complex [Cu2(glygly)2(pp2)(Hfi)4].2H^ 
for the in vitro anti—tumor activity (in fig/ml) 
Human Tissue 
of(»igm Kidney Breast Cervix Lung Colon Lung Colcm Kidney Pancreatic 
Cell line 7860 Zr.75-1 SiHa Hop62 HCT15 A549 SW620 A498 KflAPACA2 
^'» AiR 
68.8 >80 >80 >80 62.4 41.6 >80 29.0 19.5 
<10 <10 <10 <10 <10 <10 <10 <10 <10 
^^' A^R 
>80 >80 >80 >80 >80 80.7 >80 53.8 >80 
26.5 <10 14.9 10.1 37.0 42.1 17.0 13.9 20.4 
^ ADR 
>80 >80 >80 >80 174.7 >80 >80 78.6 >80 
55.9 222 32.6 31.0 66.9 77.8 343 35J3 46.8 
Where: 
• Gl5o= Growth inhibition of 50 % (GI50) calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, 
drug concentration result in a 50% reduction in the net protein increase. 
• ADR= Adriamycin (taken as positive control compound). 
• TGI = Tumor growth inhibition 
• LC50 = Lethal concentration of 50 % (LC50). 
Molecular docking study 
In order to provide a considerable insight into the interactions of HSA with complex 
[Cu2(glygly)2(ppz)(H20)4].2H20, molecular docking technique was employed to search 
the exact binding sites inside the molecular target HSA, From the 3-D structure of 
crystalline albumin, it is known that HSA comprises three homologous domains (denoted 
I, II, and III): I (residues 1-195) H (196-383) and HI (384-585) that assemble to form 
heart shaped molecule. The principal region of complex [Cu2(glygly)2(ppz)(H20)4].2H20 
binding sites of HSA are located in hydrophobic cavities in subdomain IIA and IIIA, 
corresponding to site I and site II, respectively and tryptophan residue (Trp-214) of HSA 
in subdomain HA. There is a large hydrophobic cavity in subdomain IIA to accommodate 
the complex [Cu2(glygly)2(ppz)(H20)4].2H20. The resuhing docked pattern (Figure 63a) 
indicates that complex [Cu2(glygly)2(ppz)(H20)4].2H20 is located within the subdomain 
HA of HAS [281], suggesting the existence of hydrophobic interaction between complex 
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[Cu2(glygly)2(ppz)(H20)4].2H20and HSA, correlated with the binding mode observed by 
thermodynamic analysis and fluorescence quenching mechanism of HSA in presence of 
complex [Cu2(glygly)2(ppz)(H20)4].2H20. 
Figure 63. (a) Molecular docked model of complex [Cu2(glygly)2(ppz)(H20)4].2H2O 
(stick representation) located within the hydrophobic pocket in subdomain IIA of HSA; 
(b)the interaction mode between complex [Cu2(glygly)2(ppz)(H20)4].2H20 (red colour) 
and HSA (green colour) were represented in a cartoon form and the yellow dashed line 
showing hydrogen bond interaction between them. 
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Furthermore, there are also a number of specific electrostatic interactions and hydrogen 
bonds, because several ionic and polar residues in the proximity of the ligand play an 
important role in stabilizing the molecule H—bonds and electrostatic interactions. As 
shown in Figure 63b, there are hydrogen bond interactions between the main chain 
carbonyl oxygen of Arg-257 and terminal amino group of the complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 and another between carbonyl groups of 
[Cu2(glygly)2(ppz)(H20)4].2H20 and Ala-291 and Arg-222 residues of HSA. These 
results suggest that formation of hydrogen bonds decreased the hydrophilicity and 
increased the hydrophobicity to keep complex [Cu2(glygly)2(ppz)(H20)4].2H20-HSA 
system stable. The results obtained from molecular docking indicated that the interaction 
between complex [Cu2(glygly)2(ppz)(H20)4].2H20 and HSA was dominated by 
hydrophobic forces. 
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CoMclnsioBS 
In this woric, we have explored the interaction studies of new dinuclear copper(ir) 
ctxapiex dmved fit»n the dipeptide (glycyl glyciiM) and pip^azine as metallopeptide 
drag to examine their effect on the binding propensity of HSA and to elucidate the 
mechanism of action at the molecular target. The int^tiction between complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 and HSA was investigated by employing different 
spectroscopic techniques (UV-visible, fluorescmce, CD, FTIR) in accordance with 
molecular docking techniques. The results revealed that the secondary structure of HSA 
was affected upon mteraction with the complex [Cu2(glygly)2(ppz)(H20)4].2H20. 
Fluorescence results indicated the presence of static quenching mechanism upon binding 
of complex [Cu2(glygly)2(ppzXH20)4].2H20 to HSA. On the basis of spectroscopic 
results we have concluded that the complex [Cu2(glygly)2(ppzXH20)4].2H20 was bound 
to site I of protein, which was located within hydrophobic pocket of subdomain IIA. The 
complex [Cu2(glygly)2(ppzXH20)4].2H20 shows photo-induced degradation of HSA 
induced by hydroxyl radicals as Hie reactive species. Furthermore, complex 
[Cu2(glygly)2(ppz)(H20)4].2H20 exhibits significant GI50 values specifically towards 
MIAPACA2, A498 and A549 tumor cell lines. Therefore, it is concluded that drags that 
bind and cleave HSA will not only help the transportation and distribution of drag in 
blood plasma but also elucidate the valuable information to understand the mechanistic 
pathway of drag delivery and contribute to the molecular design of novel synthetic 
protein photo-degradation agents. 
CHAPTER IV (a) 
DNA binding and cleavage studies of sulfasalazine-derived dipeptide 
Zn(II) complex: Validation for specific recognition with 5'-TMP 
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Synthesis 
Synthesis of [Zn(glygly)(ssz)(H20)].6H20 
To a stirred methanolic solution (15 ml) of zinc nitrate hexahydrate (0.595g, 2mmol) was 
added an aqueous solution of glycyl glycine (0.264g, 2mmol) followed by dropwise 
addition of KOH (0.224g, 4mmol) and pH of the resulting solution was adjusted between 
8-12. This reaction mixture was stirred for ca. 2 h at room temperature to obtain clear 
solution. A methanolic solution (20 ml) of sulfasalazine (0.80 g, 2mmol) was added to 
the above reaction mixture and stirred for another 3 h. The orange colored solid 
precipitate was filtered, thoroughly washed with ice cold methanol and dried in vacuo 
over anhydrous CaCb (Yield: 0.610g, 71%). m.p. 206 ± 2°C, Anal. Calc. for 
C22H32ZnN60i5S (%): C, 36.80; H, 4.49; N, 11.71; S, 4.46, Found: C, 36.08; H, 4.23; N, 
11.79; S, 4.02. Selected IR data on KBr/nujol, cm"': 3424 v(NH2+H20); 1603 v(C=0); 
1388 v(C-N); 424 v(Zn-N); 460 v(Zn-0). Molar Conductance, AM (1 x 10"^  M, H2O): 17 
n"'cm^mor' (Non-electrolyte). UV-vis absorption: (H2O, 10"^  M), Xmax/nm (e/lO *^ M"' 
cm"') 231 (2.6); 256 (1.30); 370 (1.81). ESI-MS (m/z, H2O): 716.4 [M] ;^ 608.6 [M-
(6H20)]^ 
' H N M R (DMSO-iiij, 400 MHz) 6(ppm): 3.36 (NCH2); 3.80 (CCH2); 4.80 (H2O); 6.86-
8.35 (ArH). ''C NMR (DMSCM5, 100 MHz) 5(ppm): 46.15-54.29 (CHj); 118.59-
150.06 (ArC); 178.86 (0-C=0); 158.09 (CO). 
Results and discussion 
In order to investigate the ability of complex towards molecular recognition and sequence 
specific cleavage of DNA by synthetic probes, new drug candidate, complex 
[Zn(glygly)(ssz)(H20)].6H20 was synthesized and characterized. The synthesis of new 
Zn(II) complex [Zn(glyglyXssz)(H20)].6H20 was achieved by mixing stoichiometric 
I()_'^  
amounts of Zn(II) nitrate hexahydrate with glycyl glycine and sulfasalazine followed 
drop wise addition of KOH (Scheme 3), in a good yield. The composition of the complex 
[Zn(glygly)(ssz)(H20)].6H20 was ascertained by elemental analysis, IR, UV-vis, ESl-
MS and NMR spectroscopy. The resulting complex [Zn(glygly)(ssz)(H20)].6H20 is 
stable towards air and moisture and readily soluble in H2O. Molar conductance value of 
complex in H2O (lxlO~^ M) at 25 °C suggest its non-electrolyte nature (17n"'cm^mor'). 
°-^ '^ ^l*(2 HO, 
sO 
X + I T } + Zn(N03)j.6H:0 Me(m,RT 
-•X 
2K0H 
f 6H20 
x_ 
N N R 
Scheme 3. Synthetic route for complex [Zn(glygly)(ssz)(H20)].6H2O 
Infrared spectra 
The IR spectra of complex [Zn(glygly)(ssz)(H20)].6H20 was recorded in the region 
4000-400 cm"' and analyzed in comparison to the IR spectra of the free ligand. The 
bands around 1575 cm"' and 1254 cm"' observed in the free dipeptides attributed to 
amide II and III bands [due to 5(NH) + v(C-N) in compound containing neutral 
secondary peptide groups] were replaced by a new absorption band at 1388 cm~' in 
complex [Zn(gIygly)(sszXH20)].6H20, which is characteristic for deprotonated 
secondary (in fact tertiary) peptide complex; the large shift towards low frequency region 
is typical of peptide N-bonding. Since, on removal of peptide proton the band becomes a 
pure C-N stretch [282]. The v(CO)pq«ide [amide I] band observed at -1665 cm"' in the 
free dipeptide was shifted to lower frequency at -1603 cm"' after complexation which 
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confirms the coordination of metal ion through peptide-N atom. The bands around 1586 
and 1410 cm"', due to Vasym (C00~) and Vjym (COO") of the amino acids appeared in the 
complex [Zn(glygly)(ssz)(H20)].6H20 at 1555 and 1476 cm"' [283]. The shift of these 
two bands suggests the involvement of the carboxylic groups of the amino acids in 
complex formation. A broad band with strong-4(>-medium intensity in the 3400-3450 
cm"' region may be assigned to the OH stretching vibration for the coordinated water 
molecules in the complex. The shift in v(CO) of phenolic group from 1281 cm"' in the 
free sulfasalazine ligand to 1260 cm"' in the complex [Zn(glyglyXssz)(H20)].6H20 
indicated the participation of the phenolic group in complex formation via deprotonation 
[284]. The medium intensity bands at 424 and 460 cm"' were attributed to stretching 
vibration of Zn-N and Zn-0, respectively. 
NMR spectroscopy 
The ' H and '^ C NMR spectra in D2O solution show signals for aliphatic and aromatic 
protons with chemical shift values in accordance with their anticipated structure. In 'H 
NMR spectrum of complex [Zn(glygly)(ssz)(H20)].6H20, signals due to free carboxylic 
(COOH), phenolic (OH) and amide linkage (-NH-) groups as expected in the range 
12.0-10.0,12.55 and 11,81 ppm, respectively were absent, which commensurate with the 
fact tfiat coordination to the metal center takes place by the deprotonation of the 
ftinctional groups [285,286]. Additionally, the charactoistic resonance signals at 3.36, 
3.80 and 4.80 ppm corresponding to the CH2 proton adjacent to the amino group (NCHj), 
CH2 proton adjacent to the carboxylate group (CCH2) of glycylglycine and coordinated 
H2O molecules, respectively were observed. The aromatic protons of sulfasalazine 
appesared as a multiple! at 6.86-8.35 ppm [287]. The broadening of the spectrum in the 
aromatic region was due to the merging of-SO2NH and NH2 protons in the same region 
[288]. The '^ C NMR spectrum of complex [Zn(glygly)(ssz)(H20)].6H20 exhibited 
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various resonances due to 0-C=0, C-O-Zn and -CH2 carbons at 178.86, 158.09 and 
46.15-54.29 ppm, respectively. In addition, aromatic carbon signals were observed at 
118.59-150.06 ppm (Figure 64). 
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Figure 64. 'Hand '^CNMR spectra of complex [Zn(glyglyXssz)(H20)].6H20 in D2O 
solution. 
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Electronic spectra 
The electronic absorption spectrum of complex [Zn(glygly)(ssz)(H20)].6H20 in freshly 
prepared aqueous solutions was carried out in the region 200-1100 nm at room 
temperature. The electronic spectrum of free dipeptide displayed an intense absorption 
bands at 220 nm due to n—*n* transition which was shifted to 231 nm upon coordination 
with Zn(II) metal ion, and has been assigned to N" -•Zn(II) charge transfer (LMCT) 
transition [283]. A broad band at 256 and 370 nm were attributed to JI-TI* transitions of 
carboxylate group of peptide and n-7r* transiticms of the carboxylic -OH and phenolic -
OH of sulfasalazine ligand to the metal ion, respectively. [284]. 
X-ray difTraction analysis 
To obtain fiirther evidence about the structure and lattice dynamics of the metal complex 
[Zn(glygly)(ssz)(H20)].6H20, Xn^y powder diffraction was performed. The XRPD 
pattern (Figure 2) obtained for the metal complex [Zn(glyglyXssz)(H20)].6H20 shows 
well defined crystalline peaks indicating that the complex [Zn(glygly)(ss2)(H20)].6H20 
is crystalline in phase due to inherent crystalline nature. The X-ray dififractogram of the 
complex [Zn(glygIy)(ssz)(H20)].6H20 shows reflecting peaks at 29 scattering angles of 
31.72, 34.40, 36.21, 47.49, 56.51 and 76.82 assigned to (100), (002), (101), (102), (110) 
and (202) crystal planes respectively, characteristic of a well ordered hexagonal 
arrangement of Zn(II) atoms (JCPDF:80-0075). The lattice parameters found for 
complex [Zn(glygly)(ssz)(H20)].6H20 are a = b = 3.23 and c = 5.19, which are consistent 
with the known lattice parameters a = b = 3.253 and c = 5.209, indicating that the 
complex particles have the same crystal structure as that of the bulk. A summary of the 
refined XRPD parameters of complex [Zn(glygly)(ssz)(H20)].6H20 is given in Table 12. 
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Figure 65. The XRPD pattern of complex [Zn(glygly)(ssz)(H20)].6H20 showing peaks 
at different scattered angles and their planes (miller indices). 
Table 12. Summary of the XRPD data and the refinement parameters for complex 
[Zn(glygly)(ssz)(H20)].6H20  
Parameter Complex fZn(glygly) (ssz) {H2O)]. 6H2O 
Formula C22H32ZnN60,5S 
FW 717.97 
Temperature(K) 298 
Method Micro crystalline 
Wavelength 1.540598 
Radiation Cu-Kal 
Crystal System Hexagonal 
Space group P 
Unit cell dimension 
a(A) 3.23 
b(A) 3.23 
c(A) 5.19 
0° 90 
P" 90 
•f 120 
26 range 20-80 
Limiting indices 0 < h < 5 
Intensity (%) 14.29-100 
DNA binding studies 
Electronic absorption titration 
Electronic absorption spectroscopy is one of the most convenient tools to examine the 
binding mode of DNA with metal complexes. Any interaction between the complexes 
and DNA is expected to perturb the ligand centered transitions of complex. Binding of 
complexes with DNA by intercalation mode generally results in hypochromism and a red 
shift (bathochromism) of the absorption band due to a strong stacking interaction between 
an aromatic moiety of the ligand and the base pairs of the DNA [289,290]. On the other 
hand, the absorption intensity of a complex is increased (hyperchromism) upon 
increasing the concentration of CT DNA owing to the degradation of the DNA double-
helix structure [291]. The extent of the hyperchromism is indicative of the partial or non-
intercalative binding modes, such as electrostatic forces, van der Waals interactions, 
dative bonds, hydrogen bonds and hydrophobic interactions. 
The absorption spectra of complex [Zn(glygly)(ssz)(H20)].6H20 in the absence and 
presence of CT DNA is shown in Figure 66. In the UV region, complex 
[Zn(glygly)(sszXH20)].6H20 displayed an intense absorption bands at 256 nm, attributed 
to intraligand n-n* transition. Upon the addition of increasing amounts of CT DNA (0.0-
3.33 X 10"^  M) to the complex [Zn(glygly)(ssz)(H20)].6H20 at constant concentration 
(1.00 X 10"^  M) showed an increase in the absorption spectral intensity of the intraligand 
"hyperchromism" absorption band with a red shift of 1-2 nm. These results suggest that 
interactions between the complex [Zn(glygly)(ssz)(H20)].6H20 and CT DNA occurs by 
non-intercalative binding modes either due to (i) external contact (surface binding) with 
the duplex through hydrogen-bonding interactions between coordinated -NH2 and 
oxygen atoms of the ligand with DNA nucleobases which are accessible both in the major 
and minor grooves, (ii) covalent coordinate bonding with base pairs of DNA due to the 
replacement of the labile water molecule. Also, the presence of aromatic moieties could 
facilitate partial intercalation by insertion of the complexes into the adjacent base pairs of 
DNA. The intrinsic binding constant (Kb) value was calculated and found to be 2.67 x lO'* 
M"'. The Kb value suggested that complex fZn(gJygJy)(ssz)(H20)].6H20 binds strongly 
to calf thymus DNA. Literature survey reveals that Zn(II) complexes in contrast to Cu(II) 
and Ni(II) binds selectively to thymine, altering the local structure of the A-T base pairs 
of DNA helix by hydrogen bond breakage [292]. 
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Figure 66. Absorption spectral traces of complex [Zn(glygly)(ssz)(H20)].6H20 in 
5mM Tris HCU 50 mMNaCl buffer at pH 7.2 upon addition ofCTDNA. Inset: Plots of 
[DNA]/ Ea-ef (1^ cm) vs. [DNA] for the titration of CT DNA with complexes m, 
experimental data points; full lines, linear fitting of the data. [Complex] 1.00 x KT^ M. 
[DNA] 0.0-3.33 X KT' M. 
Absorption titration with 5'-TMP and 5'-GMP 
In order to gam support for selective binding of the zinc metal ion to thymine base of 
DNA helix selectively involving possibly N3 thymine coordination, the interaction of 
[Zn(glygly)(sszXH20)].6H20 with DNA bases thymine and guanme was investigated 
using electronic absorption spectral technique. Addition of thymine to complex 
[Zn(glygly)(ssz)(H20)].6H20 resulted in increase in absorbance (78% hyperchromism) in 
the intraligand bands with no blue or red shift (Figure 67). The hyperchromicity implies 
that the interaction between complex [Zn(glygly)(ssz)(H20)].6H20 and the thymine 
could be due to coordination of Zn(II) metal ion after liguid dissociation or 
reorganization and hydrogen bonding with 02 and 04 oxygen atoms of thymine. 
However, on addition of guanine to the complex [Zn(glyglyXsszXH20)].6H20 exhibited 
relatively small hyperchromic changes (61%) were observed m absorbance intensity 
(Figure 68). hi order to evaluate the binding affinity of complex 
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[Zn(glygly)(sszXH20)].6H20 with 5-TMP and 5'-GMP, the intrinsic binding constant 
(Kb) values were determined and calculated to be 3.49 x 10* and 1.42 x 10* M~', 
respectively. These results revealed that complex [Zn(glygly)(ssz)(H20)].6H20 has 
stronger binding affinity towards thymine in comparison to guanine due to two effects; 
when thymine binds, hydrogen bonds are formed between the NH2 group of ligand and 
carbonyl groups of thymine, which stabilizes the complex and secondly, a significant 
stronger molecular orbital (MO) interaction is identified in thymine in comparison to 
guanine [293]. The presence of two electron withdrawing 0x0 groups C2 and C3 position 
of thymine ring lower the energy of the lone pair orbital at N3 of thymine base. 
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Figure 67. Absorption spectral traces of complex [Zn(glygly)(ssz)(H20)].6H2O in 5 
mM Tris-HCl/50 mMNaCl buffer upon addition of5'-TMP Arrow shows the absorbance 
changes upon increasing concentration of the 5'-TMP. 
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Figure 68. Absorption spectral traces of complex [Zn(glygly)(ssz)(H20)].6H20 in 5 mM 
Tris-HCl/50 mM NaCl buffer upon addition of 5'-GMP Arrow shows the absorbance 
changes upon increasing concentration of the 5'-GMP. 
NMR ('H and *'P) interactioii studies with 5'-TMP 
To validate our hypothesis, the preferential binding of complex 
[Zn(glygly)(ssz)(H20)].6H20 towards 5-TMP were carried out by employing 'H and ^'P 
NMR techniques at physiological pH (7.4). The ' H NMR of free 5'-TMP in D2O solvent 
recorded the proton resonance of N3-H at 7.64 ppm and ribose HI-H5' at 3.8-5.8 ppm 
respectively. (M mteraction of complex [Zn(glyglyXsszXH20)].6H20 with 5'-TMP, the 
N3 position was shifted downfield with a decrease in the peak intensity (Figure 69a) from 
7.64 ppm to 8.22 f^m. However, the ribose proton Hl'-HS' signals were shifted upfield 
~0.08 ppm, which indicate the presence of diamagnetic Zn(II) center in the proximity of 
these protons. 
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Figure 69. (a) 'H NMR spectra of 5'-TMP and the reaction of complex 
[2n(glygly)(ssz)(H20)].6H20 (2.5 mmol) with 5'-TMP (5 mmol) at 25 "C (b) ^'P NMR 
spectrum of 5'-TMP and the reaction of complex [Zn(glygfy)(ssz)(H20)].6H20 (2.5 
mmol) with 5'-TMP (5 mmol) at 25 °C. 
The ^'P NMR spectrum of 5'-TMP reveals a signal at 3.67 p|Mn which was shifted 
downfield to 4.60 ppm on interaction with complex [Zn(glygly)(ssz)(H20)].6H20, 
indicative of electrostatic binding mode of the complex t2^gIyglyXsszXH20)].6H20 to 
the phosphate group of 5'-TMP (Figure 69b). Since there is a large downfield shift, it 
implies that the complex involves other non-covalent DNA binding modes in addition to 
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electrostatic binding. These observations are in corroboration with spectroscopic and 
molecular docking results. 
Ethidium bromide displacement assay 
To further investigate the mode of binding of the complex 
[Zn(glygly)(ssz)(H20)].6H20, the ediidium bromide displacement assay was carried 
out. The extent of quenching of the fluorescence of EthBr bound to DNA would 
reflect the extent of DNA bindmg of complex [Zn(glyglyXssz)(H20)].6H20. EB (3,8-
diamino-5-ethyl-6^henylphenanthrium bromide), a phenanthridine fluorescence 
dye, is a typical jmbe for intercalation [294], form soluble complexes with nucleic 
acids and emits intense fluorescence when intercalated into the base pairs of DNA 
[295]. Upon addition of complex [Zn(glygIy)(ssz)(H20)].6H20 to CT DNA prefreated 
with EB ([DNA]/[EB] =1) solution caused appreciable reduction in emission 
intensities (Figure 70). Addition to the EB-DNA system induces notable fluorescence 
changes, which indicate that EB molecule, have been replaced by the complex 
[Zn(glygly)(ssz)(H20)].6H20. Further, the quenching extent was evaluated 
qualitatively by employing Stem-Vohner equation (4). 
The Ksv value for the complex [Zn(glygly)(ssz)(H20)].6H20 was found to be 2.56, 
indicating tiie strong affinity of the complex [Zn(glyglyXsszXH20)].6H20 to CT DNA. 
Smce EB was not completely displaced, partial intercalation in addition to the 
electrostatic mode of binding cannot be ruled out. 
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Figure 70. Emission spectra ofEB bound to DNA in the absence and presence complex 
[Zn(glygly)(ssz)(H20)].6H20 in 5 mM THs-HCl/50 mM NaCl buffer. Arrows show the 
intensity changes upon increasing concentration of the complex. Inset: Plots of yi xs 
[complex J/[DNA]. (m) experimental data points; full lines, linear fitting of the data. 
Thermal denaturation 
The binding of the complex [Zn(glygly)(ssz)(H20)].6H20 to CT DNA was further 
distinguished by examming the thermal denature profile of DNA. When ds-4DNA is 
heated slowly, the helix unfolds and the interaction between the base pairs of the helix 
decreases to give single stranded DNA. The mid-point temperature of this transition is 
the melting temperature (Tm) of the double strand DNA. The breakage of ds-DNA into 
single strand DNA can be detected by the "hyperchromic effect" in the UV absorption 
because the molar extinction coefficient at 260 nm of the DNA base pairs of ss-DNA is 
much higher than in ds-DNA. In general, groove binding or electrostatic binding along 
the phosphate backbone of DNA gives rise to only a small change in tiiermal denaturation 
temperature, while intercalation leads to a significant rise in thermal denaturation 
temperature of DNA due to the stabilization of the Watson-Crick base-paired duplex. 
The DNA melting curves in the absence and presence of complex 
[Zn(glyglyXsszXH20)1.6H20 is presented in Figure 71. The ATm value of DNA in the 
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presence of complex [Zn(glygly)(ssz)(H20)].6H20 is 3 °C, which is characteristic of 
electrostatic binding behavior [296]. 
0.600 
S 
B 
^ 
0 10 20 30 40 50 60 70 
Temperature (°C) 
Figure 71. Thermal melting curves of CT-DNA (pink) and DNA + complex 
[Zn(glygly)(ssz)(H20)].6H20(blue). 
Circular dichroisin(CD) spectral study 
CD spectroscopy is useful technique in diagnosing changes in DNA morphology during 
drug-DNA interactions. The CD spectrum of CT DNA exhibits a positive band at 275 
nm (UV: Xmax, 260 nm) due to base stacking and a negative band at 245 nm due to the 
right-handed helicity of B-DNA form which are quite sensitive to the mode of DNA 
interactions with small molecules. Groove binding and electrostatic interaction of the 
complexes with DNA has been shown to bring about only marginal changes in the 
intensity of negative band as well as the positive band of DNA. On the other hand 
intercalators are known to enhance the intensities of both these bands [297]. Upon the 
addition of complex [Zn(glygly)(ssz)(H20)].6H20 to CT DNA, the CD spectrum of DNA 
undergoes marginal changes both in its positive and negative bands (Figure 72). The 
intensities of both the bands decrease (negative band tending to zero levels). The decrease 
in ellipsticity is due to destabilization of DNA form attributed to the opening of DNA 
structure by the formation of intra-strand DNA cross-linkings [298]. The decrease in the 
positive band suggests Aat the complex can unwind die DNA helix and lead to loss of 
helicity [299]. 
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F^ure 72. CD spectra of (A) CT DNA alone (B) CT DNA in presence of complex 
[Zn(glygly)(ssz)(H20)].6H20 in 5 mM Tris-HCl/50 mM NaCl buffer at 25 °C. 
[Zn(glygly)(ssz)(H20)].6H201.0 x KT* M, [DNA] 1.0x KT* M. 
Chemical onclease activity 
DNA cleavage witbout added reductant 
There has been considerable interest in DNA endonucleolytic cleavages reactions 
activated by transition metal complexes. The delivery of high concentrations of metal ion 
to the helix, in locally generating oxygen or hydroxide radicals, yields an efficient DNA 
cleavage reaction. It is known that DNA cleavage is reflected by relaxation of the 
supercoiled circular form of pBR322 DNA resulting in nicked circular and/or linear 
forms. The ability of Zn(II) complexes to mediate DNA cleavage is well established in 
literature [300,301] owing to the fact that these complexes show their own selectivity for 
a cleavage mechanism, it is therefore imperative to study the effect of Zn(II) complex on 
pBR322 DNA in the presence of activators, DNA recognition elements (groove binding) 
and radical scavengers. 
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The DNA cleavage ability of complex [Zn(glygly)(ssz)(H20)].6H20 was performed 
where pBR322 DNA (300ng) was incubated with increasing concentration of complex 
[Zn(glyglyXssz)(H20)].6H20 in aqueous buffer solution (5mM Tris-HCl/50mM NaCI, 
pH 7.2) for 45 min without addition of a reductant. As shown in Figure 73, it was 
observed that complex [Zn(gIygly)(ssz)(H20)].6H20 exhibits nuclease activity at 10 ^ iM 
concratration, as evidenced by the conversion of supercoiled DNA fix)m Form I to Form 
II (Lane 2). Further increase in the concentration of complex 
[Zn(glyglyXsszXH20)].6H20 (20-30 jiM), the amounts of Form I diminishes gradually, 
whereas those of Form II progressively increased (Lane 2-6) without the formation of 
Form III, suggestmg single strand DNA cleavage. So, it is clear that cleavage of pBR322 
DNA is highly dependent on metal ions concentration and intensified nicked (Form II) 
was observed. Since the nuclease eflBciency of complexes is usually dependent on 
activators [302]. Therefore, DNA cleavage activity of [Zn(glyglyXssz)(H20)].6H20 in 
the presence of H2C)2, ascorbate (Asc), 3-mercaptopropionic acid (MPA) and glutathione 
(GSH) was ascertained. As shown in Figure 74, the cleavage activity of 
[Zn(glygly)(ssz)(H20)].6H20 follows the order H2O2 > MPA > GSH > Asc. Thus, 
complex [Zn(glyglyXsszXH20)].6H20 exhibited a significant DNA cleavage activity in 
the presence of H2O2. 
Form II 
Figure 73. The cleavage patterns of the agrose Gel electrophoresis diagram showing 
cleavage ofpBR322 supercoiled DNA (300 ng) by complex [Zn(glygly)(ssz)(H20)].6H20 
at 310 K after 45 min of incubation; Lane 1. DNA control; Lane 2, 10 fiM of 
[Zn(glygly)(ssz)(H20)].6H20 + DNA; Lane 3: 15 fiM of [Zn(glygly)(ssz)(H20)].6H20 + 
DNA; Lane 4: 20 fiM of [Zn(glygly)(ssz)(H20)].6H20 + DNA; Lane 5: 25 nM of 
[Zn(glygly)(ssz)(H20)].6H20 + DNA; Lane 6: 30 nMof [Zn(glygly)(ssz)(H20)].6H20 + 
DNA. 
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Figure 74. Agarose Gel electrophoresis pattern for the cleavage ofpBR322 supercoiled 
DNA (300 ng) by complex [Zn(glygly)(ssz)^20)].6H20 in presence of different 
activating agents at 310 K after incubationfor 45 min. Lane 1: DNA Control; Lane 2: 25 
fiM of [Zn(glygly)(ssz)(H:0)].6H20 + H2O2 (0.4 M) + DNA; Lane 3: 25 piM of 
[Zn(glygly)(ssz)(H20)].6H20 + MPA (0.4 M) + DNA; Lane 4: 25 fxM of 
[Zn(glygly)(ssz)(H20)J.6H20 + GSH (0.4 M) + DNA; Lane 5: 25 nM of 
[Zn(glygly)(ssz)(H20)].6H20 + ASc (0.4 M) + DNA; Lane 6: 25 nM of 
[Zn(glygfy)(ssz)(H20)].6H20 + DMSO (0.4 M) + DNA; Lane 7: 25 fxM of 
[Zn(glygly)(ssz)(H20)].6H20 + EtOH (0.4 M) + DNA; Lane 8 : 25 piM of 
[Zn(glygly)(ssz)(H20)].6H/) + sodium azide (0.4 M) + DNA Lane 9 : 25 nM of 
[Zn(glygly)(ssz)(H20)].6H^ + SOD (15 units) + DNA. 
Effect of radical scavengers on DNA cleavage 
In order to explore the mechanistic pathway of the cleavage activity, comparative DNA 
cleavage experiment of complex [Zn(glyglyXssz)(H20)].6H20 was carried out in 
presence of some standard radical scavengers such as DMSO and ethyl alcohol as 
hydroxyl radical scavenger (HO), sodium azide (NaNa) as singlet oxygen ('O2) quencher 
and superoxide dismutase as superoxide anion radical (O2' ~) scavenger were used prior 
to the addition of complex [Zn(glygly)(sszXH20)].6H20 to DNA solution. As shown in 
Figure 74, the DNA cleavage mediated by complex [Zn(glygly)(ssz)(H20)].6H20 in the 
presence of DMSO (Lane 6) did not show any remarkable inhibition, whereas etiiyl 
alcohol (Lane 7) even promotes the conversion of Form II to Form III, indicating that the 
freely diffiisible hydroxyl radical is one of the reactive species involved in the DNA 
strand scission. On the other hand, addition of NaNs and SOD (Lane 8 and 9. 
respectively), also do not attenuate the DNA strand scission and even in presence of SOD 
the cleavage reaction was enhanced. These results suggest that hydroxyl radical, singlet 
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oxygen and superoxide anion radicals are not involved in the DNA cleavage system. 
Therefore, an oxidative cleavage pathway of DNA by complex 
[Zn(glygly)(sszXH20)].6H20 has been excluded and evidently the cleavage proceeds by 
a hydrolytic mechanism. 
The mechanistic pathway proposed for the present complex [Zn(glygly)(ssz)(H20)].6H20 
is depicted in Scheme 4. Complex [Zn(glyglyXssz)(ll20)].6H20 contains coordinated 
water molecule, which facilitates the nucleophilic attack of water oxygen to phosphorus 
to give a five-coordinate phosphate intermediate and subsequent rearrangement of the 
phosphate, which allows the DNA to be cleaved readily. This hypothesis is consistent 
with previous literature reports which reveals that Zn(II) complexes generally cleave the 
DNA by hydrolytic pathway [303,304]. 
To ascertain the discernible hydrolytic DNA cleavage pathway mediated by complex 
[Zn(glygly)(ssz)(H20)].6H20, DNA religation experiment was further performed in 
which supercoiled pBR322 DNA was treated with T4 ligase enzyme and subjected to gel 
electrophoresis [305]. In our case, the nicked form (Form II) was religated to a large 
extent in the presence of T4 DNA ligase enzyme in comparison to control DNA alone in 
supercoiled form (Figure 75), providing a direct evidence in favor of hydrolytic 
mechanism. Therefore, complex [Zn(glygly)(ssz)(H20)].6H20 could be useful not only in 
drug design but also in elucidating the precise role of metal ions in enzyme catalysis. 
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Figure 75. Agarose Gel electrophoresis pattern for the ligation pBR322 plasmid DNA 
linearized hy complex [Zn(glygly)(ssz)(H20)J.6H20; Lane I: DNA control; Lane 2: 
pBR322 plasmid DNA cleaved by complex [Zn(glygly)(ssz)(H20)].6H2O; Lane 3: ligation 
of the cleaved pBR322 DNA by T4 DNA ligase. 
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Scheme 4. Proposed intermediate in the hydrolysis of DNA cleavage promoted by 
complex [Zn(glygly)(ssz)(H2O)]. 6H2O 
DNA cleavage in presence of recognition elements (Groove binding) 
The potential interacting site of complex [Zn(glygly)(ssz)(H20)].6H20 with pBR322 
DNA was determine in presence of minor groove binding agent, DAPI and the major 
groove binding agent, methyl green. The supercoiled pBR322 DNA was treated with 
DAPI or methyl green prior to the addition of complex [Zn(glygly)(ssz)(H20)].6H20. As 
shown in Figure 76, the cleavage reaction mediated by complex 
[Zn(glygly)(ssz)(H20)].6H20 was quenched in presence of DAPI, however no apparent 
inhibition of DNA damage was observed in presence of methyl green, suggesting tiiat 
minor groove is the preferred interacting site of complex [Zn(glygly)(ssz)(H20)].6H20 
which is further validated by molecular docking studies. 
Figure 76. Agarose Gel electrophoresis pattern for the cleavage ofpBR322 supercoiled 
DNA (300 ng) by complex [Zn(glygly)(ssz)(H20)].6H2O in presence of DNA minor 
binding agent DAPI and major binding agent methyl green at 310 K after incubation for 
45 min. Lane 1, DNA control; Lane 2, 9 fiM of complex [Zn(glygly)(ssz)(H20)] .6H2O + 
DNA + DAPI (8 fiM); Lane 3, 9 fxM of complex [Zn(glygly)(ssz)(H20)].6H20 + DNA + 
methyl green (2.5 juL of a 0.0 Img/ml solution). 
Molecalar docking with DNA 
In order to get more insight into the mode of binding, complex 
[Zn(glygly)(ssz)(H20)].6H20 was successively docked with DNA duplex of sequence 
d(CGCGAATTCGCG)2 dodecamer (PDB ID:1BNA) to search the chosen binding site 
along with preferred orientation of the ligand inside the DNA minor groove, hi general, 
minor-groove binding molecules have aromatic rings connected by single bonds that 
allow for torsional rotation in order to &cilitate into the curvature of groove with 
displacement of water molecules. The minimum aiergy docked pose (Figure 77) revealed 
that complex [Zn(glygly)(ssz)(H20)].6H20 snuggly fitted into the curve contour of DNA 
minor groove in the A-T (-10.8 A) regions compared to G-C (-13.2 A) ones, and 
slightly bends the DNA in such a way that a part of the aromatic rings of sulfasalazine 
ligand makes more effective n-n stacking interactions between DNA base pairs and lead 
to van der Waals interaction with the DNA functional groups which define the stability of 
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groove [306]. On the other hand, the dipeptide moiety arranged in a parallel fashion with 
respect to the deoxyribose groove walls of the DN A and stabilized by hydrogen bonding 
(2.8-3.0 A) between the amino group and C-2 carbonyl oxygen of T8 at a distance of 
3.71 A. 
The resulting relative binding energy of docked structures of the complex 
[Zn(glygly)(ssz)(H20)].6H20 with DNA was found to be -287.4 KJmol"', indicating the 
more potent the binding affinity between DNA and complex 
[Zn(glygly)(ssz)(H20)].6H20, correlating well with the experimental DNA binding 
studies and minor groove binder using DAPl assay. Thus, we can conclude that there is a 
mutual complement between spectroscopic and molecular docking techniques, which can 
substantiate our experimental results and provide valuable information about the mode of 
interaction between complex and DNA. 
Figure 77. Molecular docked model of complex [Zn(glygly)(ssz)(H20)].6H2O revealing 
partial intercalation into adjacent A/T base pairs from minor groove side with DNA 
dodecamer duplex of sequence d(CGCGAATTCGCG) 2 (PDB ID: IBNA). 
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Condusion 
In tiiis work, we have designed and synthesized a new zinc(II) complex possessing 
phannacoiogically active and well-tailored pharmacophore derived from the glycyl 
glycine and sulfasalazine ligand. The in vitro DNA binding studies of complex 
[Zn(glygly)(ssz)(H20)].6H20 were carried out to examine its effect on DNA binding 
propensity which reveals an electrostatic mode of binding, in addition to selective 
recognition towards the minor groove of DNA in A/T rich sequences. The complex 
[Zn(glyglyXss2XH20)].6H20 binds supercoiled plasmid pBR322 DNA and cleave DNA 
through hydrolytic mechanism. This could be attributed to its high binding affinity which 
enhances local concentration of metal complexes around DNA and consequently, results 
in better cleavage activity. The hydrolytic cleavage mechanism of the complex 
[Zn(glygly)(sszXH20)].6H20 is supported by evidence from DNA religation employing 
T4 DNA ligase assay and was validated from free radical quenching. Furthermore, 
molecular docking study was performed with DNA sequence d(ACCGACGTCGG)2 in 
order to validate the «cperimental results. The significance of such studies provides the 
design of novel metal-based drugs with proven pharmacokinetic properties that could 
overcome Ae intrinsic or acquired resistance of several tumors to platinum drugs and role 
of metal ions in enzyme catalysis. 
CHAPTER IV (b) 
Synthesis, characterization and interaction studies of copper 
based drug with Human Serum Albumin (HSA): spectroscopic 
and molecular docking investigations 
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Synthesis 
Synthesis of [Cu(gtyglyXssz)(H20)].6H20 
To a stirred methanolic solution (15 ml) of copper nitrate hexahydrate (0.483g, 2mmol) 
was added an aqueous solution of glycyl glycine (0.262g, 2mmol) followed by drop wise 
addition of KOH (0.224g, 2 mmol) and pH of the resulting solution was adjusted between 
8.0-12. This reaction mixture was stirred for ca 2 h at room temperature to obtain clear 
blue color solution. A methanolic solution (20 ml) of sulfasalazine (0.80 g, 2mmol) was 
added to the above reaction mixture and stirred for 3h. The light brown colored solid 
precipitate was filtered, thoroughly wash with ice cold methanol and dried in vacuo over 
anhydrous CaCb (Yield: 0.5lOg, 65%). m.p. 250 ± 2 "C (dec.), Anal. Calc. for 
C22H32CUN6O15S (%): C, 36.92; H, 4.51; N, 11.75; S, 4.47, Found: C, 36.64; H, 4.67; N, 
11.95; S, 4.16. Selected IR data on KBr/nujol, cm"': 3399 v(NH2+H20); 1606 v(CO); 
1387 v(C-N); 580 (Cu-0); 441 (Cu-N). Molar Conductance, AM (1 x 10"^  M, H2O): 28 
n"'cm^mor' (Non-electrolyte). UV-vis absorption: (H2O, 10"* M), X a^x/nm (e/10^ NT' 
cm"') 236 (4.00); 255 (4.20); 376 (7.50); 660 (0.70). ESI-MS (m/z, H2O): 714.7 [M] *; 
608.6 [M-<6H20)]^ 
Results and discussion 
In order to improve delivery of active drugs to their specific site of action (Figure 78), 
new drug candidate, complex [Cu(glygly)(ssz)(H20)].6H20 was designed, synthesized 
and characterized by various physico-chemical methods. The synthesis of 
[Cu(glyglyXssz)(H20)],6H20 complex was achieved by mixing stoichiometric amounts 
of Cu(II) nitrate trihydrate with glycyl glycine and sulfasalazine followed dropwise 
addition of KOH (Scheme 5), in a good yield. The resulting complex 
[Cu(glygly)(ssz)(H20)].6H20 is stable towards air and moisture and readily soluble in 
H2O. The complex [Cu(glygly)(ssz)(H20)].6H20 was characterized by using elemental 
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analysis, IR, Uv-vis and EPR spectral studies. Molar conductance value of complex in 
H2O (1 X 10"^  M) at 25 °C suggest its non-electrolyte nature (28 n"'cm^ mol"'). 
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Figure 78. Chemical equilibrium between the complex [Cu(glygly)(ssz)(H20)].6H2O-
HSA system towards targeted delivery. 
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Scheme 5. Synthetic route for complex [Cu(glygly)(ssz)(H20)].6H2O 
Electronic Spectra 
The electronic absorption spectrum of complex [Cu(glygly)(ssz)(H20)].6H20 in freshly 
prepared aqueous solutions was carried out in the region 200-1100 nm at room 
temperature. The electronic spectra of free dipeptides displayed an intense absorption 
bands at 220 nm due to n—•Jt* transition which was shifted to 236 nm upon coordination 
with Cu(II) metal ion, and has been assigned to -N~-^Cu(II) charge transfer (LMCT) 
transition [307]. The bands at 255 and 376 nm were attributed to Tt-n* transitions of 
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carboxylate group of peptide and n-n* transitions of the carboxylic-OH and phenolic-
OH of sulfasalazine ligand to die metal ion, respectively, through deprotonation [308]. 
The low energy d-d band at 660 nm was assigned to ^Big-+^B2g transitions suggesting an 
octahedral geometry around Cu(II) metal ion [309] which was also deduced by EPR. 
IR spectra 
The IR spectra of complex [Cu(glygly)(sszXH20)].6H20 was recorded in the region 
4000-400 cm"' and analyzed in comparison to the IR spectra of the free ligands with its 
metal complex as described previously in our Chapter IV (a). The formation of complex 
[Cu(glygly)(ssz)(H20)].6H20 was also deduced by the presence of new medium intensity 
bands around 441 and 580 cm"' corre^x)nding to Cu-N and Cu-0, respectively 
[311,312]. 
EPR studies 
The X-band EPR spectra of the complex [Cu(glygly)(sszXH20)].6H20 was recorded at 
room temperature in aqueous solution at a frequency of 9.1 GHz under the magnetic field 
strength 3000±1000 Gauss using tetracyanoethylene (TCNE) as field maricer at LNT 
(Figure 79). The g||, gi and gav values calculated from the expression gav^  = (gn ^  + 2gi'^ )/3 
and were found to be 2.27, 2.04 and 2.11, respectively. These values are consistent with 
an octahedral geometry of copper with d' (Cu°) configuration i.e. (eg)'* (alg)^ (b2g)^ 
(big)', occupied by an unpaired electron [312]. The trend gji > gi > ge (2.0023) reveals 
that the unpau-ed electron is localized in the dx%^ orbital. The values of gy for covalent 
complex, g|| < 2.3 and for an ionic environment, gn = 2.3 or more are reported in the 
literature. In the present complex gy < 2.3 mdicates an appreciable metal-ligand covalent 
character [313]. 
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Figure 79. EPR spectra of complex [Cu(glygly)(ssz)(H20)].6H20 at variables 
temperature in aqueous solution. 
HSA binding studies 
Fluorescence quenching of HSA by complex [Cu(glygly)(ssz)(H20)].6H20 
Fluorescence spectroscopy is an effective method to explore the interaction between 
small molecules and biomacro-nnolecules. Literature reveals that fluorescence of HSA 
comes fixMn tiie tryptophan, tyrosine and phenylalanine residues. Phenylalanine has a 
very low quantum yield and the fluorescence of tyrosine is almost totally quenched if it is 
ionized or present near to an amino group, a carboxyl group or a tryptophan. Thus, the 
fluorescence of HSA is dominated by the residue Trp-214 in subdomain IIA [314]. When 
small molecular substances bound to HSA, the changes of intrinsic fluorescence intensity 
of HSA are induced by the microenvironment of Trp residue. The fluorescence emission 
spectra of HSA at various concentration of complex [Cu(glygly)(ssz)(H20)].6H20 is 
shown in Figure 80. HSA exhibits a strong fluorescence emission with a peak at 350 nm 
at >^ = 280 nm, while complex [Cu(glygly)(ssz)(H20)].6H20 has no intrinsic 
fluorescence under the present experiment conditions. Upon increasing the concentration 
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of complex [Cu(glygly)(sszXH20)].6H20, caused a reduction of the fluorescence 
intensity. The strong quenching of HSA fluorescence clearly indicated complex 
[Cu(glygly)(ssz)(H20)].6H20 was bound to HSA takes place and the interactions of HSA 
with complex [Cu(glygly)(ssz)(H20)].6H20 changed the microenvironment around the 
Trp-214 residue and the tertiary structure of HSA [315]. 
The fluorescence intensity of a compound can be decreased by a variety of 
molecular interactions, such as excited-state reactions, molecular rearrangements, energy 
transfer, ground-state complex formation and collision quenchmg [207]. CoUisional or 
dynamic quenching refers to a process that the fluorophore and the quencher come into 
contact during the lifetime of the excited-state, whereas static quenching refers to 
fluorophorc-quencher complex formation [316], 
In order to ascertain the fluorescence quenching mechanism, the fluorescence quenching 
data at different temperatures (299, 308 and 318 K, Figure 81) was analyzed using the 
classical Stem-Vohner equation. The results (Table 13) showed that the Stem-Volmer 
quenching constant Kjv is inversely correlated with temperature, and the vahies of k<, 
being larger than the limiting diffusion constant Kdif of the biomolecule (Kdif = 2.0 x 10'° 
M~'s~ )^, suggested that the fluorescence quenching was caused by a specific interaction 
between HSA and complex [Cu(glygly)(ssz)(H20)].6H20, and the quenching is not 
initiated by dynamic collision but arises mainly due to the complex formation. 
Table 13. Stem-Volmer quenching constant of the complex 
[Cu(glygly)(ssz)(H20)].6H2O-HSA system at different temperatures 
pH T(K) Ksv(10"M"') K<, (10"M~'s"') 
299 
^^ 3.08 3.08 
'^•'^^ 308 1.89 1.89 
318 1.59 1.59 
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Figure 80. The fluorescence quenching spectra of HSA by different concentrations of 
complex Cu(glygly)(ssz)(H20)].6H2O with the excitation wavelength at 280 nm in 5 mM 
Tris-HCl/50 mMNaCl buffer, pH 7.4, at room temperature: [HSA], 1.0 xlO^ M; (a-gj 
the concentration of complex Cu(glygly)(ssz)(H20)].6H20 corresponding to 0-3.33 x 10' 
^ M, respectively. Arrow shows the intensity changes upon increasing concentration of 
the quencher. 
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Figure 81. Stern-Volmerplots showing HSA tryptophan qttenching caused by complex 
[Cu(glygly)(ssz)(H^)].6H20 at three different temperatures. 
Binding constants and the number of binding sites 
For the static quenching process, the quenching data were analyzed according to the 
modified Stem-Voimer equation (Equation (9)). As shown in Figure 82, the binding 
constant decreased with increasing temperature (Table 14), which coincided with the 
Stern-Volmer quenching constant. As static quenching, the quenching constant can be 
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interpreted as the association constant of the complexation reaction since static quenching 
occurs from the formation of a ground state complex which is non-fluorescent or weakly 
fluorescent between fluorophore and quencher. When small molecules bind 
independently to a set of equivalent sites on a macromolecule, the equilibrium between 
free and bound molecules is given by the equation (10). The binding constants K and 
binding sites "n" were calculated by the slopes of the static quenching equation (log (Fo-
F)/F versus log [Q]) curves as shown in Figure 83 and the results have been summarized 
in Table 14. The binding constants decreased with increasing temperature, which 
coincided with the Lineweaver-Burk, Stem-Volmer quenching constants. 
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Figure 82. The Linweaver^Burk plot for the binding of HSA with complex 
[Cu(glygly)(ssz)(H20)].6H20 at different temperatures. 
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Figure 83. Logarithmic plot of the fluorescence quenching of HSA at different 
temperatures. 
Table 14. Binding constant (Kb), the number of binding sites (n) and AG values for the 
complex [Cu(glygly)(ssz)(H20)].6H2O-HSA system at different temperatures 
pH T(K) Kb(10'M-') n AG (kJ/mole) 
299 2.309 1.098 -30.713 
7.40 308 1.944 1.244 -31.997 
318 1.298 1.042 -31.136 
Thermodynamic parameters and nature of the binding forces 
The binding forces between [Cu(glygly)(ssz)(H20)].6H20 complex and HSA exhibit 
weak interactions such as electrostatic forces, hydrophobic interaction, hydrogen-bond 
formation and van der Waals interaction etc. [317]. The thermodynamic parameters, 
enthalpy change (A//), entropy change (A5) and free energy change (AG) are the main 
evidence for confirming the binding modes. From the thermodynamic standpoint, AH> 0 
and AS> 0 implies a hydrophobic interaction; AH< 0 and AS < 0 reflects the van der 
Waals force or hydrogen bond formation; and AH=0 and AS > 0 suggests an electrostatic 
force. The positive AS value is frequently taken as evidence for hydrophobic interaction. 
Furthermore, the negative Mi value observed cannot be mainly attributed to electrostatic 
134 
interactions since for electrostatic interactions A/f is very small, almost zero. A negative 
AH value is observed wlienever there is hydrogen bond on tiie binding site. It is not 
possible to account for the thermodynamic parameters of the complex 
[Cu(glyglyXssz)(H20)].6H20-HSA coordination complex on the basis of a single 
intermolecular force. Consequently, the negative AH (-3.116 KJ/mole) and positive AS 
(+120.57 J/mole K) values suggest that both hydrophobic and hydrogen bond interactions 
could play major roles in the complex [Cu(glygly)(ssz)(H20)].6H20-HSA binding 
reaction and contribute to the stability of the complex. The negative value of AG reveals 
that the interaction process is spontaneous (Figure 84 and Table 14). 
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Figure 84. Van't Hoffplot for the interaction of complex [Cu(glygly)(ssz)(H20)].6H20 
andHSA. 
Energy transfer between complex [Cu(glyglyXsszXH20)].6H20 and HSA 
Fluorescence energy transfer occurs via overlapping of emission spectrum of a 
fluorophore (donor) overl^s with the absorption spectrum of another molecule 
(acceptor). The overly of the absorption spectrum of the complex 
[Cu(glygly)(ssz)(H20)].6H20 with the fluorescence emission spectra of free HSA is 
shown in Figure 85. The rate of energy transfer depends on: (i) the extent of overlapping 
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between fluorescence emission spectrum of donor and the absorption spectrum of 
acceptor, (ii) the relative orientation of the donor and acceptor dipoles, and (iii) the 
distance between the donor and the acceptor. Here the donor and acceptor were HSA and 
the complex [Cu(glygly)(ssz)(H20)].6H20, respectively. From Equations (13)-(15), the 
value of E, Ro, r and J were calculated and found to be 0.99, 2.5 nm, 3.7 nm and 
1.6x10"'" M~' cm ,^ respectively. The donor to acceptor distance r < 7 nm indicated that 
tiie energy transfer from tryptophan residue in HSA to complex 
[Cu(glygly)(sszXH20)].6H20 occur with high probability [318], which is also in 
accordance with the conditions of FRET, indicating the static quenching interaction 
between complex [Cu(glygly)(ssz)(H20)].6H20 and HSA. 
iM 4» in 
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Figure 85. The overlap of UV absorption spectra of complex 
[Cu(glygly)(ssz)(H20)].6H20 with the fluorescence emission spectra of HSA. (a) The 
fluorescence emission spectrum of HSA (1.0 x 10~^ M) and (b) the UV absorption 
spectrum of complex [Cu(glygly)(ssz)(H20)].6H20 (0.60 x 10~^ M). 
Changes of the protein's secondary structure induced by complex 
[Cu(glygIy)(ssz)(H20)].6H20 
To ascertain the possible influence of complex [Cu(glygly)(ssz)(H20)].6H20 binding on 
the secondary structure of HSA, CD measxirement was performed in the presence of 
complex [Cu(glygly)(ssz)(H20)].6H20 at different concentrations. As shown in Figure 
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86, CD spectra of free HSA (line a) exhibit two negative bands in the ultraviolet region at 
208 and 222 nm attributed to n—*K* transfer for the peptide bond of a-helix [319]. It was 
observed that in presence of [Cu(glygly)(ssz)(H20)].6H20 the CD signal of HSA 
increased. The increase of the CD signal indice^s decrease of helical secondfuy structure 
content. This phenomenon is like with the interaction of HSA with complex 
[Cu(glyglyXsszXH20)].6H20. However, the CD spectra of HSA in the presence or 
absence of complex [Cu(glygly)(ssz)(H20)].6H20 is similar in shape, indicating that the 
structure of HSA is also predominantly a-helical. From above Equations (16) and (17), 
the quantitative analysis results of the a-helix in the secondary structure of HSA were 
obtamed. They differed from that of 59.29% in free HSA to 56.54% in the complex 
[Cu(glygly)(ssz)(H20)].6H20-HSA conjugate at pH 7.4 and temperature 25 °C. The a-
helix gradually decreased in the presence of complex [Cu(glygly)(ssz)(H20)].6H20, 
which reveals that the interaction between complex [Cu(glygly)(ssz)(H20)].6H20 and 
HSA leads to a change of the protein's secondary structure. 
To furtiier understand the structural alternations of HSA induced by the binding of 
complex [Cu(glygly)(ssz)(H20)].6H20 to HSA, FT-IR spectroscopy were performed on 
HSA and complex [Cu(glygly)(sszXH20)].6H20-HSA system (Figure 87a and b). The 
spectrum in Figure 87(a) was obtained by subtracting the absorption of the Tris-HCI 
fix)m the spectrum of the protein solution. The spectrum in Figure 87(b) was obtained by 
subtracting the absorption of the complex [Cu(glygly)(ssz)(H20)].6H20-free form from 
that of the complex [Cu(glyglyXssz)(H20)].6H20-bound form, htfrared spectra of 
proteins exhibit a number of the amide bands, which represent different vibrations of the 
peptide moiety. Among these amide bands of the protein, amide I peak position occur in 
the range 1600-1700 cm"' (mainly C=0 stretch) and amide II band in the region 1500-
1600 cm"' (C-N stretch coupled with N-H bending mode). The amide bands have a 
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relationship with the secondary structure of protein, and amide I is more sensitive than 
amide II for change of secondary of protein [320]. As shown in Figure 87, the peak 
position of amide I band was shifted from 1653.27 cm"' to 1635.32 cm"', implicating that 
that the secondary structure of the HSA protein altered due to interaction of complex 
[Cu(glygly)(ssz)(H20)].6H20. 
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Figure 86. CD Spectra of the HSA-complex [Cu(glygly)(ssz)(H20)].6H20 system (a) 
1.5xlO~^MHSA and(b) 1.5 x 10'^MHSA + 3.0x 10'^M[complex]. 
1700 1600 1900 1400 
Wavenumber (cm "^) 
Figure 87. FT-IR spectra of (a) free HSA and (b) different spectra [(HSA solution + 
[Cu(glygly)(ssz)(H20)].6H20 solution)-([Cu(glygly)(ssz)(H20)].6H20 solution)] in 5 
mM Tris-HCl/50 mM NaCl buffer, pH 7.4, at room temperature in the region of 1750-
1400 cm-', [HSA], 1.5x 10'^ M; [Cu(glygly)(ssz)(H20)].6H20], 3.0x 10'^ M. 
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Molecular modeling study of the iuteraction between HSA and complex 
[Cu(glygly)(8M)(HiO)1.6H20 
Molecular docking technique was further employed to understand the interaction between 
complex [Cu(glygly)(sszXH20)].6H20 and HSA. Descriptions of the 3D structure of 
crystalline albumin have revealed that that HSA comprises three homologous domains 
(denoted I, II, and HI): I (residues 1-195) II (196-383) and HI (384-585); each domain 
has two subdomains (A and B) that assemble to form heart shaped molecule (Figure 88). 
The principal region of drug binding sites of HSA are located in hydrophobic cavities in 
subdomain HA and IIIA, which are corresponding to site I and site II, respectively and 
tryptophan residue (Tip-214) of HSA in subdomain HA [321]. There is a large 
hydrophobic cavity in subdomain IIA to accommodate the complex 
[Cu(glyglyXssz)(H20)].6H20, which play an important role in absorption, metabolism, 
and transportation of HSA. The results as depicted in (Figure 89) reveal that the complex 
[Cu(glygly)(ssz)(H20)].6H20 was half-surrounded within subdomain IIA hydrophobic 
cavity, and it is in close proximity to hydrophobic residues, such as Lysl95, Trp214, 
Ala215, Arg218, Leu219, Val216, Ala291, Glu292, etc., of subdomain IIA of HSA [48], 
suggesting the existence of hydrophobic interaction between them. Hence, this finding 
provides a good structural basis to explain the efficient fluorescence quenching of HSA 
emission in the presence of the complex [Cu(glyglyXssz)(H20)].6H20. Furthermore, 
there are also a number of weak electrostatic interactions and hydrogen bonds, because 
sevCTal ionic and polar residues in the proximity of the ligand play an important role in 
stabilizmg the molecule by forming hydrogen bonds and weak electrostatic interactions. 
As shown in Figxu-e 90, there are hydrogen bond interactions between the main chain 
carbonyl oxygen of Arg-257 and terminal amino group of the complex 
[Cu(glygly)(ssz)(H20)].6H20 and other between carbonyl and sulfone (0=S=0), groups 
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of the complex [Cu(glygly)(ssz)(H20)].6H20 and the residues Ala-291, Arg-222 and 
Lys-195 of HSA. These results suggest that the formation of hydrogen bonds decreased 
the hydrophilicity and increased the hydrophobicity to enforce stability in 
[Cu(glygly)(ssz)(H20)].6H20-HSA system. On the other hand, the amino acid residues 
with benzene ring could match with that of the structure of [Cu(glygly)(ssz)(H20)].6H20 
complex in space in order to firm the conformation of the complex. The results obtained 
from molecular docking indicated that the interaction between complex 
[Cu(glygly)(ssz)(H20)].6H20 and HSA was dominated by hydrophobic forces as well as 
hydrogen bonds, which is consistent with our experimental results. 
Binding site III 
Bindingsite 11 
Binding site I 
Figure 88. Modeling of X-ray crystallographic structure of HSA (PDB ID: lh9z). The 
domains and subdomains were displayed with different color, the every subdomain and 
classical binding site were marked in the corresponding location. 
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Figure 89. Molecular docked model of complex [Cu(glygly)(ssz)(H20)] .6H2O (stick 
representation) located within the hydrophobic pocket in subdomain IIA ofHSA. 
Figure 90. The interaction mode between complex [Cu(glygly)(ssz)(H20)].6H20 
(showing stick representation) and HSA (cartoon form) and the yellow dashed line 
showing hydrogen bond interaction between them. 
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CoBclasion 
In tiiis woiic, we have designed, synthesized and characterized a new drug candidate; 
complex [Cu(glygly)(ssz)(H20)].6H20 derived from the dipeptide (glycyl glycine anion) 
and sulfasalazine ligands to examine their effect on the binding propensity of HSA and to 
elucidate the mechanism of action at the molecular target. The interaction between 
complex [Cu(glyglyXsszXH20)3.6H20 and HSA was investigated employing different 
spectroscopic techniques (fluorescence, CD, FTIR) which was further validated by 
molecular docking study. The results revealed that the secondary structure of protein was 
affected upon interaction with the complex [Cu(glygly)(ssz)(H20)].6H20. Fluorescence 
results indicated the presence of static quenching mechanism upon binding of complex 
[Cu(glygly)(ssz){H20)].6H20 to HSA. On the basis of spectroscopic results, it is 
concluded that the [Cu(glygly)(ssz)(H20)].6H20 complex was bound to site 1 of protein, 
which is located in the hydrophobic pocket of subdomain IIA, the distance between the 
donor (protein) and the acceptor (complex [Cu(glygly)(ssz)(H20)].6H20) was also 
calculated by using FRET. Our results may provide valuable information to understand 
the mechanistic pathway of drug delivery and to pharmacological behavior of drug. 
CHAPTER V 
Synthesis, characterization of metal complexes: comparative in 
vitro DNA binding profile, SOD mimics and molecular docking 
studies. 
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Synthesis 
Synthesis of [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
The complex was prepared by a general synthetic method in which corresponding 2,2'-
bipyridyl (0.312g, 2mmol) and imidazole (0.136g, 2mmol) in 15 mL methanol was added 
to a methanolic solution (10 mL) of Cu(N03)2-3H20 (0.482g, 2mmol) with stirring for 
ca. 2 hour followed by the addition of the piperazine solution (0.388g, 2 mmol) taken in 5 
mL of methanol. The solution was refluxed for 2 hours at 60°C. On completion of the 
reaction, the Feacti<m mixture was kept at room temperature which yielded a dark bluish 
product, washed with hexane and diethyl ether and dried in vacuo. (Yield: 0.682g, 75%). 
m.p. 165 ± 2°C, Anal. Calc. for C3oH36Cu2N,40,2 (%) C, 39.52; H, 3.98; N; 21.51, 
Found: C, 38.63; H, 4.22; N, 21.41. Selected IR data on KBr/nujol, cm'*: 3405-3275 
v(N-H); 2959 v(CH); 1566 v(C=C); 1444 v(C=N); 1313 v(C-N); 1384 v(N-0); 1275 
5(imidazole N-H); 771 (Ar); 423 v(Cu-N). UV-vis absorption: (H2O, 10"^  M), 5wx/nm 
(s/lO' M"' cm"'): 299 (0.65); 311 (0.71); 590 (0.08). AM (I^IO"^ M, HjO): 140 Q" 
'cm^mor' (1:2 electrolyte), ESI-MS (m/z, H2O): 661.1 [(C3oH36Cu2N,40i2)-(4N03)]*; 
436.3 [(C30H36CU2N,4Oi2)-<C,3Hi3CuN7O9)]^ 
Synthesis of [Zn2(bipy)2(ini)2(pip)1.4CI 
This complex was synthesized by a similar procedure as described for 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 with ZnCb (0.272g, 2nunol). White coloured product 
was isolated. (Yield: 0.525g, 65%). m.p. 300 ± 2"C, Anal. Calc. for C3oH36Cl4NioZn2 (%) 
C, 44.52; H, 4.48; N, 17.31, Found: C, 44.49; H, 4.46; N, 17.28. Selected IR data on 
KBr/nujol, cm"': 3403-3204 v(N-H); 2972 v(CH); 1559 v(C=C); 1450 v(C=N); 1350 
v(C-N); 1262 5(imidazole N-H); 766 (Ar); 432 v(Cu-N). UV-vis (IxlO*^ M, H2O), 
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>W / nm (£/10^ NT' cm""): 294 (0.44); 306 (0.56). AM (I^IO"^ M, H2O): 347 fi-'cm' 
mor'(l:4 electrolyte). ' H N M R (DMSO-t/s, 400 MHz) 5(ppm): 2.55 (CH2-CH2); 3.19 
(NHCH2CH2NH); 6.97-7.34 (Ar-protons); 8.43 (NH imidazole). '^ C ISfMR (DMSO-<i6, 
100 MHz) 5(ppm): 44.53 (Pip-C); 154.9 (C=N); 121.7-148.7 (Ar-C). ESI-MS (m/z, 
H2O): 666.3 [(C3oH36Cl2NioZn2)-(4Cl)]*; 290.2 [(C3oH36Cl2N,oZn2)-(C,7H24N6Cl4Zn)]*. 
Synthesis of [Ni2(bipy)2(iin)2(pip)].4Cl 
This was syntiiesized by a similar procedure as described for 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 with NiCl2'6H20 (0.467g, 2mmol). Light green 
coloured product was isolated. (Yield: 0.557g, 70%). m.p. 320 ± IX, Anal. Calc. for 
CaoHaeCUNioNij (%) C, 45.27; H, 4.56; N, 17.60, Found: C, 45.49; H, 4.11; N, 17.43. 
Selected IR data on KBr/nujoI, cm"': 3398-3243 v(N-H); 2959 v(CH); 1562 (C=C); 
1440 (C=N); 1314 v(C-N); 1250 5(imidazole N-H); 767 (Ar); 459 v(Cu-N). UV-vis 
(1x10^ M, H2O), / W /mn (e/lO^ M"' cm"'): 294 (0.50); 306 (1.50); 540 (0.06). AM 
(1x10"^ M, H2O): 326 n"'cm^ moP' (1:4 electrolyte). ' H NMR (DMSO-de, 400 MHz) 
5(ppm): 2.97 (CH2-CH2); 3.20 (NHCH2CH2NH); 7.76-7.92 (Ar-protons); 8.37 (NH 
imidazole). '^ C NMR (DMSO-</ft 100 MHz) 6(ppm): 42.62 (Pip-C); 116.6-149.6 (Ar-
C); 166.82 (C=N). ESI-MS (m/z, H2O): 655.7 [(C3oH36Cl4N,oNi2)-(4Cl)] *; 279.9 
[(C3oH36CUN,oNi2HCl7H27N6Cl4Ni)] \ 
Resalts and discussion 
All the complexes are stable towards air and moisture and soluble in H2O. The 
coordination geometry of central metal ion Cu(II) was square pyramidal while the Zn(Il) 
and Ni(II) atom was present in square planar environment (Scheme 6), which was 
proposed on the basis of analytical and spectroscopic data. 
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Scheme 6. Synthetic route for complexes 
Infrared spectra 
The IR spectra of complexes [Cu2(bipy)2(im)2(pipXN03)2].2N03, 
[Zn2(bipy)2(im)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl exhibited characteristic broad 
envelope at -3405-3204 cm"' attributed to v(N-H) stretching vibrations. [322]. Other 
medium intensity bands observed at 1313-1350 cm~* and 1275-1250 cm"' were assigned 
to v(C-N) and 5(N-H) vibration in the complexes [323]. The strong characteristic bands 
appearing between 1450-1440 cm"' were attributed to v(C=N) of the imidazole and 
bipyridyl rings [324]. The band at 1384 cm"' in the complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 was assigned to v(N-0) stretching vibrations, 
indicating the presence of NO3 ions. The band observed at 2972-2959 cm"' in the 
complexes were ascribed to Vas(CH2) and Vs(CH2) sreching vibrations. The formation of 
complexes [Cu2(bipy)2(im)2(pipXN03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl were also revealed by the presence of medium intensity v(M-
N) stretching vibrations in the range 423-459 cm"' [325]. 
145 
NMR spectra 
The ' H and '^ C NMR spectra of complexes [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl exhibited well resolved signals and significant chemical shifts. 
The sharp signal at 8.80-8.41 ppm, is indicative of imidazole -NH. The resonance at 
2.55-2.97 ppm and ~3.19 ppm was ascribed to H2C-CH2 and -NH protons of piperazine 
ring. The peaks observed in the range of 6.97-7.92 ppm were consistent with the 
aromatic protons [326]. The '^ C NMR spectra of complexes were characterized by 
various resonances attributed to the bridge Piperazine carbons at 42.62-44.53 ppm, 
respectively, The various resonances due to the aromatic carbons of imidazole and 
bipyridyl ring appeared in tfie range 116.66-149.56 ppm [327,328] (Figure 91a-d). 
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F^ure 91.'Hand '^CNMR spectrum of complex [Zn2(bipy)2(im)2(pip)].4Cl (aandb) 
and [Ni2(bipy)2(im)2(pip)].4Cl (c and d) in D2O solution. 
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Electronic absorptioD spectra 
The UV-visible spectra of complexes [Cu2(bipy)2(im)2(pip)(N03)2].2N03, 
[Zn2(bipy)2(im)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl at room temperature were 
carried out in the region 190-1100 nm in H2O exhibited broad and intense absorption 
maxima. The complexes exhibited sharp peaks observed in the range of 230-296 nm 
attributed to intraiigand charge transfer (ILCT) transitions. However, the absorption 
bands at 306-311 nm, were assigned to a metal to ligand charge transfer (MLCT) 
transition. The complexes [Cu2(bipy)2(im)2(pipXN03)2].2N03 and 
[Ni2(bipy)2(im)2(pip)].4Cl revealed a d-d transitions in the lower frequency region 
centered at 590 (e/lO^ M"' cm"', 0.08) and 540 nm (e/lO^ M"' cm"', 0.06), respectively, 
consistent with their square pyramidal and square planar geometry, respectively. 
EPR spectra 
The solid state X-band EPR spectrum of complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
was recorded at LNT with a magnetic field strength of 3000G. The EPR spectrum 
revealed an isotropic spectrum with a broad signal indicating that the copper ion in a 
distorted square pyramidal geometry with giso value of ~2.075 [329]. Thus, an unpaired 
electron of paramagnetic 3d'coK>er(II) ion occupy d(x^-y^) orbital in (Big) ground state 
configuration with an elongated square based pyramidal geometry (Figure 92). 
Figure 92. EPR spectra of complex [Cu(bipy)2(im)2(pip)(N03)J.2N03 at LNT. 
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Mass spectral analy^ 
The formation of metal complexes and the speciation of various ionic forms in a H2O 
solution were studied with ESI-MS. The spectra of the complexes displayed prominent 
peaks corresponding to the molecular ion fragment. The complex 
[Cu2(bipy)2(im)2(pipXN03)2].2NC)3 showed three major peaks at m/z 661.1, 436.3, and 
287.9 were assigned to [C30H36CU2N10]*, [CnHzaCuNTOa]^  and [C13H13CUN4]", 
respectively. The complex [Zn2(bipy)2(im)2(pip)].4Cl exhibited two major peaks at m/z 
666.3 and 290.2 attributed to [C3oH36NioZn2]"' and [Ci3Hi2N4Zn]'', respectively. 
However, the appearance of two major peaks at m/z 655.7 and 279.9 for complex 
[Ni2(bipy)2(im)2(pip)].4Cl were ascribed to [C3oH36NioNi2+H]* and [(Ci3Hi3N4NiMH]*, 
respectively. 'Hiese observations indicate that the metal-ligated skeletons of these 
complexes are stable in solution. 
Thermal Studies 
Thermogravimeteric analysis of the complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 was 
carried out to study the pyrolysis pattern in temperature range 25-1000 ^C. The 
thermogram of [Cu2(bipy)2(im)2(pip)(N03)2].2N03 exhibited weight loss in three steps 
over the temperature range 75-350, 400-680 and 700-1000 "C (Figure 93). The weight 
loss in the temperature range 75-350 °C confirmed the removal of the coordinated 
nitrate molecule (19 %) while at 400-680 °C (48 %), the noticeable weight loss 
indicated the removal of the aryl groups [330]. Finally, the TGA curve showed a plateau 
above 772°C corresponding to the formation of metal-oxide as the final products. 
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Figure 93. TGA curve showing the degradation of bimetallic complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03. 
X-ray diffractioB analysis 
To obtain furtiier evidence about the structure of the metai complexes. X-ray powder 
diflfraction studies of the complexes [Cu2(bipy)2(«ni)2(P»PXN03)2].2N03, 
[Zn2(bipy)2(im)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)3.4Cl were performed as it was 
difficuh to isolate single crystals suitable for single crystal X-^ay crystallography. The 
dif&actograms obtained for the metal complexes are given in Figure 94a-c. The XRPD 
patterns indicate crystalline nature for the complexes [Cu2(bipy)2(im)2(pip)(N03)2].2N03, 
[Zn2(bipy)2{im)2{pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl. A summary of the refined 
XRPD parameters of complexes is given in Table 15. 
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Figure 94. X-ray powder diffraction patterns of (a) [Cu2(bipy)2(im)2(pip)(N03)J.2N03, 
(b) [Zn2(bipy)2(im)2(pip)]-4Cl and (c) [Ni2(bipy)2(im)2(pip)].4Cl complexes. 
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Table 15. Summary of the XRPD data and the refinement parameters for complexes 
[Cu2(bipy)2(m)2(pip)(NOs)2l.2N03. [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl 
Parameter fCu2(bipy)2Cm)2(pip)(N03)2j. 2NO3 [Zn2(bipy)2(im)2(pip)].4Cl [Ni2(bipy)2(im)2(pip)].4CI 
Formula C30H36CU2N14O12 CsoHsfiCUNioZna CsoHseCUNioNi: 
FW 911.76 809.28 795.94 
Temperature 298 298 298 
Method Micro crystalline Micro crystalline Micro crystalline 
Wavelengt 1.540598 1.540598 1.540598 
Radiation Cu-Kal Cit-Kal Cu-Kal 
Crystal Monoclinic Triclinic Triclinic 
Space P P P 
Unit cell 
a(A) 8.303 4.917 8.3700 
b(A) 13.382 4.916 10.520 
c(A) 11.876 5.407 10.831 
a" 90 90 90 
po 90 90 90 
y" 90 90 90 
26 range 20-80 20-80 20-80 
Limiting 0 < h < 3 0 < h < 2 0 < h < 6 
Intensity 25.42-100 38.03-100 48.64-100 
In vitro DNA binding Studies 
Absorption titrations 
The complexes [Cu2(bipy)2(im)2(pipXN03)2].2N03, [&J2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(un)2(pip)].4Cl displayed intense absorption bands at 235-270 nm in the UV 
region assigned to n-*n* transitions of aromatic chromophore and shows another band at 
290-310 nm assigned to MLCT transition, respectively. On the addition of CT DNA, 
complexes [Cu2(bipy)2(im)2(pipXN03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl show an increase in molar absorptivity (hyperchromism; 17-
33%, Table 16) with a blue shift of 4-8 nm at 235-270 nm. 
Table 16. The binding constant 
[Cu2(bipy)2(im)2(pip)(N03)2j.2N03, 
[Ni2(bipy)2(im)2^ip)].4Cl with the DNA 
(KiJ values of 
[Zn2(bipy)2(im)2(pip)].4Cl 
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complexes 
and 
Complex K(M~') % Hyperchromism Blue Shift (nm) 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 2.74x10'' 33 4 
[Zn2(bipy)2(ini)2(pip)].4Cl 2.04x10* 23 8 
[Ni2(bipy)2(im)2(pip)].4Cl 1.51x10" 17 5 
These changes are typical for complexes bound to DNA through non covalent interaction 
[331]. Hypochromism results from the contraction of DNA helix as well as the 
conformational changes on DNA, while hyperchromism results from the secondary 
damage of DNA double helix structure [332,333]. 
To quantify the extent of DNA binding, the intrinsic binding constant, Kb of the 
complexes were determined. The Kb values obtained follows the order: 
[Cu2(bipy)2(im)2(pipXN03)2l.2N03> [Zn2(bipy)2(im)2(pip)].4Cl > [Ni2(bipy)2(im)2(pip)]. 
4C1 (Figure 95). 
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Figure 95. Absorption spectral traces of complexes (a) 
[Cu2(bipy)2(im)2(pip)(N03)2].2NOs, (b) fZn2(bipy):(im)2(pip)J.4Cl and (c) 
[Ni2(bipy)2(im)2(pip)].4Cl in SmMTris HCV 50 mMNaCl buffer at pH 7.2 upon addition 
ofCTDNA. Inset: Plots of [DMA]/ £a-^(M^ cm) vs [DNAJ for the titration ofCTDNA 
with complexes m, experimental data points; full lines, linear fitting of the data. 
[Complex] 0.67X ICf M, [DNA] 0.00-0.33 x l(rM. 
An explanation for higher Kb value of copper complexes is apparently that copper 
complexes are 'borderline' metals which show high affinity for both nucleobases and 
phosphate. In particular, Cu(II) complexes bind specifically to N7 of guanine nucleobase 
of DNA helix [334] 
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iBteractioD with 5'-GMP 
To obtain concrete information and to determine the coordination of the metal ion to the 
specific site, interaction with low molecular building blocks of large DNA molecules viz; 
guanosine 5'-monophosphate becomes mandatory. Cu(II) complexes, exhibits specificity 
towards guanine nucleotide of DNA. On addition of 5'-GMP to the complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03, there is a sharp increase "hyperchromic" effect in 
the absorption bands at 235-280 nm (Figure 96). This observation supports the muhiple 
binding events of the Cu(II) complex as observed in case of CT DNA and also provides 
an authentic proof for binding to 5'-GMP through electrostatic interaction via phosphate 
backbone of the DNA helix. 
1 1 
0 1 • 
OJ • v \ \ s •• 
0 7 • M\K •" • 
0 6 • 
OS • f V\^ T 1 / \ >o» • 0* • 
0 ] \f\\\ f: • 
02 r^X y \ 
0 1 • 
0 
|<-<;Na-|»i»'^i 
no }ta no uo 4U) iK> 
Figure 96. Variation of UV-vis absorption for complex 
[Cu^ipy)2(im)2(pip)(N03)J.2N03 with increase in the concentration of 5' GMP (0.067 
xJ(r-0.33 X KTM) in buffer (5mM Tris-HCl/50 mM NaCl, pH= 7.2) at room 
temperature. Inset: plot of [5' GMPJ/(£a-£^ vs [5' GMP] for the titration of 5' GMP. 
To obtain a concrete evidence of binding via electrostatic interaction, the binding of 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 to 5'-GMP was also validated by ' H and ^'P NMR 
techniques. The free 5'-GMP exhibited H8 signal at 8.02 ppm, on addition of complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03, there was a slight shift (-0.03 ppm) in H8 signal 
(Figure 97a & b), indicative of weak binding of [Cu2(bipy)2(im)2(pip)(N03)2].2N03to the 
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5'-GMP. The ^'P NMR spectra of [Cu2(bipy)2(im)2(pipXN03)2].2N03 in presence of 5'-
GMP reveal a substantial downfield shift (3.67 ppm to 1.67ppm) to that of free nucleotide 
(without the added complex). The observations deduced from above studies demonstrate 
tiiat complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 interacts strongly with the anionic 
phosphate backbone of the DNA helix (Figure 97c & b) [335,336]. 
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Figure 97. (a) 'H NMR spectra of 5'-GMP, (b) 'H NMR spectra of complex 
[Cu2(bipy)2(im)2(pip)(N03)z].2N03 with 5'-GMP, (c) ^'P NMR spectra of 5'-GMP,and 
iln XTX P NMR spectra of complex [Cu(bipy)2(im)2(pip)(N03)2].2N03 with 5'-GMP at 25 °C. 
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Fluorescence studies 
In the absence of CT-DNA, complexes [Cu2(bipy)2(im)2(pipXN03)2].2N03, 
[Zn2(bipy)2(im)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl emit weak luminescence in 
Tris-HCI buffer at room temperature, with a fluorescence maximum ^jpearing at -325 
nm when excited at 260 nm. Upon addition of increasing concentration of CT-DNA over 
a range 0.00-3.33 x 10"^  M, to the fixed amount of complexes (0.33 x 10"* M), the 
emission intensity of [Cu2(bipy)2(im)2(pipXN03)2].2N03, [Zn2{bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl increased appreciably as illustrated in the Figure 98(a-c), 
respectively. The enhancement of the emission intensity is largely due to the change in 
the environment of the metal complex and related to the extent to which the complex gets 
into a hydrophobic environment inside the CT-DNA. Since, it is found that complexes 
with increased ligand hydrophobicities show greater increase in emission intensities upon 
buiding to polyelectrolytes via DNA, therefore, such an increase in emission intensities is 
attributed to electrostatic association. Thus, we infer that the complexes are less deeply 
accommodated inside the hydrophobic pockets inside the DNA which is indicative of 
electrostatic mode of binding of the complex to tfie CT-DNA. The relative fluorescence 
intensity plotted as a function of DNA concentration (in terms of ([M]/[DNA]), (Figure 
98a-c) showed larger increase in the emission intensity of complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 than tiie complex [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl. This implies that complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
is boimd to the DNA more strongly by means of surface binding with the DNA duplex 
(Table 17). 
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Table 17. Emission properties of complexes [Cu2(bipy)2(im)2(pip)(NOi)2].2}^0}, 
[Zn2(bipy)2(im)2(pip)].4Cland[Ni2(bipy)2(im)2(pip)].4Cl hound to CTDNA 
Complex Emission Excitation Monitored Kb(M-') 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 220 260 329 1.87x10" 
[Zn2(bipy)2(im)2(pip)].4Cl 220 260 324 1.24x10* 
[Ni2(bipy)2(im)2(pip)].4Cl 220 260 325 1.09x10* 
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Figure 98. Emission enhancement spectra of the complexes 
(a)[Cu2(bipy)2(im)2(pip)(N03)2l.2N03, (b) [Zn2(bipy)2(im)2(pip)].4a and (c) 
[Ni2(bipy)2(im)2(pip)].4Cl in presence of CT~DNA. Arrow indicates the change in the 
intensity upon increasing DNA concentration. 
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To demonstrate the interaction strength of tiie complexes 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl with CT-DNA, steady state emission quenching experiments 
using [Fe(CN)6]*" as quencher were also performed [337.338]. The propensity to CT-
DNA for the complexes follows the order: [Cu2(bipy)2(im)2(pipXN03)2].2N03 > 
[Zn2(bipy)2(im)2(pip)].4Cl > [Ni2(bipy)2(im)2(pip)].4Cl as evidenced by the binding 
constant Kjv values given in the Table 18. 
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Figure 99. Stem-Volmer quenching plots of complexes 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(iTn)2(pip)].4Cl in the (a) absence and (b)Presence of CT-DNA. 
In the absence of CT-DNA, emission intensity of complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl were efficiently quenched by [Fe(CN)6]'*" as shown in Figure 
99a,b. The greater decrease of quenching for [Cu2(bipy)2(im)2(pip)(N03)2].2N03 as 
compared to [Zn2(bipy)2(im)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl indicated higher 
DNA binding ability of [Cu2(bipy)2(im)2(pip)(N03)2].2N03. 
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Tabie 18. Emission quenching of CT-DNA bound [Fe(CN)(J^ by complexes 
[Cu2(bipy)2(im)2(pip)(N03)2j.2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl 
Complex Emission Excitation Monitored Ksv 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 220 260 330 2.55x10* 
[Zn2(bipy)2(im)2(pip)].4Cl 220 260 360 1.39x10" 
[Ni2(bipy)2(im)2(pip)].4Cl 220 260 336 1.35x10" 
Circular dkhrobm studies 
Circular dichroism (CD) is a power&l and sophisticated tool for identifying 
conformational changes of DNA. The secondary structure of DNA is greatly influenced 
by interaction of [Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl and changes in conformation of DNA from B-»Z or B -•A. 
The observed CD spectrum of CT DNA consists of a positive band at 275 nm due to base 
stacking and a negative band at 245 nm due to helicity, which are characteristic of DNA 
m right handed canonical B-form. Simple groove binding and electrostatic interaction of 
the complexes with DNA showed less or no perturbations on the base stacking and 
helicity bands while intercalator enhances the intensities of both the bands. On incubation 
of present complexes [Cu2{bipy)2(im)2(pipXNC)3)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl with CT DNA, the CD spectra of DNA undergoes changes in 
both positive and negative bands (Figure 100 a-c). 
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Figure 100. CD spectrum of CT-DNA in the absence and presence of complexes, 
(a) —, DNA alone; (b) —[Cu2(bipy)2(im)2(pip)(N03)2j.2N03+DNA, (c)-' 
[Zn2(bipy)2(im)2(pip)].4Cl +DNA, and (d) —, [Ni2(bipy)2(im)2(pip)J.4Cl+DNA. 
[Complex] 1X 10'" M, [DNA] 1 x 10'" M. 
In complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl, after addition of CT DNA the CD spectra shows an decrease 
in positive and in negative bands without shift in the band position. Such results suggest 
that the CD spectra are closely correlated with DNA binding affinity [339]. 
DNA cleavage activity 
DNA Cleavage without added reductant 
The DNA cleavage ability of complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 was studied by 
agarose gel electrophoresis using supercoiled pBR322 plasmid DNA as a substrate. The 
activity of complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 was assessed by the conversion 
of DNA from Form I to Form II or Form III. A concentration-dependent DNA cleavage 
by complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 was first performed. Briefly, pBR322 
DNA was mixed with different concentration of complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 and the mixture was incubated at 310 K for 45 min. 
With the increase of concentration of complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03, DNA 
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was converted from Form I (Supercoiled Form) to more intense Form II was observed 
(shown in Lane 2-5, Figure 101) with the simultaneous reduction of Form I, whereas no 
conversion to Form IE was observed. The reduction in the intensity of Form I and 
appearance of more intense Form n of pBR322 DNA on the gel shows the complex 
[Cu2(bipy)2(im)2(pipXN03)2l.2NC)3 are involved in an efficient double strand DNA 
cleavage pathway. 
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Figure 101. The cleavage patterns of the agarose gel electrophoresis diagram showing 
cleavage ofpBR322 supercoiled DNA (300 ng) by fCu2(bipy)2(im)2(pip)(NOi)2].2N03 at 
25 "C after 45 minutes of incubation. Lane 1, DNA control; Lane 2, 5 ^M of complex + 
DNA; Lane 3, 10 piM of complex + DNA; Lane 4, 20 fiM of complex + DNA; Lane 5, 30 
fiM of complex. With the increase of concentration offCu2(bipy)2(im)2(pip)(N03)2j-2NOs, 
DNA was converted from Form I Supercoiled Form) to Form II (Nicked Circular Form) 
and tfwn to Form III (Linear Form). 
DNA cleavage in presence of activators 
The nuclease activity of complex [Cu2(bipy)2(im)2(pipXN03)2].2N03 markedly depends 
on different activators [192,193]. Thus, activators such as ascorbate (Asc), 3 -
mercaptopropionic acid (MPA), H2O2 and glutathione (GSH) (Lanes 2-5, Figure 102) 
were also used to investigate the DNA cleavage activity of complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 at a concentration of 20 nM. The cleavage activity of 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 was significantly enhanced by these activators and 
follows the order: H202>MPA>Asc»GSH. 
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Figure 102. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 
plasmid DMA (300 ng) by complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 (0.25 mmol) in 
the presence of different activating agents at 37 °C after incubation for 45 min: Lane 1, 
DNA control: Lane 2, DNA + [Cu2(bipy)2(im)2(pip)(N03)2j.2N03 +H2O2 (0.4 fiM); Lane 
3, DNA + [Cu2(bipy)2(im)2(pip)(N03)2j.2N03 + MPA (0.4 fiM); Lane 4. DNA + 
[Cu2(bipy)2(im)20!>ip)(NO3)2j2NO3 + Asc (0.4 fiM); Lane 5, DNA + 
[Cu2(bipy)2(im)2(pip)(N03)2J.2N03 + GSH (0.4 fiM); Lane 6, DNA + 
[Cu2(bipy)2(im)2(pip)(N03)2j.2N03+ NaN3 (0.4 fiM); Lane 7, DNA + 1 + Superoxide 
Dismutase (15 units); Lane 8, DNA + [Cu2(bipy)2(im)2(pip)(N03)2j.2N03+ DMSO (0.4 
liM); Lane 9, DNA + [Cu2(bipy)2(im)2(pip)(N03)2].2N03+ tert-butyl alcohol (0.4 fiM); 
Lane 10, DNA + 1 + Methyl green C2.5fd.ofa 0.01 mg/mL solution); Lane 11, DNA + 
[Cu2(bipy)2(im)2(pip)(N03)2j.2N03+ DAPl (8 fiM). 
DNA cleavage in presence of recognition elements (Groove binding) 
Minor groove binding agent DAPI [340], and major groove binding agent metiiyl green 
[341] (Lane 10 and 11, Figure 102) were used to examine the potential interacting site of 
complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 with supercoiled plasmid DNA. The 
cleavage patterns, demonstrated that [Cu2(bipy)2(im)2(pip)(N03)2].2N03 prefers minor 
groove binding, which is further validated by molecular docking study. 
Reactive oxygen species responsible for DNA cleavage 
The interaction between metal complexes and dioxygen or redox reagents are believed to 
be a major cause of DNA damage [342]. To probe the potential mechanism of DNA 
cleavage mediated by complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03, some standard 
radical scavengers were used prior to the addition of [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
to DNA solution. The complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 did not show any 
inhibition in presence of DMSO while DNA cleavage was inhibited significantly in 
presence of tert-butyl alcohol (Lane 7). The addition of sodium azide (Lane 8) as singlet 
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oxygen scavenger and SOD (Lane 9) as superoxide anion radical scavenger also did not 
attenuate the DNA strand scission and even in presence of SOD the cleavage reaction is 
enhanced. Therefore an oxidative cleavage pathv/ay of DNA by complex 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03 was excluded and evidently the cleavage proceeds by 
a hydrolytic mechanism. 
Superoxide Dismutase Activity 
The 02«~ (superoxide radical) was generated using a non-enzymatic system in the 
presence or absence of test compounds, and 02*~ was detected by monitoring reduction 
of nitroblue tetrazolium (NBT) to monoformazan dye at 560 nm. A plot of NBT percent 
inhibition with an increase in concentration of complex 
[Cu2(bipy)2(un)2(pipXN03)2l.2N03 is shown in Figure 103. The determined IC50 values 
for the complex [Cu2(bipy)2(im)2(pipXN03)2].2N03 under investigation are given in 
Table 19. The IC50 value of complex [Cu2(bipy)2(im)2(pipXN03)2].2N03 is 0.28 nM, 
which is considered to be an excellent SOD mimic among the most active bipy-Cu(II) 
complexes but it is somewhat less active tiian the IC50 value obtained for native enzyme 
(IC50 = 0.04 nM). Furthermore, the high superoxide dismutase activity of complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 may be possibly due to cooperation of two Cu(U) 
centers in close proximity, acting in concord in five radical binding and electron transfer. 
Also may be due to a vacant coordination site that permits the bonding of superoxide 
anion and the influence of ligand on SOD activity [343]. 
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F^ure 103. A plot of percentage of NBT inhibition reduction with an increase in the 
concentration of complex [Cu2(bipy)2(im)2(pip)(N03)J.2N03. 
Table 19. ICso (liM) values of the complex [Cu2(bipy)2(im)2(pip)(N03)J.2N03, some of 
the copper (II) complexes and the native Cu,ZnSOD emyme 
Complexes ICso (MM) References 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 0.28 (This work) 
[Cu(stz)(py)3Cl] 1.31 [344] 
[Cu(Hstz)2(MeOH)Cl2] 2.51 [344] 
[Cu(Cip)2(bipym)2(pip)].5H20 0.058 [345] 
[Cu(stz)2(U-<lmHim)2] 1.03 [346] 
[Cu(stz)(py)3Cl] 1.586 [346] 
Native Cu,Zn-SOD 0.045 
Molecular docking studies 
In order to get more insight into the mode of binding, complexes 
[Cu2(bipy)2(im)2(pip)(N03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(im)2(pip)].4Cl were successively docked witii DNA duplex of sequence 
d(CGCGAATTCGCG)2 dodecamer (PDB IDrlBNA). The minimum energy docked pose 
(Figure 104a-c) revealed that complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03, 
[Zn2(bipy)2(un)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl snuggly fitted into the curve 
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contour of DNA minor groove, and slightly bends the DNA in such a way that a part of 
the aromatic rings of bipyridyl ligand makes more effective n-n stacking interactions 
between DNA base pairs and lead to van der Waals interaction with the DNA functional 
groups which define the stability of groove [347]. The resulting relative binding energy 
of docked structures of complexes [Cu2(bipy)2(im)2(pip)(N03)2].2N03, 
[Zn2(bipy)2(im)2(pip)].4Cl and [Ni2(bipy)2(im)2(pip)].4Cl with DNA were found to be 
-241.4, -220.1 and -202.3 KJmoP', respectively, indicating the more potent the binding 
affinity between DNA and complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03, correlating well 
with the experimental DNA binding studies and minor groove binder using DAPI assay. 
Thus, we can conclude that there is a mutual complement between spectroscopic and 
molecular docking techniques, which can be substantiate our experimental results and 
provide valuable information about the mode of interaction between complex and DNA. 
Figure 104. Molecular docked model of complex (a) [Cu2(bipy)2(im)2(pip)(N03)2].2N03 
(b)[Zn2(bipy)2(im)2(pip)].4Cl and (c) [Ni2(bipy)2(im)2(pip)J.4Cl with DNA dodecamer 
duplex of sequence d(CGCGAATTCGCG) 2 (PDB ID: IBNA). 
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Conclusion 
In this work, we have described the synthesis and characterization of bimetallic 
complexes [Cu2(bipy)2(im)2(pipXN03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(ira)2(pip)].4Cl which can be explored as potential cancer chemotherapeutic 
agents. In vitro DNA binding studies of these complexes 
[Cu2(bipy)2(im)2(pipXN03)2].2N03, [Zn2(bipy)2(im)2(pip)].4Cl and 
[Ni2(bipy)2(un)2(pJp)]-4Cl were carried out by using various biophysical and 
spectroscopic techniques. The binding affinity of diese complexes followed the order 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 > [Zn2(bipy)2(im)2(pip)].4Cl > 
[Ni2(bipy)2(im)2(pip)].4Cl. Experimental results indicate that the complexes bind to CT-
DNA by electrostatic groove binding mechanism. The interaction of complex 
[Cu2(bipy)2(im)2(pipXN03)2].2N03 with CT-DNA displays a hi^ier binding propensity 
as compared to the rest of the complexes. As observed for gel electrophoretic mobility 
assay, the complex [Cu2(bipy)2(im)2(pip)(N03)2].2N03 displays efficient cleavage 
activity of plasmid pBR322 DNA converting the Form I to Form II and ultimately 
leading to the formation of linearized Form III with increasing concentrations of the 
complex. The complex [Cu2(bipy)2(im)2(pipXN03)2].2N03 exhibited remaricabie ability 
to affect DNA double strand scission in hydrolytic cleavage manner. SOD activity 
exhibited by [Cu2(bipy)2(im)2(pipXN03)2].2N03 is Ae high activity with IC50 value equal 
~ 0.28 \iM. 
CHAPTER VI 
Synthesis, characterization of new bis-macrocyclic metal 
complexes: in vitro DNA binding and cleavage studies. 
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Synthesis 
Synthesis of ethylene [0,0-bis{5-{(lEH2 hydroxyphenyl)methylene]aniino}-2-
hydroxybenzoic acid] (L) 
The salicylaldehyde derivative was synthesized according to the procedure reported 
earlier [348] which is described below (scheme 7). 
To a stirred methanolic (30 mL) solution of 5-aminosalicylic acid (0.612g, 4mmol) was 
added dropwise salicylaldehyde derivative (0.54g, 2nunol) in methanol (20 mL). The 
reaction mixture was reflux for 4 hours to ensure the completion of reaction which 
yielded yellow colored solid product, washed with methanol (15 mL) and diethyl ether 
(30 mL). The yellow solid was then dried to afford ligand L. (Yield: 0.309g, 57.2%). m.p. 
240 X . Anal. Calc. for C30H24N2O8 (%): C, 66.66; H, 4.48; N, 5.18. Found: C, 66.69; H, 
4.50; N, 5.21. Selected IR data on KBr/nujol, cm"': 3081 V(AIH:H); 1606 v(C=N); 1677 
v(COOl; 1483 v(C=C); 1265; 1206 v(Ar-0); 755 v(Substituted benzene). ' H N M R 
(DMSCMJ, 400 MHz) 5 (ppm): 8.78 (s, 2H, C(H)=N); 8.22 (s, 2H, C(H)=N); 6.75-7.97 
(ov, m, 14H AT); 5.58 (s, 2H, -OH); 3.20 (s, 4H, C2H5 ). '^ C NMR (DMSO-J<j, 100 
MHz) 5(ppm): 171.7 (C=0); 159.6 (C=N); 158.4 (CO); 153.5 (CO); 112.9-142.8 (ArC). 
Synthesis of bimetallic complexes 
Complex [Cu2(L)2] 
To a stirred methanolic (15 mL) solution of Cu(N03)2.3H20 (0.24 Ig, Immol) was added 
slowly ligand L (0.54 g, Immol) in methanol (25 mL). The resuhing mixture was 
refluxed for ca 4 hours until a dark brown product was obtamed and washed thoroughly 
with methanol and diethyl ether then dried in vacuo. (Yield: 0.453g, 74%). m.p. >300 °C. 
Anal. Calc. for C60H48N4O16CU2 (%): C, 59.65; H, 4.00; N, 4.64. Found: C, 59.45; H, 
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3.98; N, 4.61. Selected IR data on KBr/nujol, cm"^ 3081 v(Ar-CH); 1602 v(C=N); 1677 
v(COO"); 1486 v(C=C); 1260, 1204 v(Ar-O); 747 v(Substituted benzene); 564 v(Cu-O). 
Molar Conductance, ylM (I^IO"^ M, DMSO): 51 Q~^ cm? mor' (non-electrolyte). UV-vis 
absorption: (10"' M, DMSO), X^/ran (e/10^ M"' cm"'): 270 (4.81); 375 (3.25); 538 
(1.73). 
Complex [Ni2(L)2] 
The [Ni2(L)2] complex was prepared by using NiCl2.6H20 (0.237g, Immol) according to 
the method outlined for complex [Cu2(L)2]. The light yellow coloured product obtained 
was washed witii methanol and dried in vacuo. (Yield: 0.308g, 51.4 %). m.p. 250 ±2 °C. 
Anal. Calc. for C6oH48N40i6Ni2 (%): C, 60.13; H, 4.04; N, 4.68. Found: C, 60.17; H, 
3.99; N, 4.70. Selected IR data on KBr/nujol, cm'': 3073 v(Ar-CH); 1602 v(C=N); 1677 
v(COO"); 1479 v(C=C); 1265,1202 v(Ar-O); 749 v(Substituted benzene); 543 v(Ni-0). 
' H N M R (DMSCMS, 400 MHz) 5(ppm): 8.80 (s, 2H, C(H)=N); 6.81-8.00 (ov, m, 14H 
Ar); 4.58 (s, 2H, -OH); 3.26 (s, 4H, C2H4). '^ C NMR (DMSOnrf^ , 100 MHz) 6(ppm): 
171.81 (CO); 159.7 (C=N); 158.5 (CO); 153.5 (CO); 112.8-142.8 (ArC)..4M (1x10'^ M, 
DMSO): 12 ii"' cm^ mol"' (non-electrolyte). UV-vis absorption: (10~^ M, DMSO), 
A^x/nm (E/10^ M"' cm"'): 265 (2.40); 377 (1.35); 490 (0.95). 
Complex [Sn2(L)2.4CI] 
The [Sn2(L)2.4Cl] complex was prepared by using SnCU.5H20 (0.350g, Immol) 
according to the method outlined for complex [Cu2(L)2]. The light pink coloured product 
obtained was washed with methanol and dried in vacuo. (Yield: 0.459g, 63 %). m.p. 305 
°C. Calc. for C6oH48Cl4N40i6Sn2 (%): C, 49.35; H, 3.31; N, 3.84. Found: C, 49.44; H, 
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3.15; N, 3.81. Selected IR data on KBr/nujol, cm"': 3080 v(Ar-CH); 1602 v(C=N); 1649 
v(COO"); 1482 v(C=C); 1252 v(Ar-0); 765 v(Substituted benzene); 573 v(Sn-O). 
' H N M R (PMSO-^6, 400 MHz) 5(ppm): 8.90 (s, 2H, C(H)=N); 6.90-8.15 (ov, m, 14H 
AT); 4.58 (s, 2H, -OH); 3.22 (s, 4H, C2H4). '^ C NMR (DMSCMs, 100 MHz) 5(ppm): 
171.62 (C=0); 160.8 (C=N); 160.4 (CO); 160.2 (CO); 112.9-139.5 ( A I H : ) . '"Sn NMR 
(DMSO-de, 5ppm): -625.8; -626.4. At^UlOT^ M, DMSO): 16 ft"' cm^ moP' (non-
electrolyte). UV-vis absorption: (10"^ M, DMSO), Xm«/nm (e/lO^ M"' cm"'): 319 (0.99); 
377 (0.62). 
Results and discussion 
The complexes [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] were synthesized as depicted in 
scheme 7. Empirical formulae and proposed structure were ascertained by elemental 
analysis, molar conductivity measurements, UV-vis, FTIR, NMR spectroscopy and 
XRPD studies. All complexes are soluble in organic polar solvents, DMSO and DMF. On 
the basis of UV-vis. and EPR data, the proposed geometry of the complexes [Cu2(L)2] 
and [Ni2(L)2] were assigned to be square planar (four-coordinated environment) while 
[Sn2(L)2.4Cl] was in six coordinated environment. 
IR spectroscopy 
The IR spectrum of free ligand (L) exhibited characteristic stretch at -1596 cm"' 
attributed to the presence of free v(OH) group of phenolic moiety. However, in 
complexes [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl], v(OH) stretching band shifted, 
indicating the coordination of the metal ions Cu(II), Ni(II) and Sn(IV) through the 
oxygen atom of both the phenolic groups. The Av (vas(C02)-Vs(C02)) value was used to 
determine the nature of binding of carboxylate to metal center. In general, the difference 
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3.98; N, 4.61. Selected IR data on KBr/nujoI, cm"': 3081 v(Ar-CH); 1602 v(C=N); 1677 
v(COO"); 1486 v(C=C); 1260,1204 v(Ar-O); 747 v(Substituted benzene); 564 v(Cu-0). 
Molar Conductance,/IM (1x10"^ M, DMSO) : 51 ft"' cm^ moP' (non-electrolyte). UV-vis 
absorption: (10"^ M, DMSO), X™.x/nm (e/10^ M"' cm"'): 270 (4.81); 375 (3.25); 538 
(1.73). 
Complex [Ni2(L)2] 
The [Ni2(L)2] complex was prepared by using NiCl2.6H20 (0.237g, Immol) according to 
the method outlined for complex [Cu2(L)2]. The light yellow coloured product obtained 
was washed with methanol and dried in vacuo. (Yield: 0.308g, 51.4 %). m.p. 250 ±2 °C. 
Anal. Calc. for C6oH48N40i6Ni2 (%): C, 60.13; H, 4.04; N, 4.68. Found: C, 60.17; H, 
3.99; N, 4.70. Selected IR data on KBr/nujol, cm"': 3073 v(Ai-CH); 1602 v(C=N); 1677 
v(COO"); 1479 v(C=C); 1265,1202 v(Ar-O); 749 v(Substituted benzene); 543 v(Ni-0). 
' H N M R (DMSO-t/e, 400 MHz) 5(ppm): 8.80 (s, 2H, C(H)=N); 6.81-8.00 (ov, m, 14H 
Ar); 4.58 (s, 2H, -OH); 3.26 (s, 4H, C2H4). '^ C NMR (DMSCMj, 100 MHz) 5(ppm): 
171.81 (C=0); 159.7 (C=N); 158.5 (CO); 153.5 (CO); 112.8-142.8 (ArC).ylM (!>< 10"^  M. 
DMSO): 12 Q"' cm^ mol"' (noft-electrolyte). UV-vis absorption: (10"^ M, DMSO), 
X« /^nm (E/10^ M"' cm"'): 265 (2.40); 377 (1.35); 490 (0.95). 
Complex [Sn2(L)2.4Cl] 
The [Sn2(L)2.4Cl] complex was prepared by using SnCl4.5H20 (0.350g, Immol) 
according to the method outlmed for complex [Cu2(L)2]. The light pink coloured product 
obtained was washed with methanol and dried in vacuo. (Yield: 0.459g, 63 %). m.p. 305 
°C. Calc. for C6oH48Cl4N40i6Sn2 (%): C, 49.35; H, 3.31; N, 3.84. Found: C, 49.44; H, 
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in Av between asymmetric (VasCCOj)) and synmietric (VsCCOa) ) absorption frequency 
below 200 cm"' suggests the bidentate caiboxylate moiety while greater than 200 cm"' 
implies the unidentate carboxylate moiety [349]. In complexes [Cu2(L)2], [Ni2(L)2] and 
[Sn2(L)2.4Cl], the Av values were 191, 198 and 169 cm"', respectively, indicative of 
bidentate carboxylate ligation through deprotonation. Other medium intensity bands at 
747-765 cm"' were attributed to the characteristic signatures of aromatic ring vibration. 
The complexes formation of [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] were also revealed by 
the presence of medium intensity (Cu-0), (Ni-O) and (Sn-O) bands around -564, -543 
and -577 cm"', respectively in the far IR region [350-352]. 
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Scheme 7 (a). Synthesis ofligand (L). 
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Scheme 7 (b). Synthesis of bimetallic complexes [Cu2(L)J, [NiifLJJ and [Sn2(L)2.4Cl]. 
NMR spectral studies 
The ' H NMR spectrum of complex [Ni2(L)2] and [Sn2(L)2.4Cl] displayed several 
interesting features in comparison to the free ligand (L) as depicted in Figure 105. The 
complexes exhibit resonance signals appeared at 4.S8 ppm is due to the presence of 
phenolic -OH group. However, the signals due to free carboxylic (-COOH) group at 
12.0-10.0 were absent indicating the coordination of metal atoms via deprotonation. 
Coupled with these observations, the characteristic signals appeared at 8.80-8.90 and 
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6.81-8.15 corresponding to -CH=N, aromatic proton, respectively [353]. The complex 
[Ni2(L)2] and [Sn2(L)2.4Cl] exhibited '^ C NMR spectrum displaying various resonances 
due to O-C=0, CH=N, C-O-Ni and C-O-Sn carbons at 171.6-171.8, 159.7-162.2, 
158.2 and 158.4 ppm, respectively. In addition, aromatic carbon signals of [Ni2(L)2] and 
[Sn2(L)2.4Cl] were observed at range 112.7-142.8 ppm (Figure 106). The '"Sn chemical 
shift, (5("'Sn) is sensitive to the chemical environments of the tin atom. "^Sn NMR 
spectrum of the complex [Sn2(L)2] displayed two sharp signals at -625.8 and -626.4 
ppm, due to the presence of two tin centers (Figure 107) [354]. 
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Figure 105(a). 'HNMR spectrum of the complex [Ni2(L)J. 
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Figure 105(b). 'HNMR spectrum of the complex [Sn2(L)24Cl]. 
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F « « « 106(a). "C NMR spectrum of the complex [Ni2(L)2]. 
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Figure 106(b). '^CNMR spectrum of the complex [Sn2(L)2.4Cl]. 
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119 Figure 107. "^Sn NMR spectrum of the complex [Sn2(L)2.4Cl]. 
EPR studies 
The solid state X-band EPR spectrum (Figure 108) of polycrystalline complex 
[Cu2(L)2] was recorded at room temperature with tetracyanoethylene (TCNE) as field 
maricer (g = 2.0027). The spectrum displayed an isotropic signal and exhibits axial 
symmetrical line shape with g||=2.133 and gx=2.055 and gav=2.08 computed from the 
formula gav^=g|p+2gi,^ /3. These parameters are consistent with the square planar 
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geometry of the copper(II) metal ion and are quite similar to the values reported for other 
related square planar copper(II) systems. The trend of g values (g||>gi>2,0023) observed 
for the copper(II) indicates that the unpaired electrons lies predominantly in the 
dx^-y^ orbital of Cu(II) ion (spectroscopic state ^Big). The exchange interaction 
parameter G = 2.42, suggesting presence of exchange coupling between the copper 
centers [355]. 
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Figure 108. X-band EPR spectrum ofcomplex[Cu2(L)J at LNT with gav=2.08. 
Electronic Spectra 
The absorption spectra of the complexes were recorded in DMSO solution. The complex 
[Cu2(L)2] reveals bands at 270 ran and a broad band at 538 nm (e/lO^ M~' cm"': 4.81 
and 1.73, respectively), which were assigned to {n—*n*) and d-d transitions, respectively 
while the absorption spectrum of complex [Ni2(L)2] revealed two bands at 265 nm and 
490 nm (e/10^ M"' cm"': 2.40 and 0.95, respectively) due to LMCT and d-d transitions, 
respectively. The complex [Sn2(L)2.4Cl] revealed two bands at 319 nm and 377 nm 
(s/10^ M~' cm"': 0.99 and 0.62, respectively), which were assigned to intraligand and 
LMCT transitions, respectively. These results are consistent with the square planar 
environment around Cu(II) and Ni(II) ions [356]. 
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X-ray powder diffraction analysis 
To obtain fiirther evidence about the structure of the metal complexes, X-ray powder 
dif&action studies of the complexes [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] were 
performed as it was difficult to isolate single crystals suitable for X-ray crystallography 
could not be obtained. The crystalline nature of the complex was authenticated by XRPD 
measurements. Figure 109a-c showed the XRPD patterns indicate crystalline nature for 
the complexes [Cu2(Lh], \^hQ-h] and [Sn2(L)2.4Cl]. A summary of die refmed XRPD 
parameters of complexes is given in Table 20. 
Table 20. Summary of the XRPD data and the refinement parameters for complexes 
[CU2(L)J, [Ni2(L)J and[Sn2(L)2.4Cl] 
Parameter [CU2(L)2] [Ni2(L)2] [Sn2(L)2.4Cl] 
Formula C60H48N4O,6CU2 C6oH48N40,6Ni2 C60H48Cl4N4Ol6Sn2 
FW 1208.12 1198.48 1460.28 
Temperature (K) 298 298 298 
Method Micro crystalline Micro crystalline Micro crystalline 
Wavelength 1.540598 1.540598 1.540598 
Radiation Cu-Kal Cu-Kal Cu-Kal 
Crystal System Monoclinic Triclinic Triclinic 
Space group P P P 
Unit cell 
a(A) 7.550 7.615 4.329 
b(A) 7.042 10.574 11.192 
c(A) 10.228 10.401 3.983 
a" 90 90 90 
po 90 90 90 
f 90 90 90 
26 range 20-80 20-80 20-80 
Limiting 0 < h < 8 0 < h < 4 0 < h < l 
Intensity (%) 17.79-100 20.6&-100 33.95-100 
: 
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Figure 109. X-ray powder diffraction patterns of (a) [Cu2(L)J (b) fNi2(L)J and (c) 
[Sn2(L)2.4Cl] complexes. 
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Interaction studies with CT DNA 
Absorption titrations 
The comparative DNA binding ability of ligand L, complexes [Cu2(L)2], [Ni2(L)2] and 
[Sn2(L)2.4Cl] and cisplatin drug were evaluated using metal complex-DNA interactions. 
Figure 110 illustrates the respective absorption spectral changes of the ligand and its 
complexes in absence and the presence of CT-DNA. Upon addition of increasing amount 
of CT-DNA (0.00-1.66 x 10"^ M) to the fixed amount of complexes/ligand, a significant 
"hyperchromic" effect with a small bathochromic shift was observed. Complexes 
[Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] and ligand [L] displayed a substantial 
bathochromic shift of 2-4 nm which supports a higher degree of binding for this complex 
towards CT-DNA, Thus, fiom these spectral changes, we deduce that the complexes bind 
to the CT-DNA by a strong electrostatic interaction mode. The complexes [Cu2(L)2], 
[Ni2(L)2] and [Sn2(L)2.4Cl] show greater propensity for DNA as compared to free ligand 
due to the presence of metal centers which is attributed to its strong tendency for 
phosphate binding. 
To study quantitatively, the binding ability of complexes with CT-DNA, the intrinsic 
binding constant Kb values determined as given in Table 21. The binding constant Kb 
values follows the order [Cu2(L)2] > Cisplatin > [Ni2(L)2] > [Sn2(L)2.4Cl] > [L]. This 
relative difference in the Kb values might be the resuU of different binding mode of the 
complexes and cisplatin. Cisplatin binds to the CT-DNA via, base specific interactions 
forming 1,2-intrastrand crosslinks between adjacent N7 atoms of guanine (GpG) and 
adenine nucleobase (ApG) and secondary interaction with phosphate backbone, which 
obscure the DNA helix to a much larger extent (Figure 110a). Moreover, the Kb values of 
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the complexes were slightly higher than that of classical minor groove binder 4',6-
diamino-2-phenylindole (DAPI-DNA, 8.90 x lO^M"' in 2 mM Tris-0.2 mM EDTA 
containing 30 mM NaCl buffer, pH 8) [357]. 
(d) 
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Figure 110. Absorption spectra of (a) complex fCu2(L)2] (b) complex and [Ni2(L)2] and 
(c) complex [Sn2(L)2.4Cl] in Tris-HCl buffer (pH= 7.2) in the absence and presence of 
increasing amount ofCT-DNA. Inset: Plots of [DNA]/(Ea-^ vs [DNA] for the titration 
of CT-DNA with complexes. Arrow indicates the increase in the absorbance upon 
increasing CT-DNA concentration. Plots of [CT-DNA]/ (sa - e^ vs. [CT-DNA]. 
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Table 21. The binding constant (KiJ values of complexes with the CT-DNA 
Complexes Kb 
(x 10*M-') 
Monitored 
at(nm) 
%Hyperchromism Bathochromic 
(nm) 
Ligand (L) 1.15 269 22.0 2 
[CU2(L)2] 3.38 276 37.5 3 
[Ni2(L)2] 2.40 271 38.8 4 
[Sn2(L)2.4Cl] 1.93 258 67.6 2 
Cisplatin 2.96 251 60.0 2 
NMR studies 
To validate our hypotiiesis the binding of complexes [Ni2(L)2] and [Sn2(L)2.4Cl] towards 
DNA, ' H and *^P NMR techniques at physiological pH were carried out. The 'H NMR of 
fi%e oligonucleotide in D2O showed aromatic base resonances appear between 8.0 and 
8.09 ppm, the cytosine H5 and sugar Hl'resonances 5.14-5.68 ppm, the sugar H3' 
resonances 4.68-5.14 ppm, the sugar H4'/H5'/H5" resonances 3.88-4.68 ppm and the 
sugar H2'/H2" and thymine methyl resonances 1.75-3.24 ppm. The base resonances are 
usually well resolved, and their assignment to an adenine, guanine, cytosine or thymine is 
relatively straight forward. The adenine H8 resonances are generally found furthest down 
field, due to experiencing only small ring cun«nt shifts fix)m neighbouring bases, while 
guanine H8 resonances appear upfield (8.09 ppm). On interaction of complex [Ni2(L)2] 
and [Sn2(L)2.4CI] with DNA, the H8 signal was shifted downfield with a slight decrease 
in the peak intensity (Figure 111) fi-om 8.09 ppm to 7.49 and 8.21ppm, respectively. 
However, the ribose proton Hl'-H5' signals for complex [Ni2(L)2] and [Sn2(L)2.4Cl] 
were shifted upfield -1.6 and 0.12 ppm, respectively, which indicate the preference for 
ribose sugar due to the presence of Ni(II) and Sn(rsr) hard Lewis acid center [358]. 
181 
To confirai the involvement of electrostatic interaction, the ^ 'P signals was appeared at 
1.59 ppm (between 1.7 and 2 ppm), are shifted upfield at 0.41 and 0.38 ppm, respectively 
for [Ni2(L)2] and [Sn2(L)2.4Cl]. The broad signal at 1.59 ppm was attributed to 
phosphodiester resonance in the DNA. The upfield shift (-1.0 ppm) observed during 
binding with Ni(II)/Sn(IV) complexes (Figure 112) were attributed to bound metals 
centers to polyanionic phosphate backbone in DNA [359]. 
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Figure 111. 'HNMR spectra of (a) DNA alone (b) [Ni2(L)J with DNA and (c) 
[Sn2(L)2.4Cl] with DNA at 25 °C. 
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Figure 112. ^'P NMR spectra of (a) DNA done (b) [Ni2(L)2j with DNA and (c) 
[Sn2(L)2.4Cl] with DNA at 25 °C. 
Fluorescence spectroscopic studies 
The complexes [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] exhibited luminescence either in 
DMSO or in presence of CT DNA. Hence, binding studies of all metal complexes to CT 
DNA were carried out by fluorescence spectral titration in absence of any fluorophore 
[360]. Fixed volumes (1.0 x 10"^  M) of the studied complexes were titrated, respectively 
with increasing concentration of DNA in the range from (0.00-1.66 x lO'^M). As seen 
from the Figure 113(a-c), the intensity of emission increased appreciably in the presence 
of DNA. The observed enhancement could be due to relatively non-polar environment of 
the bound metal complex in the presence of DNA, such that the complexes were less 
deeply inserted inside the hydrophobic pockets or grooves of CT-DNA [361]. Cationic 
complexes usually bind to DNA non-covalently as the cationic core of the complexes 
exerts a strong electrostatic attraction to the clonic phosphate backbone of DNA thus 
precluding substantial overlap with the base pairs leadmg to higher emission intensity 
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indicative of electrostatic binding of the probe to the DNA. The binding constant (K) 
estimated for complexes [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] by Scatchard equation 
were 3.06 x lO" M~', 1.82 x 10"* M~' and 1.20 x 10* NT', respectively. The binding 
constant K values were of the order [Cu2(L)2] > [Ni2(L)2] > [Sn2(L)2.4Cl]. These results 
are consistent with tiie findings obtained fit)m UV-vis spectral studies. 
Wav4ntlk(ni) 
(c) 
Figure 113. Emission spectra of (a) complex [Cu2(L)J (b) complex [Ni2(L)^ and (c) 
complex [Sn2(L)2.4Cl] in Tris-HCl buffer the absence and presence ofCT-DNA. Arrow 
shows the intensity change upon increasing CT-DNA concentration. 
To demonstiate the interaction strength of the complexes [Cu2(L)2], [Ni2(L)2] and 
[Sn2(L)2.4Cl] with CT-DNA, steady state emission quenching experiments using 
[Fe(CN)6]^ as quencher were also performed [362,363]. The propensity to CT-DNA for 
the complexes follows the order: [Cu2(L)2] > [Ni2(L)2] > [Sn2(L)2.4Cl] as evidenced by 
the Ksv values given in the Table 22. 
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Table 22. Stem Volmer quenching constant of complexes[Cu2(L) J, [Ni2(L)2] and 
[Sn2(L)2.4Cl] in absence of DNA (Ksvi) and in presence of DMA (Ksvz) with increasing 
concentration ofquencherfFefCNJeJ^ 
Complex Emission Excitation Monitored at Ksvi KsV2 
[CU2(L)2] 377 260 340 4.50 1.50 
[Ni2(L)2] 378 260 320 0.90 0.68 
[Sn2(L)2.4Cl] 355 260 303 0.70 0.61 
In the absence of CT-DNA, emission intensity of complex [Cu2(L)2] > [Ni2(L)2] > 
[Sn2(L)2.4Cl] were efficiently quenched by [Fe(CN)6]'*~ as shown in Figure 114. The 
greater decrease of the Ksv value for [Cu2(L)2] as compared to [Ni2(L)2] and 
[Sn2(L)2.4Cl] indicated higher DNA binding ability of [Cu2(L)2]. These results are 
consistent with the electronic absorption titration (Table 22). 
w^ 
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Figure 114. Emission quenching curves of [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] in 
absence of CT-DNA and in the presence of CT-DNA. [Complex] = l.OxKF^ M. 
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Circular dichroic studies 
The circular dichroism pattern observed for CT-DNA provide further and definitive 
confirmation of the probable mode of CT-DNA binding of complexes [Cu2(L)2] > 
[Ni2(L)2] > [Sn2(L)2.4Cl] which is depicted by the perturbation induced in the DNA 
morphology upon the binding of complexes to CT-DNA (Figure 115). Complexes 
[Cu2(L)2] > [Ni2(L)2] > [Sn2(L)2.4Cl] displays increase in the positive band with respect 
to DNA accompanied by a large increase in the negative band. This corroborates well 
with the hypothesis in literature that simple groove binding and electrostatic interaction 
of the complexes with DNA shows less or no perturbation on the base stacking and 
helicity bands while intercalator enhances the intensities of both the bands [364]. These 
results support groove binding nature of the complexes [Cu2(L)2] > [Ni2(L)2] > 
[Sn2(L)2.4Cl] probably due to some partial intercalative interactions which modifies the 
CT-DNA morphology during drug-DNA interactions. 
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Figure 115. CD spectrum of CT-DNA in the absence and presence of complexes (1.0 x 
ICr'M). (a) — DNA alone; (b) —,[Cu2(L)J +DNA, (c)— [Ni2(L)2]+DNA, and (d) —, 
[Sn2(L)2.4Cl] +DNA. 
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Grel electrophoresis 
The complex [Cu2(L)2] showed maximum binding propensity with CT-DNA, therefore, 
the cleavage activity has been evaluated for complex [Cu2(L)2]. It has been well 
established in literature that copper(II) complexes are selective for the cleavage of DNA 
either through oxidative or hydrolytic mechanism. The nuclease activity of complex 
[Cu2(L)2] was studied using supercoiled pBR322 DNA as a substrate (Figure 116). To 
ascertain the DNA cleavage ability of complex, supercoiled pBR322 DNA was incubated 
with different concentiration of complex in aqueous buffer solution (5mM Tris-HCl/40 
mM NaCl, pH 7.4) without addition of any reductant. 
» Fonnll 
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Figure 116.The cleavage patterns of the agarose gel electrophoresis for pBR322 plasmid 
DNA (300ng) by [Cu2(L)J; Lane 1: DNA control; Lane 2: lOfiM complex + DNA; Lane 
3:15 piM complex + DNA; Lane 4: 20 fiM complex + DNA; Lane 5: 30 /nM complex + 
DNA; Lane 6: 40 /JM complex + DNA. 
As shown in Figure 116, there was a gradual decrease in the amount of Form I with a 
simultaneous increase in Form 11 (Lanes 2 and 4) on increasing the concentration of the 
complex. A notable cleavage feature observed for this complex is the q)pearance of Form 
III before die disappearance of Form I (Lanes 5 and 6). The reduction in the intensity of 
Form I and appearance of more intense Form II of pBR322 DNA on the gel shows that 
the complex [Cu2(L)2] is involved in an efficient double strand DNA cleavage pathway. 
In the presence of activators viz; glutathione (GSH), ascorbic acid (Asc), hydrogen 
peroxide (H2O2) and mercaptopropionic acid (MPA), the complex [Cu2(L)2] showed 
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significant increase in the cleavage of the DNA and follows the order H202> MP A >GSH 
»Asc (Figure 117). 
Fonnll 
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Figure 117. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 plasmid 
DNA (300ng) by complex [Cu2(L)zl (30 ixM) in presence of different activating agent at 37 
"C after incubation for 45 min. Lane 1, DNA control; Lam 2, DNA + [Cu2(L)J + Asc (40 
(xM); Lane 3, DNA + [Cu2(L)2j+ H2O2 (40 fiM); Lane 4, DNA + [Cu2(L)2]+ GSH (40 ixM); 
Lane 5, DNA + fCu2(L)2]+MPA (40 nM). 
Minor groove binding agent (DAPI) [365] and major groove binding agent (Methyl Green) 
[366] were used to probe the potential interacting sites of complex [Cu2(L)2] with pBR322 
DNA (Figure 118). The cleavage patterns, demonstrated that in presence of methyl green 
DNA cleavage activity is affected significantly, suggesting that minor groove are involved in 
the complex-DNA interactions. 
Fonnll 
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Figure 118. Agarose gel electrophoresis pattern for the cleavage of pBR322 plasmid 
DNA (300ng) by complex [Cu2(L)2j (30 nM) in the presence of DNA minor binding agent 
DAPI and major binding agent methyl green at 37 °C after incubation for 30 min. Lane 1, 
DNA control; Lane 2, DNA + [Cu2(L)2]+ DAPI (8 ftAf); Lam 3, DNA + [Cu2(L)2]+ 
Methyl green (2.5 fiL of a 0.0 Img/ml solution). 
In order to identify the reactive oxygen species that are responsible for the DNA cleavage 
reaction, experiments in the presence different common scavengers such as DMSO and 
Ethyl alcohol (hydroxyl radical scavengers), NaNa (singlet oxygen scavenger) and SOD 
(superoxide oxygen scavenger) were carried out, respectively with [Cu2(L)2]. 
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As shown in Figure 119. The cleavage activity of [Cu2G-')2] is reduced dramatically by the 
presence of hydroxyl radical scavengers ethyl alcohol and DMSO (Figure 119, lanes 2,3), 
indicatmg that the freely difiusible hydroxyl radical is one of the intermediates involved in 
the DNA scission process. On the other hand, addition of sodium azide (singlet oxygen 
scavenger) decreases the cleavage efficiencies, this reveals that 'Oa is also the activated 
oxygen intermediate responsible for the cleavage (Figure 119, Lane 5). Addition of 
superoxide dismutase (superoxide scavenger) to the reaction mixture reveals no significant 
quenching of the cleavage reaction indicating that superoxide anion is not the active species 
responsible for the cleavage (Figure 119, Lane 4) [367]. Thus, freely diffusible oxygen 
intermediate or hydroxyl radical may be involved in the strand scission and hence a simple 
diffusible radical mechanisms applicable. Since the complex [Cu2(L)2] are able to cleave 
DNA in the absence of any reducing agent, it may be assumed that DNA might be cleaved by 
a discernible hydrolytic path. 
Figure 119. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 
plasmidDNA (300 ng) in the presence of different activating agents at 310 K after 45 min 
of incubation in buffer (5mM Tris-HCl/50 mMNaCl. pH = 7.2) by [Cu2(L)2] (30 fiAf), 
Lane 1, DNA control; Lane 2, DNA+metal complex+DMSO (0.4 fiM); Lane 3, 
DNA+metal complex+EtOH (0.4 fiM); Lane 4, DNA+metal complex+NaNj (0.4 
fiM), Lane 5, DNA+metal complex+Superoxide Dismutase (15 Units). 
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Conclusion 
An analogous parallel series of complexes of metals {Cu(II)/Ni(II) and Sn(rV)} was 
designed and synthesized to ascertain structure-activity relationship of these complexes 
towards cellular target DNA. The synthesis of macrocyclic-Schiff base ligand derived 
from salicylaldehyde derivative and 5-aminosalicylic acid was carried out and sub 
equally, the ligand was allowed to react with metal ions to yield binuclear complexes in 
the solid form and their structure was proposed by various physico-chemical and 
spectroscopic data. 
The in vitro DNA binding studies viz; absorption titrations, fluorescence, NMR and 
circular dichorism in free complexes and in presence of DNA supported that the 
complexes [Cu2(L)2], [Ni2(L)2] and [Sn2(L)2.4Cl] bind to DNA by noncovalent mode of 
binding by electrostatic interaction via phosphate backbone of the helix. 
The complex [Cu2(L)2] exhibited highest DNA binding affinity and Cu(rr) complex 
[Cu2(L)2] binds DNA more avidly than the other metal complexes Ni(II) and Sn(IV), 
respectively, which was quantified by their intrinsic binding constant Kb values. 
Interaction between complex [Cu2(L)2] and pBR322 DNA has also been investigated by 
agarose gel electrophoresis, noticeably, Ae Cu(II) complex [Cu2(L)2] exhibited an 
outstanding ability to affect DNA double strand scission in hydrolytic cleavage. 
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